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ABSTRACT 
New technologies or methods of image acquisition are driven by the need for increased anatomical 
information to improve diagnostic accuracy or surgical planning. These new technologies are often 
accompanied with additional radiation dose yet this can be justified through the consideration of the 
benefit it brings. Examples include the use of CT colonography instead of double contrast barium 
enemas, CT urography replacing intravenous urography and, in nuclear medicine imaging the 
increased use of CT imaging as part of single photon emission tomography and positron emission 
tomography to correct emission data or localise or characterise identified lesions. Manufacturers are 
quick to promote their systems as “low-dose” but little independent evaluation of this claim existed. 
In the context of nuclear medicine, the additional imaging raised questions as to the use of the 
attenuation correction data specifically. The question of should the cross sectional images be 
reviewed for pathology was has been the focus of debate. It was recognised that the quality of these 
images is poor due to the “low-dose” acquisition. 
The research presented in this thesis and portfolio of published work aimed to establish an accurate 
method of assessing the radiation dose, initially from the CT attenuation correction acquisition, but 
later in other imaging modalities. In this thesis eight papers are used to illustrate the methods 
developed in this work, and how they were applied to other fields of medical imaging. Six of these 
papers were completed as the first author and the remainder as co-author. Initially, the concepts of 
radiation dose were critically evaluated. Following identification of sub-optimal techniques, steps 
were taken to improve the accuracy of dose measurement using thermoluminescent dosimeters, 
digital dosimeters and simulation through software. These techniques have been analysed critically 
and where appropriate improvements are recommended.  
Radiation dose, in particular the associated risk, is a challenging concept to convey to patients and 
care givers and simply providing a figure of dose does not convey the required information needed 
to allow consent to be given. Methods by which radiation dose and risk can be interpreted is 
critiqued with reference to published literature. The thesis concludes with a description of the 
intellectual contribution illustrating the role played as first author and as a co-author in the works 
included in the portfolio and a review of impact considering citation metrics and downloads. It was 
also decided to include citations from within the Diagnostic Imaging Research Programme and PhD 
theses from The University of Salford to demonstrate how research activities within the portfolio of 
published works have influenced other methodologies and outputs. 
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PREFACE 
This thesis is a critical review of a portfolio of eight papers that were accepted for publication 
between 2012 and 2017. The aim of this review is to demonstrate the work’s fulfilment of the 
requirements of doctoral degree presented by The Quality Assurance Agency (QAA, 2008).  
 
 The creation and interpretation of new knowledge, through original research or other 
advanced scholarship, of a quality to satisfy peer review, extend the forefront of the 
discipline, and merit publication 
 Systematic acquisition and understanding of a substantial body of knowledge which is at the 
forefront of an academic discipline or area of professional practice 
 The general ability to conceptualise, design and implement a project for the generation of 
new knowledge, applications or understanding at the forefront of the discipline, and to 
adjust the project design in the light of unforeseen problems 
 A detailed understanding of applicable techniques for research and advanced academic 
enquiry 
 
The work is structured in chapters discussing critically the aims of the work and a summary of the 
methods, findings and conclusions. A discussion of the author’s contribution to the papers and 
analysis of the published works’ impact is presented. The work concludes with a critical discussion 
on the advancement of knowledge, limitations and proposal for post-doctoral work.  
Due to copyright reasons the portfolio of published work presented in the appendices are versions 
that are available through the University Of Salford Institutional Repository (USIR) 
(https://usir.salford.ac.uk/) and versions that were accepted for publication.   
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1. INTRODUCTION 
The adoption of new technologies and/or methods of image acquisition are often driven from the 
desire to improve clinical care (Ladapo, Horwitz, Weinstein, Gazelle, & Cutler, 2009). Additional 
radiation dose can be justified with increased accuracy in diagnoses; for example double contrast 
barium enema examinations in the UK had a mean radiation dose of 2 mSv compared to a mean of 
12 mSv for CT colonography in the corresponding year (2008) (Hart, Wall, Hillier, & Shrimpton, 2010; 
Public Health England, 2011). The additional radiation dose can be justified due to the additional 
benefits the technique brings and the new higher radiation dose technique has been adopted into 
clinical practice (British Society of Gastrointestinal and Abdominal Radiology & The Royal College of 
Radiologists., 2014). As noted by Shrimpton, Hillier, Meeson, & Golding (2014) there has been an 
upward trend in the contribution CT brings to the UK annual per caput radiation dose while 
“conventional” radiographic techniques have declined partly due to the increase in the use of lower 
dose technology (for example digital radiography (DR)) and partly due to CT replacing imaging 
techniques for example radiographic projections of the lateral cervical spine, the chest and pelvis 
referred following major trauma being replaced by the trauma CT protocols (Royal College of 
Radiologists, 2015). On first glance this could be regarded as concerning but the benefits, such as 
increased accuracy in diagnoses through quicker acquisitions and sub-millimetre resolution, have 
been considered during the justification process. 
An essential part of any clinical practitioner involved in the imaging of patients using ionising 
radiation is the need to consider the radiation dose their patients receive. Of the average 2.7 mSv a 
UK citizen receives per year, 16% can be attributed to medical exposure (the second largest after 
exposure due to radon and thoron (Public Health England, 2016)). The detrimental effects of ionising 
radiation are well documented and include carcinogenesis, mutagenesis, teratogenesis and acute 
toxicity (Nations Scientific Committee on the Effects of Atomic Radiation, 2000). However, at 
diagnostic levels, the potential for developing cancer is the most significant factor that should be 
considered (Smith, 2011). That is to say, in diagnostic imaging, the aim of radiation protection of 
patients is to prevent deterministic effects and, as far as reasonably practicable, limit stochastic 
effects.  
The introduction of this review focuses on Paper 1 (Tootell, Vinjamuri, Elias, & Hogg, 2012). This 
paper questions the use of the non-emission data acquired as part of myocardial perfusion imaging 
using single photon emission computed tomography and computer tomography (SPECT-CT) hybrid 
imaging systems and highlights the additional radiation dose and therefore the increased risk the CT 
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acquisition brings. The need for accurate dose estimation or measurement to quantify risk will be 
considered.  
An issue that proved to be the catalyst for the research included in this portfolio of works follows a 
similar theme of new technology increasing radiation dose but bringing with it additional benefits. At 
the time of publication of Tootell et al., (2012) [Paper 1] it was apparent that hybrid imaging 
technology had brought numerous benefits to nuclear medicine imaging including the correction of 
emission data, localisation of areas of increased or decreased radiopharmaceutical uptake or 
characterisation of identified lesions or pathology. Observations at national nuclear medicine 
conferences and a review of published guidelines evidenced the increase adoption of the technology 
into common practice. Tootell et al., (2012) (Paper 1) discusses critically the use of the CT data 
acquired for attenuation correction of myocardial perfusion single photon emission computed 
tomography (SPECT) studies and made a number of observations. It is noted that; 
 the acquisition results in a radiation dose that was greater than the “standard” emission only 
imaging of myocardial uptake 
 axial CT images of the chest will include extracardiac anatomy and there is a possibility that 
pathology may be identified on these images 
 the image quality is low due to the lower tube current and higher slice thickness compared 
to diagnostic CT imaging of the chest and movement artefacts due to respiration. 
However, there is an ethical question regarding the review of data to check actively for extra cardiac 
pathology. The work fed into the research theme within the Diagnostic Imaging Research 
Programme at University of Salford and, although not directly cited, stimulated a number of projects 
that considered the prevalence of incidental findings and viewer’s ability to correctly identify these 
(Coward et al., 2014, 2015; Thompson, Hogg, Manning, Szczepura, & Chakraborty, 2014). As 
reported in Tootell et al., (2012) [Paper 1] the quality of CT data is significantly affected by the 
acquisition parameters used which also impact on the radiation dose the patient receives as part of 
the acquisition. Many manufacturers promoted the “low-dose” acquisitions of their hybrid systems 
and quoted effective dose figures that were inarguably lower than diagnostic CT acquisitions of the 
equivalent area and were quick to demonstrate the additional benefits the acquisitions brought. 
Literature soon agreed that the ability to fuse emission and transmission data on the same piece of 
equipment was beneficial in aiding definitive diagnoses (Delbeke, Schöder, Martin, & Wahl, 2009). 
There was little independent research undertaken to evaluate additional radiation dose and 
subsequent risk that these acquisitions brought. 
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Work arising from the Diagnostic imaging Research Programme after the publication of Tootell et al., 
(2012) [Paper 1] showed that in a population of 1819 patients, 27.3% had a positive extracardiac 
findings on the CTAC dataset of which 2.8% were potentially clinically significant (Coward et al., 
2014). To date no consensus on the use of the CT attenuation correction data has been reached and, 
while citing the considerations of the moral and legislative obligation of the clinician discussed in 
Tootell et al., (2012) [Paper 1], Kauling, Post, Rensing, Schaap, & Verzijlbergen (2015) note that this 
topic remains incompletely discussed by the European Association of Nuclear Medicine and 
European Society of Cardiology guidelines (Flotats et al., 2011).  
To fully appreciate the two sides of risk and benefit in any decision, those involved in the referral 
process should have adequate information to consider the risk the exposure would bring. The work 
undertaken in the portfolio of published works as lead author considers the effective dose and 
subsequent risk the additional CT or conventional X-ray imaging brings. The methods developed in 
this work were applied to research where contributions were made as a co-author in other contexts 
to evaluate changes in protocol to include new imaging techniques or technology.  For example, in 
the two co-authored papers (Thompson et al., 2015, and Thompson et al., 2016) [Paper 6, Paper 7], 
the techniques were used to measure the organ dose and calculate effective dose in CT acquisitions 
of the chest and used in the optimisation process comparing filtered-back and iterative 
reconstructions. 
The methods developed and data generated has the potential to aid referrers, practitioners and 
operators in the decisions of referral, justification and optimisation. The Ionising Radiation (Medical 
Exposure) Regulations 2017 (2018) originates from Council Directive 2013/59/EURATOM (2013) and 
came into force in the UK in February 2018. It is stated that there is a requirement to strengthen the 
information provided to patients on the radiation doses and risks from medical procedures. This 
information should be presented in a manner that is understandable to patients and should allow 
them to make informed decisions when giving consent to proceed with radiological imaging 
investigations. This review will consider the recognised limitations with effective dose in translating 
absorbed organ doses to data that can be understood by referrers and patients and alternative 
methods, such as calculation of effective risk as proposed by Brenner (2009, 2011, 2012) are utilised 
in this portfolio of published works (Tootell, McEntee, Szczepura, & Hogg, 2016; Tootell, Szczepura, 
& Hogg, 2014b, 2017). This approach is novel when compared to published literature and goes 
beyond the normal approach of reporting of dose by applying organ dose data to specific patient 
types. 
4 
 
There are a number of methods by which radiation dose can be measured, calculated or estimated 
and are described and discussed in detail in (Tootell, Szczepura, & Hogg, 2014a) [Paper 2]. For 
example, measurement using thermoluminescent dosimeters (TLDs), metal-oxide semiconductor 
field effect transistors (MOSFET), calculation using data supplied by the imaging equipment (dose 
length product [DLP], CT dose indices [CTDIvol CTDI100] or dose area product [DAP]) or estimation 
through simulation using Monte Carlo modelling. 
Papers 2-7 describe the genesis of the project focussing on the development and applications 
thermoluminescent dosimeters as a means of radiation dosimetry. In this thesis, the methods 
developed will be analysed critically and where applicable improvements will be identified and 
evaluated against the current body of knowledge.  Tootell et al., (2017) [Paper 8] has been included 
as a closing paper to illustrate how the research described within the thesis will develop in the 
future. TLDs or MOSFETS are effective in direct dose measurements in phantom studies. However, in 
the clinical studies or in patient dose monitoring, direct dose measurement is challenging due to the 
different patient sizes and body habitussen. The pilot work in Tootell et al., (2017) [Paper 8] 
demonstrates the start of the development of a method to make dose estimation or simulation 
more accurate by accounting for differing patient habitussen. Incorporating corrections to dose 
estimates based on specific patient types has the potential to allow more accurate dosimetry audits 
to be performed and allow for less generic diagnostic reference level to be developed.   
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2. REVIEW OF DEVELOPED METHODS AND ANALYSIS OF 
THE DATA 
The following section will analyse critically the portfolio of published works in the context of 
published literature in the field. It is recognised that over the timeline of publications (see Figure 6 
Gantt Chart showing research and writing activities page 47) research and technology has 
progressed but the following chapters aim to reflect the state of literature at the time of writing and 
to consider recent developments.  
As considered in the introduction and in Tootell et al., (2012) [Paper 1], the exposure parameters 
used to acquire CT data affects the quality of the image. CT acquisitions for attention correction are 
produced using imaging parameters that are much lower than those used in diagnostic CT 
examinations of the chest (Tootell, Vinjamuri, et al., 2012), yet these are adequate for the purposes 
for which they are acquired. At the time of writing, four main hybrid systems were in clinical use, 
two used “low-dose” fixed output CT components, one a full diagnostic capable CT component and 
one that sat between the two. It was noted that the parameters used in CT attenuation correction 
acquisitions were different yet were used for the same purpose, to correct emission data. Work was 
undertaken to compare the effective dose and effective risk from these acquisitions and compared 
to the effective dose and risk arising from the administration of radiopharmaceuticals only.   
The development of this and subsequent publications in the assessment of patient dose from a 
number of scenarios using “conventional” radiographic imaging and CT, was preceded by the 
development of accurate, efficient methods for data collection and methods by which the data can 
be analysed to present meaningful findings and information to health professionals and potentially 
patients. 
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2.1 ACQUIRING DOSE DATA 
Radiation dose assessment can be carried out in a number of ways; through direct measurement, 
estimation through modelling or calculation. Tootell et al., (2014a) [Paper 2], discusses in detail the 
definitions of radiation dose and how quantities can be established through the use of analogue or 
digital dosimeters, calculation or simulation using software. Prior to any comparison between 
measured and estimated radiation dose, it is essential that the accuracy of any measurement is 
assured.  
Tootell et al., (2014a) [Paper 2], has had a significant impact in the teaching and learning activities 
associated with dosimetry and dose monitoring of patients i.e. Research Informed Teaching Project 
Experience (RiTE) in years 1 & 2 and Level 6 Dissertation Module. The paper is a core text within the 
undergraduate diagnostic radiography programme and provides a single reference point to enable 
students to develop an understanding of the concepts of radiation dose, its measurement and how 
the results can be interpreted and used to calculate the risks from exposures.  
Within the RiTE 1 and 2 projects, students investigate the effect of changing kilovoltage (kV) and 
milliampere-seconds (mAs) have on image quality and patient dose. The paper is used to facilitate 
their understanding of the concept of dose and how the different metrics (for example dose area 
product (DAP) and entrance surface dose (ESD)) and units (for example mGy and mSv) can be used 
to report dosimetry data. When combined with image quality measurements it has facilitated the 
understanding of dose optimisation (Higgins, Hogg, & Robinson, 2013, 2017; Higgins R.N, n.d.). 
Comments from students in module evaluations and reported in Higgins, Hogg, & Robinson, (2013, 
2017) demonstrate that they feel they have an understanding of radiation dose and image quality 
optimisation. They feel the knowledge they have acquired has influenced their clinical practice by 
encouraging them to be critical of their selection and manipulation of imaging parameters  
2.1.1 DIRECT DOSE MEASUREMENT 
There are many options available when a direct measurement of radiation dose is to be performed. 
Analogue or digital dosimeters such as thermoluminescent dosimeters (TLD) or metal-oxide 
semiconductor field effect transistors (MOSFET) offer advantages and disadvantages and, again, are 
discussed in Tootell et al., (2014a) [Paper 2]. Radiation dose measurements on live patients were not 
performed within this portfolio of published works due to ethical considerations and it was also felt 
that there was a need to establish a robust, valid and reproducible method for data collection before 
clinical colleagues and patients were included. Instead, phantoms were used in the collection of 
radiation dose data. While some argue this limits the external validity of research, it is a widely 
accepted and recognised approach to radiation dose assessment in radiological imaging (White, 
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1978).  The advantage of phantom based studies is that “patient” size was controlled and it allowed 
the direct measurement of organ doses to be performed which is all but impossible in real patients. 
The dosimeters were placed inside the phantom in specific locations corresponding to those listed in 
the International Commission on Radiological Protection’s publication number 103 (ICRP, 2007).  
As discussed above and in Tootell et al., (2014a) (Paper 2) researchers conducting direct radiation 
dose measurement have a choice between analogue (for example TLD) and digital (for example 
MOSFET) dosimeters.  Both measuring devices have advantages and disadvantages and bring with 
them their own challenges when ensuring accurate data are acquired. Whichever device is used to 
obtain accurate organ dose data, it is critical that it should provide accurate and reproducible data. 
As part of this portfolio of works, radiation dose measurement was performed using TLDs (TLD-100 
and TLD-100H) or digital dosimeters MOSFET. The following sub-sections provide a discussion on the 
features of the measuring devices, and the development and considerations made in order to 
produce quality data.  
 
ANALOGUE DOSIMETERS 
TLDs have a long established pedigree in the measurement of radiation dose in diagnostic 
radiography. The similar density to tissue, negligible amount of fading (i.e. loss of information from 
the TLD over time) and the high reproducibility in radiation dose measurement make the material 
ideal  in measuring the quantity of absorbed radiation in biological tissue (Del Sol Fernández et al., 
2016). All but one of the empirical papers use TLDs to directly measure radiation dose (Tootell et al., 
2013, Tootell et al., 2014b, Thompson et al., 2016, 2015, Tootell et al., 2017) [Paper 3, Paper 4, 
Paper 5,Paper 6 and Paper 7]. Paper 3 and Paper 4 use Lithium Fluoride doped with Magnesium and 
Titanium (LiF, Mg, Ti) and are referred to as TLD-100. This type of TLD have a measurement range of 
10 µGy to 1 Gy. Another type of TLD material is used in Paper 5, Paper 6 and Paper 7 are Lithium 
Fluoride doped with Copper and Phosphorus (LiF, Cu, P) and are referred to as TLD-100H. TLD-100H 
have a measurement range of 1 µGy to 10 Gy (ThermoFisher Scientific, n.d.).  TLD-100H have a 
negligible fade over 3 months where TLD-100 have a fade of less than 20% over 3 months. In the 
context of the work in the portfolio of publications fading is not a concern as TLDs were read within 
24 hours of exposure. 
Using TLD-100H in place of TLD-100 addresses the concern of device sensitivity, with the TLD-100H 
offering greatly increased sensitivity with figures of 15-20 times the sensitivity compared to TLD-100 
(Del Sol Fernández et al., 2016). The change to the more sensitive type of TLD material was made in 
recognition of the small levels of radiation dose being measured; in many cases in the dose 
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measurements in Tootell et al., (2014b) [Paper 4] were at the lower end and below of the sensitivity 
of TLD-100. In terms of the data collected in Tootell et al., (2014b) [Paper 4], the reliability of the 
data could be questioned, however as demonstrated by da Rosa, Regulla, & Fill, (1999), through 
careful annealing, the pre-heating of the TLD before reading the accuracy of lower radiation doses is 
possible. It was found that these additional steps did increase the time needed to read the TLDs.    
The change to TLD-100H meant that radiation dose below 10 µGy could be measured accurately. 
However, the increased sensitivity meant that there was increased potential for contamination by 
background radiation. When making measurements of small levels of radiation, the background 
levels recorded by the dosimeters had the potential to be a significant factor in any radiation dose 
readings. This was of particular concern when the phantom was transported to a nuclear medicine 
department for the collection of data in Tootell et al., (2016) [Paper 7]. In this environment it is 
possible that the phantom would be in close enough proximity to unsealed sources and patients 
attending for examinations using radiopharmaceuticals that they may be influential on the dose 
measurements made with the TLD-100H. Care was taken to ensure that a selection of TLDs remained 
with the phantom at all times (expect during data acquisition) to ensure radiation dose levels were 
representative of the imaging and not from environmental sources. In other words, this would allow 
either a correction of the data, accounting for background radiation, or rule out any influence of the 
radioactive sources. 
On reflection there is a risk that this background correction could over correct the readings from 
TLDs within the phantom. TLDs within the phantom are surrounded by attenuating material at 
various thicknesses, for example a TLD in the centre would record less background radiation dose 
than a TLD near the outside of the phantom and both would receive less than a TLD used for 
background correction purposes as these would not have any attenuating material surrounding 
them. On analysis it was decided that this source of error is negligible for a number of reasons; the 
time spent in the nuclear medicine departments is short (maximum of 1 hour) but more importantly 
the phantom and TLDs remained no longer than required in a supervised or controlled area 
therefore the dose rate was below the 7.5 µGy/h level specified for Controlled Areas (The Ionising 
Radiations Regulations, 2017). Care was taken to ensure the positioning and scanning of the 
phantom was performed efficiently to minimise the time taken to acquire the data. As will be 
discussed later in this chapter, other methods were developed and utilised to ensure the signal from 
the acquisition was significantly greater than any noise from background.  
A second factor that needed consideration was a characteristic of dosimetry using TLDs referred to 
as residual signal. Residual signal is defined as a carry-over of the TLDs exposure history into current 
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readings and TLD-100H are more susceptible to this characteristic than TLD-100 (~5% compared to 
1.5% for TLD-100H and TLD-100 respectively) (Freire, Calado, Cardoso, Santos, & Alves, 2008). 
Annealing of the TLDs is a method of preventing historical data from contaminating dosimetry data 
(Yifrah et al., 2014). To reduce error and the impact of residual energy an annealing phase was built 
into the TLD reader’s cycle. However this cycle is relatively short - 10 seconds at a temperature of 
240oC (Thermo Electron Corporation Radiation Measurement & Protection, 2002). Therefore to 
ensure that as much residual energy was released as reasonably practicable, prior to each use the 
TLDs were annealed using a temperature controlled annealing oven and tray. The TLDs were heated 
and held for 10 minutes at 240oC and then cooled rapidly. Incorporating this step into the method 
ensured that the TLDs were prepared consistently and all were free from stored energy that would 
contribute to the dosimetry data. It did increase the preparation time and the heating and rapid 
cooling of the TLDs has the potential to shorten the TLD’s useful life but given the reduction in 
residual energy and the low doses being measured it is a justifiable step.  
Noise is unavoidable in the measurement of radiation dose and arises from the TLD reader’s 
components, the TLD or background radiation. Noise arising from the TLD reader is unavoidable but 
is constant. By exposing the TLD to repeated exposures the radiation dose received by the TLD (and 
so the signal detected by the reader’s photomultiplier tube) will increase, overcoming the constant 
noise from the reader. For areas within and immediately close to the area of exposure the signal to 
noise ratio is large but where only scattered radiation is being measured it is small. building up a 
radiation dose on the TLD would improve the signal and reduce the effect of noise.  
A further time saving method was developed and used in Thompson et al., (2015a), Thompson et al., 
(2016) and Tootell et al., (2016) [Paper 5, Paper 6 and Paper 7]. Instead of replacing a set of TLDs 
after each exposure a “cumulative dose” approach was utilised. Following annealing and placement 
of the TLDs within the phantom, the phantom was exposed three times without removing and 
replacing the TLDs. The TLDs were read and the dose data calculated. This data was corrected for 
background and then the dose for each TLD divided by three (the number of exposures). A 
disadvantage of this method is the inability to identify random error or to calculate a standard 
deviation of the data. An approach that would use both methods i.e. repeated measures and 
cumulative approach, would give the most reliable data and would allow erroneous results to be 
identified and a standard deviation to be calculated. However, the time required to change TLDs 
between measurements is significant and, where research was carried out in the clinical 
department, was impracticable due to limited access to clinical equipment. Work by Mraity, (2015) 
based on the developed approach showed that there was no statistically significant difference in the 
10 
 
cumulative and repeated measure method. A practical advantage of this method process was an 
increase in efficiency and could be used by others when access to resources are an issue. 
An observation that was made early in the research was the time needed to complete a full 
dosimetry measurement using TLDs. The phantom used throughout this work was an ATOM 
dosimetry phantom model 701C adapted to the 701D configuration (CIRS Tissue simulation and 
Phantom Technology, Norfolk, Virginia). This phantom contains 268 locations where dosimeters can 
be located to measure radiation dose. These TLDs required reading using a Harshaw manual TLD 
reader (Thermo Fisher Scientific, Walton, Massachusetts) meaning a single full-phantom 
measurement required approximately six hours of reading time. When combined with repeated 
measures the time required for collation of radiation dose data from TLDs was significant, running 
into several days depending of the number of variables.  
To further improve the accuracy of the radiation dose measurements, an approach to reduce 
systematic errors arising from the TLDs was developed (Tootell, Lundie, Szczepura, & Hogg, 2012).  
The method involved grouping together TLDs of similar responses and performing calibrations on 
these. Manufacturer guidelines suggest a method of calibrating each individual TLD however this 
would be a very time-consuming exercise and would require an impracticable amount of effort to 
ensure the ordering of the TLDs remains unchanged during the repeated loading and unloading of 
the dosimetry phantom. By exposing all the TLDs to the same radiation dose, it was possible to rank 
and then group together TLDs of a similar response. The coefficient of variation (CV) defined as  
𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛
𝑀𝑒𝑎𝑛
∗ 100% 
for a set of 273 TLDs (268 for the phantom and 5 for background correction) was found to be 7.61%. 
By grouping TLDs of a similar response it was possible to reduce this to ~2%. The more groups, the 
smaller the CV could be. Given that the manufacturers quote values of around 7% as an acceptable 
variation it was decided that 2% was acceptable and 5 groups was a practicable compromise 
between efficiency and accuracy (Tootell, Lundie, et al., 2012). Each group was calibrated and a TLD 
from each set was used to measure background radiation levels.  
The above methods were used in all the empirical publications in this portfolio of works(J. D. 
Thompson et al., 2015; JD Thompson et al., 2016; Tootell et al., 2013, 2016, 2014b) [Paper 3, Paper 
4, Paper 5, Paper 6 and Paper 7] and has been included in PhD work and other research activities (Ali 
et al., 2017;  Ali, England, McEntee, & Hogg, 2015;  Ali, 2016; Mraity, 2015; Robinson, Ali, Tootell, & 
Hogg, 2017). 
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DIGITAL DOSIMETERS 
During the period of time that the portfolio of works was produced, digital dosimeters became 
available and the dosimetry work in Paper 8 made use of these instead of TLDs (Tootell et al., 2017). 
Initially these dosimeters were predominantly used in radiotherapy dosimetry which is characterised 
by higher doses but their use in diagnostic dosimetry has become more popular due to the instant 
readout of radiation dose data, non-destructive measurement and good linearity (Bower & 
Hintenlang, 1998; Koivisto, Wolff, Kiljunen, Schulze, & Kortesniemi, 2015). Their function is described 
in Tootell et al., (2014a) [Paper 2].  
It was predicted that the use of digital dosimeters (Metal Oxide Semiconductor Field Effect 
Transistor (MOSFET)) would increase the efficiency as the measurements could be carried out 
without having to physically remove the dosimeters to obtain radiation dose data. To some extent 
this was found to be true as the data collected in Tootell et al., (2017) [Paper 8] took significantly less 
time to collate compared to data collection using TLDs. However, during the development of the 
method a number of key lessons were learned with the use of MOSFET and from this a number of 
novel methods were developed to ensure that the data collected was as accurate as practicable. 
Since the publication of this paper it has been recognised that further steps can and should be taken 
to improve the accuracy of the data. The following paragraphs will discuss critically the approaches 
developed and further steps that could be taken should dosimetry using MOSFET dosimeters be 
performed. 
Dosimetry data using the ATOM dosimetry phantom requires the measurement of radiation dose in 
268 locations (CIRS Tissue Simulation and Phantom Technology, 2012). Resources dictated that 20 
MOSFET dosimeters were available (4 readers with 5 dosimeters each). A choice existed between 
distributing the 20 across the 268 locations or repeating acquisitions and repositioning the 
dosimeters between each repeat so all locations had associated data. The latter approach was 
chosen to comply with the phantom manufacturer’s guidance on radiation dose measurement as 
the locations had been optimised to allow accurate representation of the radiation dose distribution 
to and within the organs. A disadvantage of this method was the need to move the dosimeters to 
acquire data for each location. As can be seen in Figure 1 taken from Tootell et al., (2017) [Paper 8], 
this process required each scan to be repeated 14 times using 20 dosimeters.  
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FIGURE 1 PROCESS FOLLOWED IN TOOTELL ET AL., (2017) [PAPER 8] TO ACQUIRE ABSORBED ORGAN DOSE. 
The challenge was to ensure the same anatomical region was imaged each time, to guarantee the 
data was consistent. This required special considerations since this study was concerned with 
automatic tube modulation in CT acquisitions, so a slight change in position could be influential on 
the output of the x-ray tube. The method developed as part of Paper 4 (Tootell et al., 2014b) was 
utilised here where small radiopaque markers were attached to the phantom to correspond with the 
superior and inferior location of the scan range. The median-sagittal plane and mid-axillary line of 
the phantom were marked in permanent marker to ensure that accurate and reproducible 
positioning using the CT scanners laser lights was possible. From the result of the development work 
involved in the development of this portfolio of works, the use of indelible and radiopaque markers 
has been employed by researchers in their empirical work and by PhD students undertaking 
dosimetry and image quality research (Ali et al., 2017, 2015; Ali, 2016; Mraity, 2015; Robinson et al., 
2017).  
During the acquisitions it was noted that the results demonstrated variation especially in low dose 
regions, i.e. regions where scattered radiation was being measured (below 1.5mGy). There were 
occasions when a number of additional repeats were necessary due to the apparent randomness of 
Scan plan radiograph 
performed 
Phantom positioned 
for CT abdomen
MOSFETS readied
MOSFETs read
Scan repeated
(3 in total)CT performed. 
Phantom positioned 
for CT pelvis
Phantom positioned 
for CT chest
Dosimeters located into phantom
(locations 1-20, 21-40… 269)
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the readings. Reflecting on this finding it was felt that this statistical error could be addressed better 
than simply repeating until the results were consistent.   
Reviewing literature in this area found that the statistical error using MOSFET dosimeters in low 
dose research is an issue that has been encountered. Koivisto et al., (2015) in research characterising 
MOSFET dosimeters for low-radiation dose measurements in maxillofacial anthropomorphic 
phantoms demonstrated that despite the statistical error at low dose, repeating MOSFET exposures 
eight times results in a confidence level of 95% in the MOSFET data. This research was carried out at 
energies of 80kV and used the less sensitive TLD-100 as the “standard” which differs from the energy 
and TLD type used in Paper 8  of 120kV and the more sensitive TLD-100H (Tootell et al., 2017). 
Increasing the number of repeats will decrease the uncertainty and the method by Koivisto et al., 
(2015) should be utilised. However direct dose measurements in patients would be subject to this 
statistical uncertainty and unavoidable as multiple repeats would be unethical.  
Research undertaken in the portfolio of works was undertaken using dosimetry phantoms but post-
doctoral research could involve the measurement of radiation doses to patients and/or operators. 
Ethical reasons would prevent any number of repeated measures being taken using patients so there 
would be significant lack of evidence on the accuracy of the results and this would need 
consideration should any data collection be undertaken using patients. In the context of the 
publication with data acquired using MOSFETS, acquisitions were taken three times and where 
readings were identified as different, a further repeat performed. On reflection, considering the 
work undertaken in this portfolio of works and data from published literature, the method described 
earlier where the cumulative dose approach could have been used to overcome the low-dose (less 
than 0.3 mGy (Koivisto et al., 2015)) statistical error. This could be further combined with repeated 
measures as this would be much easier to perform using MOSFET dosimeters compared to TLDs in 
that the MOSFETs do not need to be removed from the phantom to be read.  
The above demonstrates how the method for radiation dosimetry was developed using published 
literature, manufacturers’ documentation and evolution through simple trial and error. The above 
development fed directly into work undertaken as part of this portfolio of works and other research 
projects at undergraduate, postgraduate and doctoral levels ensuring results were as accurate and 
reproducible as practicable. This review has highlighted where additional steps could be taken to 
improve further measured dosimetry data.  
In summary, to be critical of the empirical works in the portfolio of works that use TLDs and 
MOSFETS, it is recommended that results should propagate any errors and display these in any 
results in the way they were shown in Tootell et al., (2017) [Paper 8]. Despite the inability to 
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calculate standard deviations as repeated measures were not used, each batch of TLDs had an 
associated error of approximately 2%. This error was not propagated through the calculations for 
organ or effective dose or carried through into the effective risk calculations. It could be argued that 
performing this action could have permitted deeper statistical comparisons between the variables.  
This is an issue with many published dosimetry papers despite the ease in which systematic errors 
can be identified. A search of literature demonstrates that error propagation is not well represented 
in diagnostic dosimetry research and the vast majority of papers quote, absorbed, equivalent and 
effective doses without reference to errors arising from the measuring tool. The same can be said 
for work where doses have been simulated with software. Software such as PXCMC (STUK, 2012) 
provide a value for the error in its calculations of organ and effective dose yet published literature 
does not quote this value on a regular enough basis. 
2.1.2 MODELLING RADIATION DOSE 
Direct dose measurement was used extensively in this portfolio of work despite the noted 
disadvantages of the time needed to acquire the data and the fixed characteristics of the dosimetry 
phantoms used. In clinical practice direct dose measurement for patients is challenging with the 
inability to directly measure organ dose, the ethical reasons preventing repeated measures and the 
retrospective nature of the data cited (Tootell et al., 2014a, Wall et al., 2011 and Groves et al., 
2004). Dose reporting using metrics such as Dose Length Product (DLP), CT Dose Index (CTDIVol) or 
dose area product are adequate in intra-modality dose assessments but as noted in Tootell et al., 
(2014a) [Paper 2], this is not patient dose per se, just a measurement of the radiation quantity 
leaving the x-ray tube. Inferences can be made as to patient dose but to compare radiation dose 
across modalities the figured need to be converted to effective dose.  
Dose modelling through simulation or through calculation using exposure parameters and 
conversion factors is a quicker method and is the most frequently used method in clinical practice. In 
the time during and since publication there has been a move towards automation of dose 
assessment using Digital Imaging and Communications in Medicine (DICOM) systems due to the 
increased accuracy of the data (Boos, Meineke, Bethge, Antoch, & Kröpil, 2016; Noumeir, 2005). 
NICE, (2017) in their report on radiation dose monitoring software for medical imaging with ionising 
radiation, quote figures of up to £20 000 per year which may make the purchase and upkeep of such 
software uneconomical when compared to manual methods. It is recognised that these systems are 
now becoming more popular in practice but until they are widely available the manual recording of 
data is required. Tootell et al., (2014a) [Paper 8]aimed to compare the accuracy of these approaches 
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to the measured organ and subsequent effective dose calculations for CT examinations of the chest, 
abdomen and pelvis.  
The two methods of dose estimation considered; 1) the use of software (specifically ImPACT 
CTDosimetry v1.0.4 (ImPACT, 2011)) or 2) DLP to effective dose conversion factors in CT 
examinations of the chest, abdomen and pelvis. Literature reports underestimation of CT doses 
using computer simulation with magnitudes of 18- 40% (Groves et al., 2004). Conversely though, the 
results of Tootell et al., (2017) [Paper 8] demonstrated an overestimation of effective dose when 
compared to calculated effective dose from directly measured organ doses using TLDs or MOSFETS.  
At the outset, it was anticipated that the work comparing estimated and calculated effective dose 
would have been a relatively simple task. However, the initial results demonstrated that there was 
significant disagreement (an range of of 50.3%, 2%-101%). In response, work was undertaken to 
identify where the differences could originate from. A number of key findings were noted and are 
discussed in detail in Tootell et al., (2017). In summary the following was noted, ImPACT 
CTDosimetry v1.0.4 (ImPACT, 2011) has only one single size virtual phantom available and an 
incompatibility with automatic tube modulation. The software’s guidance documentation 
recommends that the same scan range is used when estimating the dose from a clinical examination, 
for example for a CT of the chest the apices to below the diaphragm should be set (ImPACT, 2011). 
This may differ from the measured scan range used due to the different lengths/height of the 
patient. In Tootell et al., (2017) a novel approach of scaling the dosimetry phantom to match the 
taller software’s phantom was developed. This allowed for the same scan range to be set. This 
approach has not been used in published literature and is simple enough to be employed in clinical 
practice to accurately replicate the clinical scan in the software simulation. The distance between 
two anatomical landmarks in the patient can be measured from the scan plan radiograph and scaled 
to allow a scan range to inputted into the software rather than manually selecting a scan range.  
The inability to account for automatic tube current modulation was addressed by comparing three 
methods of inputting an mA value into the software. An average mA, and effective mA were used as 
single values and a third method involving the calculation of the effective dose per CT slice and the 
calculating the sum of these. This was done through the creation of a macro-programme in the Excel 
file of the ImPACT CTDosimetry software. It was found that using average mA or the mA modulated 
data brought the effective dose closer in agreement yet over estimation was still an issue (27-53% 
over estimation). Work by Castellano, (2010) demonstrated that effective dose is affected by the 
mass of the patient with effective dose lower in larger patients for the same imaging parameters. 
Using the provided ratios for scaling effective dose and the method described in Tootell et al., (2017) 
16 
 
[Paper 8] it was shown that effective dose could be brought into close agreement for CT of the chest 
and abdomen, yet over estimation persisted for CT of the pelvis. The same improvement was noted 
when the mass correction was applied to the conversion of dose length product to effective dose 
using published conversion factors.  
A method that is not, and arguably should have been investigated in this research area was the use 
of size-specific-dose estimation (SSDE) (AAPM Task Group 204, 2011). This method was proposed 
due to the inability of CTDIvol to reflect patient size as it is a measurement of tube output and not 
patient dose (Tootell et al., 2014a [Paper 2], (Brink & Morin, 2012). This method uses the 
combination of the anterior-posterior (AP) and the lateral (Lat) dimensions.  These values are used 
to estimate the patient size by using either, the AP  or Lat dimension only, 𝐴𝑃 + 𝐿𝑎𝑡 or the effective 
diameter √𝐴𝑃. 𝐿𝑎𝑡  (i.e. the diameter of the circle whose area is the same as that of the patient 
cross section). This figure is then used to multiply the CTDIvol to provide the size specific dose 
estimate.  
SSDE is able to provide users with an indication of dose to patients giving due consideration to their 
size. It should not however be used in further calculations to estimate effective dose using the DLP 
to effective dose calculations. It does not correct for differences in the organ dose distribution and 
so the resulting figure is for comparative purposes only and would demonstrate that an increasing 
patient size reflects an increased CTDIvol. Therefore the unit is regarded as a dose estimate not a 
calculation (AAPM Task Group 204, 2011). Its use is limited to CT examinations only and so should 
comparisons between modalities be required, the use of the DLP to effective dose or the use of 
software remains. The work in Tootell et al., (2017) [Paper 8] has the potential to allow the 
calculation of effective dose that reflects the patients size, thus allowing inter-modality comparison 
of radiation dose. As described in (Tootell et al., 2014a) [Paper 2], figures such as DAP, DLP or CTDI 
are not patient dose per se, and so when trying to compare imaging with CT to X-ray imaging this 
method of accurately calculating effective dose will allow comparisons to be made.  
It is recognised that further work is required as a number of findings were made and require further 
exploration. This work is planned as post-doctoral research and will focus on expanding the work 
undertaken in Tootell et al., (2017) [Paper 8] by considering other CT scanners and the still evident 
discrepancy in the effective dose estimated and calculated in the pelvis. Patient mass alone is the 
only one of a number of features that could affect the accuracy of dose estimates. Work by Boos et 
al., (2015), considered accounting for body mass Index (BMI) in radiation dose assessment in CT 
examinations of the abdomen. BMI does not provide an estimate for the percentage of body fat 
compared to muscle, patients of a muscular build have an incorrectly elevated BMI due to the higher 
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density of muscle over fat. Other metrics, for example the body adiposity index, waist circumference 
measurement or waist to hip ratio provide an indication of habitus and have the potential to be 
applied to dose estimations to allow a specific dose estimation for a patient type to be made. This 
data could be used to create diagnostic reference levels that are more reflective of patient type or 
build.  
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2.2 THE DOSIMETRY PHANTOM 
Measurement of radiation dose was carried out using dosimetry phantoms due to the ethical issues 
in using patients or volunteers and it offered an element of control of the “patient” size. As will be 
discussed later, there are methods of assessing radiation dose on “real patients” using calculation 
and this approach does offer increased external validity. A disadvantage of using physical phantoms 
is the inability to alter these to reflect different medical conditions or anatomy thus limiting the size 
of population available to conduct research (Xu & Eckerman, 2010). A range of dosimetry phantoms 
are available (Figure 2) but resources dictated that in this portfolio of works only the adult male was 
available (the neonate and one-year phantom were available but research in this portfolio of works 
focussed on adult dosimetry). Radiation dose measurements and the calculation of effective risk 
wasperformed using the adult male phantom only and as can be seen in Figure 2, this phantom is 
larger than the adult female phantom. This limitation is noted in the published works.  
 
 
FIGURE 2 THE CIRS ATOM DOSIMETRY PHANTOM FAMILY MODELS 701-706 (CIRS, NORFOLK, VIRGINIA) 
 
As described throughout the portfolio of published works, the effective dose is calculated following 
the measurement of absorbed radiation dose of organs within the phantom. This is done by 
measuring specific locations in the organs, averaging these to provide a tissue or organ dose, 
converting absorbed dose to equivalent dose and then multiplying the data by the tissue weighting 
factors listed in ICRP report 103 before summing the weighted doses (ICRP, 2007). During planning 
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and pilot work it was discovered that there was a mismatch in the locations and the phantom’s 
specification and the organs that required dose data to be collected; i.e. the sum of the weighting 
factors in the phantom data did not add up to unity as anatomical areas and/or structures were 
identified that did not have corresponding locations for measurement. For example, bone surface, 
skin and salivary glands and within the remainder category of organs/tissues, the extrathoracic 
region, lymphatic notes, muscle, oral mucosa and uterus/cervix (ICRP, 2007). While the 
recommended method for calculating the equivalent dose for the remainder organs and tissues is to 
calculate the average dose between the fourteen tissues regardless of how many have data 
associated with them, it was felt that there was an opportunity to improve the accuracy of the data 
by examining closely the locations that were already in use within the phantom and reapplying the 
data to correspond to the required locations.  Locations in the anterior aspect of the vertebral body 
of C2 and the upper oesophagus were used to calculate extra thoracic tissue dose, locations in the 
left and right lingula of the mandible and to the left and right of the sublingual fossa were used to 
calculate salivary gland organ dose and locations in the left and right lingula of the mandible were 
used to calculate oral mucosa organ dose. Skin, muscle and lymph nodes were excluded as it was 
decided that in the context of this portfolio of work, only a small proportion of the tissue’s total 
mass was included in the primary field of view and so the total organ/tissue dose would be 
negligible. This method allowed for more organs/tissues to be included in effective dose calculations 
meaning that more of the tissues are sampled providing an improved value of the effective dose. 
The effect of including and excluding dosimetry data of the salivary glands, extrathoracic tissue and 
oral mucosa in data taken from Tootell et al., (2017) [Paper 8] (CT examinations of the chest, 
abdomen and pelvis) are shown in Table 1. 
 
 
Remainder organ dose (mSv) effective dose (mSv) 
Anatomical region Including Excluding Including Excluding 
Chest 8.64 6.41 12.07 11.78 
Abdomen 9.17 9.14 8.44 8.43 
Pelvis 3.21 3.20 4.57 4.57 
TABLE 1 COMPARISON OF REMAINDER ORGAN AND EFFECTIVE DOSE WHEN SALIVARY GLANDS, EXTRATHORACIC AND 
ORAL MUCOSA DOSE WERE INCLUDED AND EXCLUDED. 
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Interestingly, this comparison shows that when analysed using a t-test, the inclusion or exclusion of 
these data was not statistically significant in both the remainder organ dose and effective dose 
calculations (p>0.1). Therefore it could be concluded that this extra data is not required. However, 
from the above data, it is observed that the impact on the CT chest data is greater than the effect on 
the CT abdomen which in turn is greater than the data for the CT pelvis. If the location of the 
excluded tissue is considered it can be seen that they are close to the field of view in the chest and 
become progressively further away from the scan region. The effect of the exclusion of these organs 
is greater the closer they are to region exposed. For this reason the organs were included in dose 
calculations in this portfolio of work (Thompson et al., 2015, 2016, Tootell et al., 2016, 2014b, 2017). 
This method has been used extensively in other research undertaken in dosimetry in the Diagnostic 
Imaging Research programme (Ali et al., 2017, 2015; Ali, 2016; Mraity, 2015; Robinson et al., 2017). 
As stated earlier and in Tootell et al., (2014b, 2016, 2017) [Paper 4, Paper 7 and Paper 8]. The 
absence of additional breast tissue that would be present in the female phantom would affect the 
measured dose for that organ. However, as will be discussed, effective dose calculations do not 
account for male and female breast tissue only the reproductive organs (testes and ovaries) and 
gender specific organs in the remainder tissues (prostate gland and uterus/cervix). To account for 
the different locations of the reproductive organs the location of ovaries was established by 
reviewing cross sectional anatomy texts and locating the equivalent location in the adult male 
phantom.  This is an approach that has been used successfully in publications generated from 
completed and ongoing PhD and other research activities within the Diagnostic Imaging Research 
Programme (DIRP) (Ali et al., 2017, 2015; Ali, 2016; Mraity, 2015; Robinson et al., 2017).  
Research was undertaken to establish a process to allow the number of TLDs to be reduced without 
compromising on the accuracy of the dosimetry data. A full detailed description and analysis of this 
can be found in (Tootell et al., 2013) [Paper 3]. In summary this paper developed a method where 
TLDs could be sited in locations where they would receive a measurable quantity of radiation. This 
paper was inspired by methodologies from dental radiography dosimetry where organs and tissue a 
distance from the exposed area were not included in measurements due to the negligible quantity of 
radiation they would receive. These areas were identified as regions where the dose readings were 
below the 50 µGy limit of the TLDs (Table 1 and Figure 3). On reflection this approach was effective 
and reduced the required number of TLDs by 82 (268 to 186) saving around 2 hours of reading time 
per dataset using the manual TLD reader. On further reflection there are limitations in this method. 
The main one is the way the dose to the phantom’s slice was measured. The TLDs were placed in a 
central column and exposed. Due to attenuation by the surrounding material the central TLD would 
record less radiation dose than one that situated at the periphery of the phantom therefore there is 
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the potential for locations to be excluded when a radiation dose of greater than 50 µGy would have 
been recorded.  
Slice number Mean Dose (mGy) 
2 0.00 
3 0.00 
4 0.00 
5 0.02 
6 0.00 
7 0.01 
8 0.00 
9 0.02 
10 0.03 
11 0.07 
12 0.20 
13 0.32 
14 0.67 
15 1.34 
16 1.88 
17 2.57 
18 8.66 
19 9.83 
20 10.01 
21 8.11 
22 3.68 
23 2.10 
24 1.44 
25 0.68 
26 0.51 
27 0.37 
28 0.10 
29 0.02 
30 0.00 
31 0.00 
32 0.07 
33 0.05 
34 0.00 
35 0.01 
36 0.01 
37 0.02 
38 0.02 
39 0.01 
TABLE 2 RECORDED DOSE FROM A SIMULATED CT ATTENUATION CORRECTION ACQUISITION OF EACH SLICE SHOWING 
WHERE LEVELS WERE ABOVE (GREY SHADED) AND BELOW THE 0.05 MGY THRESHOLD. 
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FIGURE 3 CHANGE IN ABSORBED DOSE ALONG A CENTRAL COLUMN OF TLDS IN THE DOSIMETRY PHANTOM. THE 
DECISION TO EXCLUDE ABOVE SLICE 10 AND BELOW SLICE 28 WAS ARBITRARY. 
An alternative approach would have been to place the TLDs in an arrangement illustrated in Figure 4. 
Measuring radiation dose at the periphery could have expanded the range over which TLDs should 
have been placed.  
 
 
 
Anterior 
Posterior 
Rt Lateral Lt Lateral 
FIGURE 4 SUGGESTED PLACEMENT OF TLDS TO ASSESS THE RANGE OF PHANTOM SLICES WHERE 
DOSIMETRY DATA SHOULD BE ACQUIRED 
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Despite the acknowledged limitations and suggested improvements, the paper did prove that, in the 
context of myocardial perfusion imaging at least, a reduced number of TLDs gives a comparable 
effective dose readings at only 1.75% lower than if the full set was used. In this paper a number of 
organs demonstrated a 100% reduction in dose (brain, prostate and testes) yet the impact on the 
final calculation of effective dose was small due to the small weighting factor that is applied to the 
organ dose. A 61.4% reduction was noted in the organ dose for the colon due to the exclusion of 
TLDs located in the caecum, distal ascending and descending colon and the sigmoid colon. This 
reduction was calculated by calculating the mean dose for all TLD locations, including those at an 
assumed level of 0. This underestimates the organ dose and arguably a better approach would have 
been to take the mean of the areas that were measured.  
Revisiting the data and comparing the calculated organ dose to the colon using the two above 
options is illustrated in Table 3. The following data is part of the full dataset from Tootell et al., 
(2013) [Paper 3]. The calculated organ dose using all locations in the phantom is 0.191mGy. 
Exclusion of readings below 50 µGy and assuming a dose of 0 results in an organ dose of 0.074 mGy 
compared to 0.171 mGy if the average of the measured areas is calculated. It is advisable that the 
whole of the organs with the highest weighting factors (i.e. breast, colon, lungs and stomach) should 
be included in any measurement. However, as an alternative approach, a mean of the TLDs can be 
taken and excluded areas should not be assumed as zero dose. 
 
 
Measured TLD dose (mGy)  
 
(n=10) 
Exclusion of TLD below 50 µGy 
*assumed zero dose (n=10) 
Exclusion of TLD below 50 µGy  
(n=6) 
0.112 0.112 0.112 
0.112 0.112 0.112 
0.117 0.117 0.117 
0.168 0.168 0.168 
0.113 0.113 0.113 
0.074 0.074 0.074 
0.048 *0.000 - 
0.033 *0.000 - 
0.000 *0.000 - 
0.013 *0.000 - 
MEAN       = 0.191 =0.074 =0.171 
% difference 61.4% 10.5% 
TABLE 3 COMPARISON OF METHODS IN CALCULATING ORGAN DOSE IN THE COLON. 
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This method used in the data collection of Paper 4 (Tootell et al., 2014b) for a number of mainly 
logistical reasons. Firstly, the data collection took place in clinical departments where access to the 
imaging equipment was time restricted. Secondly, the method used a repeated measure design 
whereby the TLDs were removed and replaced after each repeat and, as noted, this is a very time-
consuming process and by reducing the number of TLDs required increased the efficiency of the 
process.  
Further dosimetry studies that were conducted involved a larger CT scan range than that used in CT 
attenuation correction of myocardial perfusion SPECT data.  Paper 5, Paper 6, and Paper 7 used a full 
set of TLD dosimeters and Paper 8 utilised the full set of dosimeter locations with MOSFET 
dosimeters (Thompson et al., 2015, 2016; Tootell et al., 2017). However, efficiency was increased by 
using the previously described cumulative method.  
The above development work demonstrates the steps taken to optimise and improve the use of the 
dosimetry phantom in the measurement of radiation dose. It is recognised that there are potential 
further improvements through the use of the relevant dosimetry phantom but in this portfolio of 
works, resources dictated otherwise. As before, these methods and development work was used in 
all of the empirical publications in this portfolio of works (Tootell et al., 2013, 2014b, Thompson et 
al., 2016, 2015 and Tootell et al., 2016) and has been included in PhD work and other research 
activities (Ali et al., 2017, 2015; Ali, 2016; Mraity, 2015; Robinson et al., 2017).  
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2.3 RADIATION DOSE- EFFECTIVE DOSE & EFFECTIVE RISK 
Effective dose is a relatively new concept introduced by the ICRP in the 1977 Recommendations of 
the International Commission of Radiological Protection (ICRP, 1977). Initially used in the monitoring 
and control of radiation exposure in relation to stochastic risks the concept has been extended to 
members of the public including exposures to embryos and foetuses (ICRP, 1991, 2006, 2007). The 
method of calculating effective dose and its use in reporting research findings has been heavily 
criticised and suggestions for alternative approaches have been made. This chapter will review these 
discussions in the context of the portfolio of works. 
2.3.1 EFFECTIVE DOSE 
Effective dose is a figure that can be used in the comparison between techniques within and across 
imaging modalities using ionising radiation. The process of effective dose calculation is described in 
detail in Tootell et al., (2014a) [Paper 2] but in summary it is a three stage process; establishing the 
absorbed dose to organs and tissues identified in Table 3 in Gray (Gy), converting this to equivalent 
dose in Sieverts (Sv) through the application of the radiation weighting factor, and finally summing 
the equivalent dose after the application of the appropriate tissue weighting factor. The weighting 
factors are an indication of the sensitivity of the tissue or organ to ionising radiation.  
In the comparison of techniques, measured dose quantities is the most appropriate method and for 
this reason dose measurement was used in Thompson et al., (2015, 2016) [Paper 5 and Paper 6]. It 
could be argued that in these papers, a comparison between the techniques could have been 
performed using volume averaged computed tomography dose index (CTDIvol) and/or dose length 
product (DLP) as the same anatomical area of the phantom was imaged on the same piece of 
imaging equipment under different tube current values (Harrison et al., 2016). However, the 
technology being used in this study was relatively new (volumetric CT) and it was felt that taking the 
time to acquire measured dosimetry data would be of value as a comparison between techniques. 
The methods developed and described in 2.1.1 Direct Dose Measurement were used to measure the 
organ dose and calculate effective dose for the different techniques. 
Measurable dose indices are unable to convey meaningful comparisons, for example dose length 
product cannot be compared to dose area product or techniques that result in different distributions 
of radiation dose within the body. Effective dose is able to fulfil this requirement (Dietze, Harrison, & 
Menzel, 2009; Harrison et al., 2016).According to Harrison et al., (2016) there has been confusion in 
the practical application of effective dose in the communication of information to non-experts in 
ionising radiation,  i.e. referrers and patients. There is a “problematic and growing application to the 
assessment of risk to individuals”; something that effective dose is not suitable for. Effective dose 
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does not take into account the age of an individual and only accounts for gender differences in the 
calculation of the remainder organs (prostate and uterus/cervix).  
David J Brenner is director for the Centre for Radiological Research at the Colombia University 
Medical Centre and is interested in the field of risks and benefits for imaging techniques using 
ionising radiation in the field of medical imaging. In his publications focussing on the reporting of 
radiation dose, he notes that there is an increasing number of publications in which effective dose is 
calculated, and then used to estimate lifetime cancer risks (Brenner, 2012). As presented in Paper 2, 
(Tootell et al., 2014a), Brenner, (2009, 2011, 2012) is uncompromising in his criticisms of effective 
dose and its use in published literature. The author goes on to not only criticise the use of effective 
dose for purposes it was not intended but the method by which it is devised. Issues cited target the 
ICRP’s approach to effective dose citing its calculation being based on tissue weighting factors that 
are from subjective judgements by a committee and are inflexible in their inability to reflect age and 
gender differences in radiation sensitivity (Table 3). 
 
Tissue or Organ 
Weighting Factor 
ICRP 26 
(1977) 
ICRP 60 
(1990) 
ICRP 103 
(2007) 
Bone marrow 0.12 0.12 0.12 
Breast 0.15 0.05 0.12 
Lung 0.12 0.12 0.12 
Stomach - 0.12 0.12 
Colon - 0.12 0.12 
Gonads 0.25 0.2 0.08 
Thyroid 0.03 0.05 0.04 
Bladder - 0.05 0.04 
Liver - 0.05 0.04 
Oesophagus - 0.05 0.04 
Bone surface 0.03 0.01 0.01 
Skin - 0.01 0.01 
Salivary Glands - - 0.01 
Brain - - 0.01 
Remainder 0.3 0.05 0.12 
TABLE 4 ICRP TISSUE WEIGHTING FACTORS FROM 1977 TO PRESENT DATE 
Since its conception in 1977, these weightings have been reviewed and changed. These changes do 
make long-term trends in levels of radiation dose challenging to identify yet if the ICRP were to not 
change these weightings then they would be open to criticism for not responding to new 
observations or advances in scientific knowledge (Dietze et al., 2009). However, changes in 
weightings have been made for reasons other than through the discovery of new knowledge, for 
27 
 
example the change in the weighting to the breast from 0.05 in 1991 to 0.12 in 2007 was due to the 
committee deciding to emphasise cancer incidence rather than mortality (Brenner, 2011). 
Considering effective dose in isolation can mask significant changes in radiation dose to specific 
organs. An example of this is a finding that was made in Tootell et al., (2014b) [Paper 4]. This 
research compared the additional radiation dose and risk that a CT attenuation correction 
acquisition would bring compared to the radiation dose and risk from the administration of the 
radiopharmaceutical alone for a rest and stress myocardial perfusion study. Four commonly used 
hybrid imaging systems were included in the study and compared to the two most common 
radiopharmaceuticals. The results demonstrated that the effective dose was increased by 1.8 to 3.0 
mSv. However, if individual organs are considered, specifically the radiosensitive organs and tissues 
such as lung and breast it can be seen that there is a significant increase in radiation dose to these 
organs. Breast dose in particular was found to increase by 4.1 mSv to 8.2 mSv from 3.7 (121%) for 
99mTc Tetrosfosmin or 5.7 mSv (54.1%) for 99mTc Sestamibi.  
 
 
 
 
 
Organ  
Dose (mSv) 
99mTc 
Tetrofosmin  
99mTc 
Sestamibi 
 
GE 
single 
slice 
GE four 
slice 
Siemens 
Symbia 
T6 
Philips 
Precedence 
Lung 5.1 7.1 3.6 5.4 3.1 5.5 
Oesophagus 5.3 6.5 2.5 3.8 2.4 5.6 
Colon 28.8 34 0.2 0.2 0.6 0.5 
Liver 5.3 16 2.6 4.7 2.7 4.9 
Stomach 7.4 10 1.1 2.4 1.7 3.1 
Breast 3.7 5.7 7.1 6.6 4.1 8.2 
Effective dose (mSv) 11 13.3 1.9 2.5 1.8 3.0 
TABLE 5 COMPARISON OF SELECTED ORGANS AND EFFECTIVE DOSE RESULTING FROM ADMINISTRATION OF 
RADIOPHARMACEUTICAL COMPARED TO CT ATTENUATION CORRECTION ACQUISITIONS (TOOTELL ET AL., 2014B) 
[PAPER 4] 
 
This paper has successfully highlighted that although the effective dose is low compared to the 
radiopharmaceutical dose, practitioners and operators should be aware of changes to dose profiles 
and the individual organs and tissues that could be affected by a change in protocol. This conclusion 
is supported by the results in Tootell et al., (2016) [Paper 7], in a similar approach to Tootell et al., 
(2014b) [Paper 4], the effect on radiation dose from supplementary imaging of the lumbar spine 
following an isotope bone scan is investigated. In this case the changes in effective dose are greater 
with results showing that the effective dose from lumbar spine imaging using X-ray images was 0.56 
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mSv (±0.09), “low-dose CT” 0.80 mSv (±0.12) and diagnostic CT was 3.78 mSv (±0.56). The calculated 
effective dose from the administration of 800 MBq of 99mTc labelled phosphate or phosphonate is 
4.56 mSv. Thus the additional effective dose from supplementary imaging is 12.3% for X-ray images, 
17.5% for low-dose CT and 82.9% for diagnostic CT. Given the small difference in effective dose 
between x-ray and low-dose CT reported in Tootell et al., (2016) [Paper 7] it can be seen in the 
appendix (p160) that the findings have influenced clinical practice and has led to a change in 
protocol at a local nuclear medicine department. The department no longer refers for x-ray imaging 
of the lumbar spine to characterise lesions as the benefits of fused SPECT-CT images for the now 
proven small additional amount of radiation dose can be justified  
Consideration of individual organ doses reveals that the stomach receives one of the lowest doses 
from the radiopharmaceutical (0.96 mGy). Following supplementary imaging this figure increased to 
10.82 mGy (+1027.35%) for diagnostic CT, 3.10 mGy (+222.95%) for low-dose CT and 2.25 mGy 
(+134.74%) for X-ray Images. These results are due to the organ being directly in the field of view 
when imaging the lumbar spine. While these results are specific to lumbar spine imaging they have 
shown that the supplementary imaging can significantly increase organ dose and subsequent risk to 
that organ. It is for this reason that accurate organ dose assessment is required supporting the 
recommendations made in ‘2.2 The Dosimetry Phantom’ stating that the whole of the organ’s 
dosimetry locations be used or, as stated in this thesis, the mean of the locations used should be 
calculated without assuming a zero value of excluded locations.  
An issue discussed in Tootell et al., (2014a) [Paper 2] and supported by Harrison et al., (2016) is the 
confusion between dose quantities, specifically equivalent and effective dose. The SI unit for both of 
these quantities is the Sievert and difficulties in communication have been identified when 
equivalent dose and effective dose have not been distinguished adequately. Potential confusion 
could be avoided if specific organ and tissue doses were referred to using the absorbed dose (Gy) 
(Harrison et al., 2016). This recommendation supports the decision taken in presenting the results in 
Tootell et al., (2016) [Paper 7] to use absorbed dose (Gy) rather than equivalent dose (Sv). 
In conclusion, effective dose is a useful figure in the comparison of techniques where dose 
distributions are different or the dose indicators do not permit direct comparison, for example DLP 
and DAP. The identified trend of using the figure to calculate individual risk is of concern as effective 
dose calculations does not take into account for age and to a lesser extent gender.  
2.3.2 EFFECTIVE RISK  
An alternative to effective dose is proposed by Brenner, (2009, 2011, 2012) and applied in a number 
of papers in this portfolio of works (Tootell et al., 2016, 2014b, 2017) [Paper 4, Paper 7 and Paper 8]. 
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Referred to as “effective risk”, it provides a statistical figure of risk of cancer induction for a given 
examination and this figure can reflect age and gender. As described by Brenner, (2009, 2011, 2012) 
and in Tootell et al., (2014a) [Paper 2], the calculation of effective risk is a similar process to the 
calculation of effective dose in that the absorbed dose to organs is established, but instead of being 
applied to tissue weighting factors defined by the ICRP, these values are applied to statistical data 
produced from epidemiological studies of cancer induction such as National Research Council (U.S.) 
Committee to Assess Health Risks from Exposure to Low Level of Ionizing Radiation., (2006) and Wall 
et al., (2011). The approach used by the papers in this portfolio of works has been applied in other 
publications and PhD work within the Diagnostic Imaging Research Programme (R. M. . Ali et al., 
2017, 2015; R. M. K. Ali, 2016). 
Effective risk could be used to provide referrers and patients with an easily interpretable value that 
can be used to inform the imaging pathway or the decision to give consent for the examination. The 
method used in this portfolio of works and other publications from the Diagnostic Imaging Research 
Programme could be argued to be relatively simplistic in the approach as they do not follow the full 
method described by the BEIR VII committee. The development of the method relied heavily on the 
work undertaken but the Radiation Effect Research Foundation (RERF) who undertook research and 
documentation of the after effects of the 1945 atomic bombing of Hiroshima and Nagasaki.  The 
adopted philosophy is of a linear non-threshold (LNT) hypothesis involves the scaling of higher 
radiation doses and recorded effects to low dose scenarios. Other models do exist as illustrated in 
Figure 5 and with some authors advocating the use of the non-linear threshold model due to the 
potential significant over estimation of risk in low dose exposure and the assumption that cells 
respond similarly to high and low-dose exposure (Harvey, Brink, & Frush, 2015; O’Connor, 2017; 
Siegel et al., 2018). The linear non-threshold model is the “worst case scenario” where any exposure 
to ionising radiation carries a risk. It could be argued that this is erring too much on the side of 
caution and could impact on uptake of radiological procedures due to perceived risks. 
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FIGURE 5 MODELS FOR EXTRAPOLATING RADIATION-INDUCED CANCER RISK TO LOW DOSES (DASHED LINE AND 
CURVES). LINEAR NO-THRESHOLD (LNT) MODEL = DASHED STRAIGHT LINE (HENDEE & O’CONNOR, 2012). 
 
Competing models of risk were developed, the Excess Relative Risk (ERR) and the Excess Absolute 
Risk (EAR). These are defined in detail by O’Connor, (2017) but in short ERR is the rate of disease in 
an exposed population divided by the rate of disease in an unexposed population, minus 1.0. This 
method assumes that the there is a proportional relationship between the excess risk of cancer to 
the baseline cancer incidence, that is to say the ERR is the same for a Japanese and a US or European 
population. The EAR model is the rate of disease in an exposed population minus the rate of disease 
in an unexposed population and is more suited if there are significant differences between the 
reference population and the population under investigation. It is assumed that the baseline cancer 
incidence does not influence the rate of radiation induced cancers.  
These models allow the calculation of the risk of cancer at a specified time post exposure. To allow 
the calculation of the lifetime risk of cancer, a third method was developed. The Lifetime 
Attributable risk (LAR) is the sum of ERR and EAR for each year after exposure out to a specified 
lifespan of approximately 80 years (Nations Scientific Committee on the Effects of Atomic Radiation, 
2000). O’Connor, (2017) states that BIER VII committee were confronted with a decision in which 
method to use to calculate LAR as there was poor correlation between EAR and ERR models and the 
large discrepancy between risk coefficients from medical studies and the atomic bomb survivor 
studies. In order to generate a single estimate of LAR the BEIR VII committee created the final risk 
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model as 𝑥. 𝐸𝑅𝑅 + (1 − 𝑥). 𝐸𝐴𝑅 where 𝑥 was determined subjectively by the committee. 
Subjectivity is one of the arguments Brenner uses against the use of effective dose where the tissue 
weighting factors are decided by the ICRP committee (Brenner, 2009, 2011, 2012). An alternative 
approach would be to quote the range of risk quoting both ERR and EAR. This would reflect the error 
that is inherent in any risk from low-dose radiation exposure.  
Data is presented in BEIR VII in easy to interpret tables and the data that is frequently in dose 
estimations. It could be argued that the degree in error, from the TLD’s performance and in the risk 
estimates are considerable. These are a reflection in the limitations of the epidemiological data 
which are generated from atomic bomb survivor studies. For future work involving risk analysis it is 
important that results should be presented with an indication of any uncertainty. Failure to do so 
could potentially give a misleading impression of statistical precision. For this reason care should be 
taken when conveying risks to patients and carers as misinterpretation could lead to imaging 
avoidance leading to greater harm to patients (Siegel et al., 2018).  
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2.4 CONVEYING RISKS TO PATIENTS 
Referrers, Practitioners and Operators do have a duty to convey the risks from an examination to 
their patients in a manner that is understandable (Brenner, 2009, 2011, 2012). This is a requirement 
as set out in The Ionising Radiation (Medical Exposure) Regulations, (2017) and recommended 
practice is for communication of the risks through two-way dialogue between Referrer, Practitioners 
and/or Operators and their patients is at a level  that is understandable to each party (Society of 
Radiographers, 2018). Providing an indication of the level of risk is a better approach than a patient 
specific risk value is an approach that should be adopted. This supports the opinion of BEIR VII; to 
quote the report directly specific estimates of LAR should be regarded…  
“…with a healthy scepticism, placing more faith in a range of possible values”              
(Nations Scientific Committee on the Effects of Atomic Radiation, 2000). 
O’Connor, (2017) goes further in recommendations stating that a case can be made for imaging 
procedures with effective doses below the upper limit of natural background radiation, the practice 
of associating any risk estimate should be discontinued as scientifically unsound. There is a danger 
that reporting risks to patients without context could lead to patients withholding consent for 
radiological examinations (Boutis et al., 2013).  There is a history of sensational headlines in the 
media based on research stating use of ionising radiation causes tens of thousands of cancers every 
year (Berrington de González et al., 2009; Brenner & Hall, 2007).  
The key is contextualising the risks but also considering the current benefits against any future risk. 
One of the criticisms cited in Tootell et al., (2014a) [Paper 2] about effective dose is that it is 
meaningless to non-radiology groups, for example telling a patient that the additional CT exposure 
would increase their dose by 0.8 mSv. Similarly telling the patient that the cancer induction risk from 
ionising radiation would increase from 143 per million to 154 per million could be a challenging 
concept to understand. The avoidance of overly technical terminology can lead to confusion and 
misconceptions in the information. In effect practitioners and operators should be able to 
communicate the risk to their patients rather than educate them. How this can and should be done 
is open to debate and work in the field is ongoing. The challenge with statistical figures is in the 
conveyance of the risk being a population risk not the risk to an individual (Broadbent & Hubbard, 
1992; Peck & Samei, 2017).  
In any discussion the benefit of the exposure needs to be considered. In the context of this portfolio 
of works, specifically Paper 4 and Paper 7 (Tootell et al., 2016, 2014b), in the initial discussion about 
the procedure to the patient, they should be made aware of the radiation risks and that on 
occasions additional imaging is required (CT for attenuation correction or CT for lesion 
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localisation/characterisation). Patients could be informed of the benefits of additional imaging and 
also the risks of not performing the imaging. For example, a false-positive diagnosis of ischaemic 
heart disease or the misdiagnosis of a lumbar spine lesion identified on a SPECT acquisition.  
A simplified method by which risks can be conveyed to patients is to use comparative data. A 
commonly used method is to compare the risk to odds of accidental death as shown in Table 5. This 
is poor practice for a number of reasons and can lead to patients perceiving an overestimation of 
risk as a factor that isn’t incorporated into this data is time. The latency factor of cancer occurrence 
should not be compared to accidental injury and also the above mentioned risk of not performing 
the procedure carries its own risk.  The exposure involves a stochastic risk with very long latency 
period but not performing the procedure would have another risk, probably much larger with a 
much shorter time horizon (Peck & Samei, 2017). 
 
Type of incident / Manner of injury Number of deaths in 2005 Probability of occurrence 
All causes of mortality from injuries 176,406 4.5% 
Transport accidents 48,441 1.3% 
Automobile 14,584 0.4% 
Pedestrian 6,074 0.2% 
Air travel 590 0.02% 
Non-transportation accidents 69,368 1.8% 
Falls 19,656 0.5% 
Being struck by objects 2,845 0.07% 
Intentional self-harm 32,637 0.9% 
Assault 18,124 0.5% 
Complications from medical care 2,653 0.07% 
TABLE 6 ODDS OF DEATH FROM INJURY AS AN EXAMPLE OF POOR COMPARISON FOR RADIATION RISK (PECK & 
SAMEI, 2017) 
 
A recommended method of conveying risks of the radiation alone is to compare the dose to the 
number of days of background radiation. For example, Table 6, while this method does provide 
patients with some relative scale to compare the dose against, it does not contextualise the risk. 
Wall et al., (2011) suggests an approach advocated by (Calman, 1996) that divides risk into four 
broad risk bands illustrated in Table 7. A criticism that could be made against the table 
recommended by Wall et al., (2011) is the change in denominator that could cause confusion. Using 
a common denominator of 1 000 000 would make the change in risks easier to interpret.  
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TABLE 7 TYPICAL DOSE AND EQUIVALENT AMOUNT OF BACKGROUND RADIATION 
 
Category Risk 
Negligible < 1/1,000,000 
Minimal 1 / 1 000 000 to 1 / 100 000 
Very Low 1 / 100 000  to 1 / 10 000 
Low 1 / 10 000  to 1 / 1 000 
TABLE 8 THE FOUR BROAD RISK CATEGORIES RELEVANT TO DIAGNOSTIC IMAGING (WALL ET AL., 2011) 
 
Category Risk 
Negligible < 1/1,000,000 
Minimal 1/1 000 000 to 10/1 000 000 
Very Low 10 / 1 000 000  to 100 / 1 000 000 
Low 100 / 1 000 000  to 1 000 / 1 000 000 
TABLE 9 ALTERNATIVE PRESENTATION OF THE FOUR BROAD RISK CATEGORIES (WALL ET AL 2011) 
 
Radiographic x-ray examinations of the knee and foot are seen typically to involve such ‘negligible’ 
risks for patients of all ages and both genders and the same is likely to be true for all examinations of 
the distal parts of the arms and legs. Radiographic examinations of the chest and cervical spine also 
involve ‘negligible’ risks for patients over about 30 years of age, but just creep into the ‘minimal’ risk 
band for younger patients of either gender, if no account is taken of the fact that the actual doses 
given to children are likely to be lower than those to adults. When this is taken into account, chest 
examinations remain in the ‘negligible’ risk band for patients of all ages and both genders, and 
cervical spine examinations remain in this band for male patients of all ages but could move into the 
‘minimal’ risk band for younger females (Wall et al., 2011). 
In the context of Tootell et al., (2016, 2014b), myocardial perfusion imaging and bone imaging using 
radiopharmaceuticals, the additional imaging using CT for attenuation correction or lesion 
X-ray Examinations Typical Dose (mSv) 
Equivalent period of 
 natural background radiation 
Limbs or Joints <0.01 <1.5 days 
Teeth <0.01 <1.5 days 
PA Chest 0.02 3 days 
Cervical Spine 0.08 2 weeks 
Lumbar Spine 1.3 7 months 
CT Head 2.5 1 year 
CT Chest 8 3.6 years 
CT Abdomen and Pelvis 10 4.5 years 
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localisation using low-dose parameters or diagnosis using diagnostic imaging parameters does not 
affect the categorisation of the examinations as both remain in the low risk category. In conveying 
this risk to the patient, the information about the additional benefits and the lack of change in the 
risk classification would provide the patient with adequate and comprehendible information to allow 
them to consent to the examination. 
In conclusion, there is a requirement to provide patients with information about the dose they will 
receive from an examination using ionising radiation.  This information needs to be provided in 
terms that are understandable and given context to allow patients to give informed consent for the 
examination. The use of risk statistics as used in Tootell et al., (2016, 2014b) is one such method but 
the level of uncertainty that is inherent in estimating risk for low radiation doses means that 
providing patients with absolute risk statistics without an indication of error or range could be 
misleading. These figures have a value although the range of risk should be used in the conveyance 
to patients and would provide referrers and practitioners additional data over effective dose alone 
due to the ability to take into account the gender and age of the patient group. Translating these 
into a level or category of risk to convey to patients would be a better approach and would provide 
patients with adequate comprehendible information. Effective dose still has a value in the 
comparison between modalities or anatomical areas.  
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3. INTELLECTUAL OWNERSHIP AND CONTRIBUTION 
The intellectual ownership, type and percentage contribution all co-authors for each paper (1-8) 
included in this thesis are displayed in Table 8. 
The method used is based on a subset of categories for authorship as recommended by the 
International Committee of Medical Journal Editors (ICMJE, n.d.). All co-authors took the opportunity 
to review the final submission of manuscripts. 
The type of contribution is summarised as: 
a. Concept and Design 
b. Data Collection 
c. Data Analysis 
d. Drafting and Revision 
e. Final Approval 
 
Authors Papers /  Contribution (%) and Type 
 1 2 3 4 5 6 7 8 
AKT 60 
a.d.e. 
70 
a.d.e 
70 
a.b.c.d.e. 
65 
a.b.c.d.e. 
8 
b.d.e. 
8 
b.d.e 
60 
a.b.c.d.e. 
65 
a.b.c.d.e. 
PH 15 
d.e. 
20 
a.d.e. 
20 
a.d.e 
15 
a.d.e 
9 
a.d.e 
9 
a.d.e 
13 
a.d.e. 
15 
d.e. 
KRS  10 
d.e. 
10 
c.e. 
20 
a.c.d.e. 
8 
c.e. 
8 
c.e. 
10 
c.d.e. 
20 
b.c.d.e. 
MMc       17 
c.d.e. 
 
JT     44 
a.b.c.d.e. 
44 
a.b.c.d.e 
  
SV 15 
a.d.e 
       
ME 10 
d.e 
       
DJM     11 
a.d.e 
11 
a.d.e. 
  
DPC     15 
a.c.d.e. 
15 
a.c.d.e. 
  
IV     5 
b.d.e. 
5 
b.d.e. 
  
TABLE 10 CONTRIBUTION OF EACH AUTHOR TO THE PAPERS INCLUDED IN THE PHD BY PUBLISHED WORKS 
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4. CITATION ANALYSIS 
While the number of citations per article can be regarded as a good indication of the impact 
published work has had or is having it should not be regarded as the only measure (Meho, 2007; 
Nightingale & Marshall, 2012). While research in the radiography community has developed, it has 
yet to fully filter through to the clinical environment and be fully adopted as a core element. The 
number of research active radiography professionals is relatively small in number. As noted by 
Seglen, (1997), articles published in niche areas are likely to gain fewer citations than those in 
general areas. While the majority of the radiography profession will engage with published 
literature, this is likely to be used in the development of their knowledge and skills for continued 
professional development (CPD) purposes. For this reason additional measures have been used in 
Table 11 including number of reads and downloads. The Diagnostic Imaging Research Programme 
has a number of themes and there is overlap in their activities. As a results there are a number of 
citations from within the group either in published research or in PhD theses.  
 
TABLE 11 CITATION ANALYSIS OF THE PORTFOLIO OF PUBLISHED WORKS (DATA COLLECTED MAY 2018) 
 
Paper 1 2 3 4 5 6 7 8 
Year of publication 
 
2012 2014 2013 2014 2016 2015 2016 2017 
Journal Impact Factor  (present) 1.472 0.289 0.289 2.050 2.617 0.37 0.25 0.289 
(at the time of publication) 1.379 0.346 0.232 2.026 2.617 0.37 0.25 0.289 
Google Scholar Citations 12 11 10 1 7 2 0 0 
Scopus Citations 6 4 5 0 2 1 0 0 
ResearchGate Reads 75 74 6 22 - 63 44 - 
ResearchGate Citations 9 9 9 0 - 1 0 - 
DIRP Citations  
(Google Scholar) 
4 5 10 0 4 1 - - 
PhD Thesis Citations (UoS) 0 4 4 2 2 2 0 0 
Self-citations 1 2 3 - - 1 - - 
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5. FUTURE DIRECTION OF RESEARCH 
Completion of this PhD will provide an ideal time to reflect on the research that has been 
undertaken over the last six years. The quality of the research has improved and as can be seen 
through the portfolio of works has evolved. Interestingly during the research, a number of 
qualitative issues were highlighted.  
The ability to calculate risk statistics raises the question of what information should be provided to 
patients. As discussed in chapter 2.4 (Conveying Risks to Patients) there is a risk that patients could 
be dissuaded from an investigation or intervention due to their interpretation of the radiation risks. 
It would be interesting to use the data that has been generated as part of this research to investigate 
how patients and carers would interpret the risks as part of the decision making process. This would 
be of particular interest in the research using methods developed in this portfolio of works produced 
by Ali et al (Ali, England, Tootell, & Hogg, 2016; Ali, England, Tootell, Mercer, & Hogg, 2017; Ali et al., 
2017) where the risks from breast screening programmes are investigated.  
From this portfolio of works, further empirical research is planned in improving the accuracy of dose 
estimations compared to dose measurements. Since the completion of this portfolio of works 
additional dosimetry phantoms from the ATOM dosimetry phantom family have become available, 
meaning research can be performed using paediatric, adolescent and adult female patients. The 
research conducted in Paper 8 (Tootell et al., 2017) has shown the potential in the improvement of 
accuracy in assessing patient dose through the correction due to mass but other metrics can be used 
to provide information on patient habitus. Work establishing if and how these can used in the 
correction of dose estimations is planned. 
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6. CONCLUSION 
This portfolio of works and accompanying narrative has demonstrated the development of the 
research. From Paper 1 that sets the scene for the need to accurately measure radiation dose in light 
of what was then new technology, through to a review of how radiation dose can be measured or 
estimated and how this data can be interpreted to provide referrers, practitioners, operators and 
patients and their carers with understandable information about the potential risks an exposure 
could bring and finally the application of the methods developed. 
The commentary provides an appraisal of the methods and then manner in which they have been 
presented and interpreted. Where applicable, the limitations of the chosen methods have been 
identified and recommendations for improvements made. 
In summary, this thesis and accompanying portfolio of works has demonstrated the ability to 
conceptualise and develop original research resulting in the creation and interpretation of new 
knowledge. This has been supported by developing a detailed understanding of the applicable 
techniques through critically reviewing the current body of knowledge.  
The impact of the work has been demonstrated, not only through the number of citations, but the 
number of reads and downloads the published works has had. The impact in the Diagnostic Imaging 
Research Programme has been illustrated showing the cohesion of the group where research 
activities are complimentary.  
The direction of future work is anticipated to continue in dosimetry with research planned to 
improve the accuracy of dose measurements, calculation or simulations to aid referrers, 
practitioners and operators in the conveyance of risks to patients and carers and also in the 
development of less generic diagnostic reference levels.  A qualitative evaluation of what patients 
and carers want to know would allow the integration of the dosimetry research finding with clinical 
practice.
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PAPER 1 
CLINICAL EVALUATION OF THE COMPUTED TOMOGRAPHY ATTENUATION CORRECTION MAP FOR 
MYOCARDIAL PERFUSION IMAGING: THE POTENTIAL FOR INCIDENTAL PATHOLOGY DETECTION 
 
Tootell AK, Vinjamuri S, Elias M and Hogg P (2012). Nucl Med Commun, 33(11), 1122-1126. doi: 
http://10.1097/MNM.0b013e3283571b35   
Introduction 
Since the origins of hybrid imaging in nuclear medicine many papers have established the diagnostic 
benefits that computed tomography (CT) can bring to the emission data. Initially CT was shown to 
have value for attenuation correction (AC); more recently its role in lesion localisation and 
characterisation has been demonstrated [1-3] The benefits of hybrid systems have been so well 
illustrated that it has become virtually impossible to purchase a PET scanner without integral CT; also 
the availably of SPECT/CT systems has increased tremendously [4]. Contemporary SPECT/CT and 
PET/CT systems can now have state-of-the-art CT technology such that the CT component could have 
the same specification and capability to that of standalone multi-detector diagnostic scanners.  
This paper focuses on SPECT/CT in the context of myocardial perfusion imaging (MPI); it addresses the 
question ‘should the low resolution CT images for AC in SPECT be interpreted for the detection of 
incidental extra-cardiac disease’? Recently, debate has raised questions on whether additional clinical 
information might be gained from CTAC image data - particularly to determine whether incidental 
extra-cardiac pathology might be detected [5, 6]. Surprisingly, guidelines jointly issued by the 
European Association of Nuclear Medicine (EANM) and European Society of Cardiology (ESC) [7] give 
no mention to the clinical evaluation of the CTAC data for detection of incidental pathology. 
The aim of this paper is not to provide a definitive answer to whether the CTAC (MPI) image should 
be interpreted; rather the intention is to initiate discussion and suggest a way forward. This paper will 
consider a number of issues that have been raised by clinicians from within and outside nuclear 
medicine, it will draw parallels to other imaging modalities that have similar quandaries, and it will 
consider pertinent regulatory matters. 
Incidental findings 
Literature highlights that incidental findings are an acknowledged phenomena within medical imaging 
and many discussions are documented about whether evaluation of all available data should take 
place. Discussions similar to this paper have and still are taking place in modalities outside the nuclear 
medicine field with many authors considering how the additional data that is acquired as part of 
cardiac CT, CT urography and CT colonography  might be used [8-10]. Similarly, in medical research, 
there is a growing opinion that acquired data may contain information that could have significant 
health implications for the patient. It may be possible to make decisions regarding nature and 
significance, and whether further investigation is warranted [6, 11]. 
A question worth considering is ‘how often are incidental findings detected’? The Royal College of 
Radiologists suggest that they are relatively common, quoting figures of up to 30% in radiological 
examinations of the abdomen and chest imaging (depending of the population being studied) [11]. 
There is surprisingly little published on incidental findings on the CTAC image of MPI acquisitions; 
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however figures indicate that 8.1% to 18% of CTAC images may demonstrate some abnormality [5, 12, 
13].  
The study carried out by Pandey et [5] involved the review of CTAC for MPI images from 494 cases 
over a 20 month period acquired on a Philips Precedence 16-slice hybrid system. Forty cases (8.1%) 
were found have extra-cardiac pathology with four of these diagnosed with lung cancer following 
further investigations. Similarly the work of Kane [5] found that of 1001 cases 217 (18%) demonstrated 
abnormalities. Of these 217 (10.6%) had minor findings deemed unlikely to affect management, 67 
(5.5%) had minor findings with possible cardiac significance (eg coronary artery calcification), 17 
(1.4%) had possible clinically significant pathology, with four (0.3%) having significant pathology. 
These findings demonstrate that the incidence of clinically important pathology is small but cases that 
have significant bearing on immediate and long term health of a patient can be identified.  
It is difficult, if not impossible, to indicate the false negative rate - that is to say in how many cases 
significant pathology are missed without a long term follow up of normal and abnormal CTAC for MPI 
acquisitions. This does make the specificity and accuracy difficult to calculate. It is reasonable to say 
that the image quality of CTAC for MPI images is low making it difficult if not impossible for reporters 
to detect smaller lesions. 
Quality of the CTAC Image for MPI  
Thompson et al [14] found that in a Free Response Receiver Operating Characteristic (FROC) 
anthropomorphic chest phantom study there was no deterioration in lesion pick up rates in CT 
acquisitions using lower mA values but the false positive rate did increase. This study suggests that 
review of the CTAC for MPI image could lead to unnecessary investigations. However the images 
generated in this study were acquired on a standalone “diagnostic quality” system with higher rotation 
speeds and images were not subject to breathing artefact which plays a major role in degrading the 
quality of CTAC for MPI images. A comparative phantom-based FROC study on a range of SPECT/CT 
systems demonstrated that lesion pick up varied significantly between the different image qualities, 
with the early generation SPECT/CT systems performing much worse than the newer multi-slice 
alternatives [15]. The decision to review CTAC for MPI images should bear in mind the CT system’s 
capabilities. 
The relatively poor image quality and the limited volume of the chest imaged during CTAC for MPI are 
possibly the main arguments for not reporting. Generally speaking the CTAC images are acquired using 
a low mA, no breath hold and slow gantry rotation speed (together incurring motion artefact) and, in 
lower specification CT systems, a slice thicknesses of up to 10mm. (See Fig 1) 
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Fig1 Examples of CTAC for MPI images acquired on different specification hybrid gamma 
cameras. (a) 16 slice scanner, 4mm slice 0.3s/slice, (b) 6 slice scanner, 5mm slice, 0.8s/slice, 
(c) 4 slice scanner, 5mm slice, 15s/slice, (d) single slice scanner, 10mm slice, 15s/slice 
 
 
  
 
Fig 1a shows an attenuation correction image for MPI that was acquired on a higher specification 16 
slice-CT scanner using non-breath hold technique. Comparing this to the other types of CT equipment 
using in hybrid systems there is a clear decrease in quality through Figures 1b to 1d. Fig 1d is a CTAC 
for MPI image acquired on the lowest specification CT scanner using a very slow rotation time of 15 
seconds and a 10mm slice thickness. 
 
Perhaps an interesting parallel that can be drawn is to screening for lung cancer using low dose CT. As 
can be seen in table 1, screening protocols use exposure factors that are lower than typical diagnostic 
acquisitions; these are likely to exhibit lower image qualities. Nevertheless, studies by Jett [17] and 
Swensen et al [18] found that lung nodules and other pathologies are detectable on images acquired 
using low dose acquisition parameters. It is also recognised that a definitive diagnosis was not always 
possible yet it was feasible to identify cases that would benefit from further investigation. The work 
of Thompson et al [15] found that there is large disparity in the CT systems’ ability to demonstrate 
simulated lesions in an anthropomorphic phantom. This disparity is likely due to the aforementioned 
specifications of the CT component of the different hybrid systems. However as noted by Kane [5], 
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and as  seen in Fig 2, lesions can be identified, if not characterised, within CTAC for MPI images and 
followed up for definitive diagnosis.   
 
Table 1 Comparison of typical CTAC and Diagnostic CT parameters [5, 16, 17] 
 
  
Characteristic 
 
Typical CT AC Screening CT “Diagnostic” CT 
Tube current 
 
2.5 80/auto 80/auto 
Tube voltage 
 
140 120 120 
Slice thickness 
 
5-10mm 3mm 3mm 
Field Of View Left ventricle  
 
(ascending aorta to 
apex) 
 
Entire thorax Entire thorax 
Scan Time 
 
5min  5-10 seconds 5-10 seconds 
Axial resolution 
(mm) 
 
10 0.5 0.5 
Breath-hold 
 
No Yes Yes 
Intravenous Contrast 
 
No No Yes 
Radiation dose 
 
<1mSv <2mSv 5-6mSv 
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Fig 2 Example of significant pathology found on CTAC for MPI acquisition. (a) Significant 
breathing artefact is evident but lesion in the right lung can be clearly seen. (b) Diagnostic CT 
scan of the same area. (c) PET-CT of the same area showing uptake of FDG in the lesion. A 
previously unknown malignant lung lesion was diagnosed [5].  
 
 
 
 
Ethical and Legal Considerations 
The fact that in some cases a lesion can be identified raises the ethical question of whether the CTAC 
for MPI image should be examined for incidental extra-cardiac pathology. This question is one that 
has been considered previously in other areas of imaging [6, 11]. However, the counterpoint to the 
ethical question is the risk of over investigating clinically insignificant pathology and the potential for 
unnecessarily increasing patient anxiety. Budoff and Gopal [19] presented an argument that a 
reporting physician should not actively look for extracardiac pathology on CT angiography for this very 
reason. They argue that although it is possible to reconstruct a larger field of view to include the lung 
fields, soft tissue and bony structures, this “over reading” should not be done as it will lead to 
additional costs, liability and patient anxiety without proven benefit. The pragmatic and perhaps 
questionable approach this paper suggests is that to prevent the reporter from missing an incidental 
lesion is simply to not look for them. This appears to conflict with guidance issued by professional 
bodies and statements in UK legislation where it is stated that the review of images may reveal 
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incidental findings unrelated to the initial request and that clinical evaluation of the outcome of each 
medical exposure should recorded [11, 20-22]. Whilst it could be argued that the outcome of the CT 
exposure does occur as evaluation of the corrected and non-corrected emission data is recommended 
in the EANM/ESC guidelines [7], it could be said that the acquired data is not being used to its full 
potential and clinical review of the CTAC for MPI images should take place.   
Financial 
The economic impact of investigating incidental pathology is a topic that is raised quite frequently in 
literature [8-10, 12, 19, 23, 24]. With rising economic pressures on health service delivery there is a 
need to make best use of resources. Liu et al [9] found that the impact on costs of investigating 
extraurinary findings in CT urography was an increase of $3257 and $10974 for clinically moderate 
and clinically significant findings respectively. The study used a relatively small sample (n=259) but it 
was found that a protocol of following up moderate and significant incidental findings added $41.37 
per patient. Similarly Gluecker et al [25] found that in a larger sample (n=681) undergoing CT 
colonography investigation found that further investigation and, where required, intervention added 
$34.33 per CT colonography investigation. In UK MPI examinations cost around £600, investigation of 
incidental findings using chest radiography would add around £50 where investigation with contrast 
enhanced CT chest would add an additional £600. Applying this to the findings of Kane [5], 
investigating with CT the 17 patients with probable significant pathology and the 4 diagnosed with 
lung cancers would add just £12.59 to each of the 1001 patients in the study. This figure, however 
only takes into consideration a follow-up diagnostic chest CT and costs of biopsy, intervention and/or 
therapy would need a longer term study to be undertaken. 
Rumberger [26] considers that arguments around the economics of diagnosing incidental findings are 
weak as many consider a single case and follow this through to the worst case scenario whereby a 
patient undergoes invasive tests such as biopsy on a benign, clinically insignificant lesion. It is argued 
that there are evidence based guidelines on the management of pulmonary nodules that are identified 
on CT that allow the clinicians and practitioners to proceed in the most economical, legal and moral 
manner thus preventing unnecessary imaging and testing [27, 28].  
 
Expertise of the Reporter 
The focus should not be purely on the technicalities of the imaging process and quantitative data 
concerning lesion detection. Consideration should be given to the knowledge and skill of the reporting 
clinician/healthcare professional [21, 24]. There are many instances when MPI studies are reported 
by non-radiological professionals and there are examples of non-nuclear medicine professionals (such 
as cardiologists) and non-medically qualified professionals (physicists, radiographers, and 
technologists) undertaking reporting of nuclear medicine studies. Whoever reports the examination 
including the CTAC dataset should be appropriately trained should operate within the boundaries of 
their knowledge and expertise.  
In a discussion regarding the interpretation of extracardiac findings in CT angiography it is suggested 
that it is the reporting clinician (in the case of CT angiography, cardiologists) should be able to interpret 
extra-cardiac findings but to do so may require additional training. Conversely it is argued that there 
are radiologists with this expertise in reporting CT chest images and so why not make use of this 
knowledge and experience and issue a two-part report [23]. Guidelines on non-medical reporting state 
that any reporter should be able to at least offer an opinion on whether the appearances are normal, 
abnormal or normal variant and, if indicated, recommend further imaging or investigations for 
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correlation [21]. A comment on the appearance of the CTAC for MPI image (with or without possible 
diagnosis) may adhere to these guidelines. 
Summary 
How the above issues manifest themselves into a protocol that includes evaluation of the CTAC for 
MPI image and how this is communicated to the Referrer would be a matter for individual 
departments to address. Any issued report should not only note the clinical findings but should 
provide a summary of how the examination was performed and any information that may impact on 
the diagnostic accuracy of the procedure [20]. Reporters who are not competent in the clinical 
evaluation of CT chest examinations should consider not undertaking the task of reviewing the CTAC 
for MPI image. Instead a multi-disciplinary approach might be taken to involve radiology input into 
the final report. A standard caveat regarding the CTAC for MPI image could be included in the MPI 
report that conveys the technical details and limitations of the CT acquisition. For example: “a limited 
CT scan through the lungs has been performed as part of the imaging protocol. This has not been 
performed as a diagnostic scan of the chest, and the whole thorax has not been imaged.” Following 
this statement there could be a brief report on any normal or abnormal appearances in the image.  
Controversy exists on whether or not the CTAC for MPI image should be reported. For certain 
specifications of CT in SPECT the image quality is undeniably poor suggesting that lesion identification 
and definitive diagnoses would be difficult, if not impossible. Legislation suggests that all data should 
be clinically evaluated, and therefore used to its full potential. However Thompson et al [15] suggests 
that there may a “threshold specification” below which the hybrid camera may produce genuinely 
non-diagnostic CT chest images. Adopting this stance would be in line with evidence based practice. 
Perhaps the strongest pro-argument is based on ethical and moral grounds as, despite the poor image 
quality, is that it has been shown that pathology can be detected. There are likely to be instances when 
over investigation will occur or significant pathology missed. Equally there will be instances when 
significant pathology will be detected, investigated further and managed. The outcome of current 
research projects concerning the prevalence of incidental pathology, the clinical impact of the 
evaluation of the CTAC for MPI images and empirical work on lesion perception and detection on low 
dose/non-diagnostic systems is awaited to clarify the usefulness or otherwise of the CTAC for MPI 
image. 
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PAPER 2 
AN OVERVIEW OF MEASURING AND MODELLING DOSE AND RISK FROM IONISING RADIATION FOR 
MEDICAL EXPOSURES 
Tootell AK, Szczepura K and Hogg P, 2014, Radiography, 20(4), 323-332. doi: 
http://dx.doi.org/10.1016/j.radi.2014.05.002  
Abstract 
PURPOSE:  This paper gives an overview of the methods that are used to calculate dose and risk from 
exposure to ionizing radiation as a support to other papers in this special issue.  
BACKGROUND: The optimization of radiation dose is a legal requirement in medical exposures. This 
review paper aims to provide the reader with knowledge of dose by providing definitions and 
concepts of absorbed, effective and equivalent dose. Criticisms of the use of effective dose to infer 
the risk of an exposure to an individual will be discussed and an alternative approach considering the 
lifetime risks of cancer incidence will be considered.  
Prior to any dose or risk calculation, data concerning the dose absorbed by the patient needs to be 
collected. This paper will describe and discuss the main concepts and methods that can be utilised 
by a researcher in dose assessments. Concepts behind figures generated by imaging equipment such 
as dose-area-product, computed tomography dose index, dose length product and their use in 
effective dose calculations will be discussed. Processes, advantages and disadvantages in the 
simulation of exposures using the Monte Carlo method and direct measurement using digital 
dosimeters or thermoluminescent dosimeters will be considered. 
Beyond this special issue it is proposed that this paper could serve as a teaching or CPD tool for 
personnel working or studying medical imaging. 
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Introduction 
Within this special issue of Radiography several articles use Monte Carlo mathematical methods to 
estimate radiation dose to humans. It is appreciated that readers may have a limited knowledge of 
these methods, or indeed measurement methods which are used to estimate dose. For readers with 
limited knowledge in dose estimation this article explains a range of approaches which might be 
used. This article also outlines concepts and defines terms associated with dose and it discusses how 
data can be used to provide an indication of risk to an individual. 
Ionising radiation is made up of sub-atomic particles or, in the case of X and gamma rays, it comprises 
electromagnetic waves from the high energy part of the electromagnetic spectrum. At energies 
associated with medical imaging, these particles and waves have sufficient energy to ionise an atom 
and liberate an electron. This process may lead to tissue damage which can result in cell mutation or 
apoptosis. The higher the dose of radiation, the greater chance that tissue damage will occur [1]. This 
probability model of biological damage is referred to as the stochastic effect. It suggests that no dose 
of radiation is safe. It is this worst case scenario that radiation protection is based on, in that Operators 
should aim to minimise the probability of tissue damage by using the least practicable amount of 
ionising radiation [2]. 
In medical imaging a range of professionals are responsible for ensuring doses are As Low As 
Reasonably Practicable (ALARP). The Operator performing the exposure is required to have an 
understanding of the steps that they can take to optimise dose thus minimising the chance of 
stochastic affects.  
Absorbed Dose 
Interactions of ionising radiation with matter can result in a proportion of radiation energy being 
deposited. The amount of energy deposited per unit mass is the absorbed dose (represented by the 
letter D) and is defined as joules per kilogram (Jkg-1). The SI unit of absorbed is the Gray (Gy). Quantities 
of absorbed dose are usually quoted as milli-Gray (mGy, 1/1 000 of a Gray) or a micro-Gray (µGy, 1/1 
000 000 of a Gray). 
 
Equivalent Dose 
The chance of tissue damage occurring does not just depend on the absorbed dose but also the type 
and energy of the radiation. Equivalent dose (represented by the symbol H) takes these factors into 
consideration and is obtained by applying a radiation weighting factor (W) to the absorbed dose. 
Radiation weighting factors are published by The International Commission On Radiation Protection 
(ICRP) [1]; they reflect the biological damage potential of different radiation types (Table 1). It can be 
considered a less fundamental quantity than absorbed dose but it is useful for indicating the health 
risk of radiation exposure. Equivalent dose is still defined as joules per kilogram, but is assigned the SI 
unit Sievert (Sv). Figures are often quoted as milli-Sieverts (mSv) or micro-Sieverts (µSv).  
The equation for equivalent dose is defined in Figure 1. 
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TABLE 1 RECOMMENDED RADIATION WEIGHTING FACTORS FROM ICRP 103[1] 
 
 
 
 
 
 
 
 
 
Ionising radiation that forms part of the electromagnetic spectrum (e.g. X and gamma radiation) ionise 
atoms through the photoelectric absorption and the Compton Effect. Both these interactions will eject 
an electron from an atom; this electron may ionise many more atoms. Since most of the affected 
atoms are ionised indirectly by the secondary electrons, photons are considered to be indirectly 
ionising. 
Using the data in Table 1 it can be seen that an absorbed dose of 1 mGy of X-ray photons results in an 
equivalent dose of 1 mSv, i.e. 1 mGy x 1 (radiation weighting factor for X-ray photons), where 1 mGy 
of alpha particles results in an equivalent dose of 20 mSv i.e. 1 mGy x 20 (radiation weighting factor 
for alpha particles). In other words alpha particles have a higher risk to biological tissue. 
Effective Dose 
Effective dose (represented by the symbol E) takes into account the type and amount of exposed 
tissue. Different tissues within the body have difference sensitivities to radiation meaning a dose 
applied to one area of the body can carry a higher risk than the same dose applied to another. Effective 
dose takes the equivalent doses of a number of organs and through the application of a tissue 
weighting factor, the sum of these aims to provide a single number that is proportional to the 
detriment from a particular exposure. It allows comparisons of the risks associated with different 
imaging techniques or modalities. 
The tissue weighting factors (Table 2) represent the sensitivity of their respective tissue, for example 
bone marrow is highly sensitive to radiation and so has a weighting factor of 0.12 where the brain is 
less sensitive and so has a weighting factor of 0.01. The sum of the tissue weighting factors is 1 and so 
the sum of the weighted equivalent doses would provide a whole body effective dose. Performing this 
process for different techniques allows for a comparison of doses and an indication of the detriment 
of these. 
 
 
 
 
Radiation Type Radiation weighting factor 
Photons (X-ray and gamma ray) 1 
Electrons 1 
Alpha particles 20 
Protons 2 
𝐻𝑇 = 𝑊𝑅 ∙ 𝐷𝑇,𝑅 
Where  HT is the equivalent dose 
 WR is the radiation weighting factor obtained from  
 DT,R is the absorbed dose is tissue (T) by radiation type (R). 
FIGURE 1 EQUATION FOR CALCULATING EQUIVALENT DOSE FROM ABSORBED DOSE. [1] 
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TABLE 2 TISSUE WEIGHING FACTORS FROM ICRP 103 [1] 
Organ Tissue Weighting 
Factor 
Gonads 0.08 
Bone marrow 0.12 
Colon 0.12 
Lung 0.12 
Stomach 0.12 
Breast 0.12 
Bladder 0.04 
Liver 0.04 
Oesophagus 0.04 
Thyroid 0.04 
Skin 0.01 
Bone (surface) 0.01 
Salivary Glands 0.01 
Brain 0.01 
Remainder* 0.12 
TOTAL 1.00 
*Remainder tissues: Adrenals, 
Extrathoracic (ET) region, Gall 
bladder, Heart, Kidneys, Lymphatic 
nodes, Muscle, Oral mucosa, 
Pancreas, Prostate (♂), Small 
intestine, Spleen, Thymus, 
Uterus/cervix (♀) 
 
Effective dose is still defined as joules per kilogram and also has the same SI unit as equivalent dose, 
Sievert (Sv, with figures quoted as milli-Sieverts (mSv) or micro-Sieverts (µSv)). The equation for 
calculating effective dose is shown in Figure 2. 
Figure 8 Equation for the calculation of effective dose. [1] 
 
Where  E is the effective dose to the entire body 
 WT is the tissue weighting factor of tissue (T) defined by ICRP 103 
 HT is the equivalent dose absorbed by tissue (T) 
 
Controversies with Effective dose 
Effective dose is commonly used in medical imaging to compare the risks from different modalities 
(for example, CT of the cervical spine versus conventional radiographic imaging of the same 
anatomical area) or examinations that have differing dose distributions (for example, comparison of 
effective dose from an antero-posterior hip to that from an antero-posterior shoulder). The 
application of the tissue weighting factors to the equivalent doses of the organs provides the whole 
 
T
TT HWE
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body effective dose from that exposure. The application of effective dose is useful in these situations 
as it provides Referrers, Practitioners and Operators with data that allows them to make decisions 
during the referral, justification and optimisation of medical imaging procedures [2, 3]. When used for 
this purpose effective dose is a useful figure to use, however a number of publications use this figure 
to calculate the risk of the exposure to an individual. As noted by a number of authors, and the ICRP 
themselves, the effective dose concept is not intended to be used this way as a number of factors are 
not taken into consideration [3-8].  
The tissue weighting factors are averaged over all ages and both genders in the general population 
and so it cannot be applied to an individual patient [9]. For example a measurement of organ doses 
and effective dose calculations from a chest radiograph could be the same in a 15 year old and a 35 
year old female. Using data published by Wall et al [9] the lifetime risk of cancer incidence for breast 
tissue in 10-19 year olds of 3.34% per Gray and 30-39 year olds  of 1.44% per Gray it can be seen  that 
the risk to female breast in 10-19 year old  is higher. This difference in sensitivity due to age and gender 
is not captured within conventional effective dose calculations.  
The tissue weighting factors published by the ICRP are derived using data that is assessed and analysed 
by The United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR) on cancer 
risks from follow-up studies of the Japanese atomic bomb survivors [10]. As a result of these ongoing 
long term studies the tissue weighting factors have undergone a number of revisions as new data on 
cancer incidence has been collected [11]. The effect of these revisions can be seen in Table 3. 
 
TABLE 3 COMPARISON OF THE TISSUE WEIGHTING FACTORS FORM ICRP PUBLICATIONS 26, 60 AND 103 [1, 12, 13] 
Organs Tissue Weighting factors 
 ICRP 26 
(1977) [12] 
ICRP 60 
(1990) [13] 
ICRP 103 
(2007) [1] 
Gonads 0.25 0.20 0.08 
Red Bone Marrow 0.12 0.12 0.12 
Colon - 0.12 0.12 
Lung 0.12 0.12 0.12 
Stomach - 0.12 0.12 
Breasts 0.15 0.05 0.12 
Bladder - 0.05 0.04 
Liver - 0.05 0.04 
Thyroid 0.03 0.05 0.04 
Skin - 0.01 0.01 
Bone Surface 0.03 0.01 0.01 
Salivary Glands - - 0.01 
Brain - - 0.01 
Remainder 0.03 0.05 0.12 
TOTAL 1.00 1.00 1.00 
 
From Table 3 it can be seen that weightings assigned to the gonads have undergone significant 
changes over the three publications, from 0.25 in ICRP 26 to 0.08 in ICRP 103 that is a reflection of the 
understanding of heritable risk and the change in breast tissue changed from 0.05 in 1990 to 0.12 in 
2007 due to a decision by the ICRP committee to put more emphasis on cancer incidence rather than 
mortality [4-6]. Brenner, in a number of publications, suggests that these tissue weighting factors 
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represent a subjective balance between the diﬀerent stochastic endpoints of cancer incidence, cancer 
mortality, life shortening and hereditary risk. This subjectivity is an example of the “flaws in the 
science” behind the derivation of these factors [4-6]. However Dietze [11] argues that this revision 
was in response to the publication of more reliable cancer incidence data published by UNSCEAR [10] 
rather than a change in the committee’s emphasis. Whatever the reason, it is clear that these revisions 
do have an impact on effective dose calculations making comparisons to older data difficult. 
 
Lifetime Risk of Cancer Induction  
It is with these criticisms in mind that Brenner proposes an alternative to effective dose that can be 
applied to individual patients - this is referred to by Brenner as “effective risk”. Effective risk considers 
the life time risk of cancer induction from an absorbed dose of radiation and the equation for this is 
shown in Figure 3 [4]. 
 
 
 
 
 
 
 
 
This equation is very similar to that used to calculate effective dose. It is proposed that the tissue 
weighting factors are replaced with organ-specific radiation-induced cancer risk, such as those 
published by The Nuclear and Radiation Studies board ([14] or more recently by Wall [9] (a selection 
of data is shown in Table 4). 
 
 
 
 
 
 
 
 
 
 
Where R = Effective risk 
 rT = lifetime radiation-attributable tissue-specific cancer risks  
       (per unit equivalent dose to tissue T) 
 
HT = is the equivalent dose absorbed by tissue (T) 
FIGURE 2 EQUATION FOR CALCULATING EFFECTIVE RISK [2-4] 
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TABLE 4 LIFE TIME RISKS OF CANCER INCIDENCE FOR MALES AND FEMALES BY ORGAN AND AGE FOR A EURO-
AMERICAN POPULATION (% PER GY) 
Organ 
(Male) 
Age at exposure (y)     
0-9 10-19 20-29 30-39 40-49 50-59 60-69 
Lung 0.65 0.69 0.73 0.78 0.80 0.76 0.61 
Stomach 0.93 0.73 0.57 0.43 0.31 0.20 0.12 
Colon 1.49 1.22 0.98 0.79 0.60 0.43 0.25 
Red Bone Marrow 1.06 1.05 0.77 0.76 0.78 0.65 0.49 
Bladder 0.89 0.76 0.65 0.55 0.46 0.35 0.23 
Liver 0.56 0.44 0.34 0.26 0.18 0.12 0.07 
Thyroid 0.18 0.10 0.05 0.03 0.01 0.01 0.00 
Oesophagus 0.12 0.11 0.11 0.11 0.12 0.14 0.15 
 
Organ 
(Female) 
Age at exposure (y)     
0-9 10-19 20-29 30-39 40-49 50-59 60-69 
Breast 4.92 3.34 2.21 1.44 0.84 0.45 0.21 
Lung 1.36 1.46 1.58 1.70 1.78 1.72 1.39 
Stomach 1.45 1.14 0.88 0.67 0.48 0.33 0.20 
Colon 0.73 0.59 0.48 0.38 0.29 0.21 0.14 
Red Bone Marrow 0.48 0.48 0.50 0.45 0.77 0.49 0.29 
Bladder 0.70 0.61 0.52 0.45 0.39 0.32 0.24 
Liver 0.24 0.19 0.15 0.11 0.08 0.06 0.03 
Thyroid 0.92 0.52 0.26 0.13 0.06 0.02 0.01 
Oesophagus 0.10 0.09 0.10 0.12 0.15 0.21 0.28 
 
The lifetime risk figures (Table 4) are calculated from stronger data as they are based directly on 
epidemiological studies and not decided by committee [10, 14]. . The organ-specific radiation-induced 
risk data reflects current knowledge in the biological effects of radiation. The results would be easier 
to interpret (for example x per 1 000 000) for medical imaging professionals and non-medical imaging 
professionals too. The lifetime risk can be used to provide risk to different genders and age groups  
Conveying risk to patients is arguably one of the more challenging aspects the radiography profession 
has to contend with. To this end Wall suggests using a category based approach to convey the risk 
from the radiological examination (Table 5) [9].  
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TABLE 5 FOUR BROAD RISK BANDS FOR THE TYPICAL TOTAL LIFETIME CANCER RISK FOR PATIENTS [9] 
Category Total lifetime cancer risk 
 
Negligible risk 
 
Less than 1 in a million 
 
Minimal Risk 
 
1 in a million 
To 
1 in 100,000 
 
 
Very Low Risk 
 
1 in 100,000 
To 
1 in 10,000 
 
 
Low Risk 
 
1 in 10,000 
To 
1 in 1,000 
 
 
Prior to any analysis of risk, dose data has to be collected. Dose data can be measured or estimated. 
In medical imaging either method can be used to determine dose data in most situations, although 
there could be occasions where only one method is suitable.  
Modelling Dose 
Mathematical modelling of dose using commercially available software is relatively quick and easy. 
Software is available that allows for organ and effective dose values for conventional radiographic 
techniques and CT imaging to be estimated. The software employs Monte Carlo modelling which is a 
mathematical technique that simulates as closely as possible the real interactions suffered by photons.  
The process involves the computer simulation of an anthropomorphic phantom being exposed to a 
large number of photons of varying energies emitted from a point source. The path of each photon is 
followed through a sequence of interaction points and subsequent energy losses and outgoing 
directions (through coherent scattering or Compton scattering). This chain of interactions forms a so-
called photon history. At each interaction point the energy deposited to the organ is calculated and 
used in the dose calculation. A large number of independent random photon histories are generated 
and estimates of the mean values of the energy depositions in the various organs are used for 
calculating the dose in these organs  Eventually the photon loses sufficient energy to allow 
photoelectric absorption to occur [15, 16].  
PCXMC (STUUK, Helsinki, Finland [16, 17]) is one such programme that allows for organ and effective 
dose to be estimated in many conventional radiographic techniques. Figure 4 illustrates the 
positioning of a PA chest with landscape orientation of the image receptor. Other parameters can be 
manipulated in the software including X-ray anode angle, tube filtration material and thickness to 
obtain final dose estimates.  
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FIGURE 4 EXAMPLE OF DATA ENTRY PAGE OF PCXMC FOR THE CALCULATION OF ORGAN AND EFFECTIVE DOSE FROM 
A PA CHEST RADIOGRAPH 
 
 
Dose modelling software is also available for CT dose estimations. For example, ImPact’s CT Dosimetry 
Tool (ImPact, London [18, 19]) software simulation allows for quick and easy calculation of organ and 
effective dose through the use of Monte Carlo data for normalised organ doses. However, as can be 
seen in Figure 5, results are dependent on selecting the imaging parameters and CT model as 
calculations take into account specific features of each CT unit (e.g. radiation quality and field 
geometry) [20]. Selection of the correct scanner may not always be possible as new technology and 
systems are constantly being introduced. These systems are currently not included in dose simulation 
software meaning that dose simulation has to rely on “best fitting” the attributes of these scanners to 
those of a similar design. As noted by Groves et al [21], this introduces the potential for significant 
error in the estimated doses. Automatic mA manipulation by the scanners can also lead to error as 
the software only allows a single value to be used. 
66 
 
FIGURE 5 EXAMPLE OF THE DOSE REPORT GENERATED BY IMPACT CT DOSIMETRY SOFTWARE 
 
 
 
Underestimation of CT doses using computer simulation is frequently reported with magnitudes 
between 18 and 40% [5, 12, 13]. Reasons for these underestimations have been explained by the 
differences in the physical dosimetry phantoms and the virtual phantoms used by dose modelling 
software. Close examination of this highlights the simplified geometric shapes of the organs. 
Subsequently, as can be seen in Figure 6, in CT examinations of the chest the CT virtual phantom 
67 
 
suggests that the liver is not exposed to primary X-ray beam and thus the calculated liver dose would 
be low. In reality a significant volume of this organ is included in the scan and so will contribute to the 
effective dose calculations.  
 
          
 
 
 
 
 
 
 
 
 
 
 
However, accuracy of CT dose modelling can be improved by careful selection of the scan range to 
match the fractions of organs irradiated and to include overbeaming and overranging that is a feature 
of helical scanning. The use of an average mAs for the scan parameters will further improve the 
accuracy of the dose calculations [22]. 
Measuring dose 
There are many tools which may be used to measure the dose absorbed during a radiographic 
procedure that will allow dose to be calculated. The one that most Operators will be familiar with is 
the Dose Area Product (DAP) meter. DAP combines two quantities- as its name suggests absorbed 
dose in air and the field size giving the unit Gray centimetre squared Gycm2 (or cGycm2 or mGycm2) 
(NB not Gray per square centimetre). DAP meters are mounted onto the X-ray tube in front of the 
collimators making readings easy to acquire, however it is important to note that DAP is not patient 
dose per se [23]. It is independent of the distance between the source and the patient meaning that 
if this figure is to be used to estimate patient dose the source to patient distance, the field size and 
the location of the area exposed are required [24].  
CT acquisitions have similar values that are often used as a reference for patient dose; the computed 
tomography dose index (CTDI) and dose length product (DLP). The CTDI measurement was based on 
an axial CT scanner and was defined as the dose from the primary beam plus scatter from surrounding 
slices from a single slice in an acrylic phantom (Figure 7). Phantoms come in two diameters, 16cm and 
32cm, to represent the head and body respectively [25].  
 
 
FIGURE 3 COMPARISON OF THE VIRTUAL PHANTOM IN IMPACT CT DOSIMETRY 
SOFTWARE AND ATOM DOSIMETRY PHANTOM 
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Developments in technology and the advent of multislice CT equipment lead to variations in CTDI. 
CTDI100 reflects the dose contribution from a 100mm range (50mm either side of the reference slice). 
The weighted CTDI (CTDIw) reflects the weighted sum of two thirds the peripheral dose and one third 
the central dose in a 100mm range. The most commonly quoted CTDI value in modern CT technology 
is the volume CTDI (CTDIvol). This value is obtained by dividing CTDIw by the beam pitch factor [22, 26].  
As before CTDI in any form is not patient dose but a quantification of the radiation output of the CT 
system so does not take into account differing patient sizes and area of the body that is being imaged 
[27]. 
A derivative of CTDI is Dose length product (DLP). This figure takes into account the length of the scan 
and is calculated by multiplying the CTDIvol by the length of the scan. In a similar way to CTDI and 
CTDIvol, DLP is not patient dose as it does not take into account what part of the body is being exposed, 
the size of the patient, or the patient’s age.  
Conversion of DLP to patient dose is possible using a conversion coefficient (k) shown in (Table 6). This 
conversion factor is defined as the effective dose per dose-length product and has the unit mSv / mGy 
cm. Multiplying the DLP by the relevant conversion factor gives a value for effective dose.  
TABLE 6 NORMALISED VALUES OF EFFECTIVE DOSE PER DOSE-LENGTH PRODUCT (DLP) OVER VARIOUS BODY REGIONS 
Region of the body Normalised effective dose 
(E/DLP) (mSv/mGycm 
Head 0.0023 
Neck 0.0054 
Chest 0.017 
Abdomen 0.015 
Pelvis 0.019 
 
Criticisms of k state that the factors are based on old technology and old data; they are based on 
several scanners that were in use circa 1990 and the tissue weighting factors used in their calculation 
are from ICRP 60 [13, 26, 28]. There are also a number of assumptions made that would increase the 
error in the calculated effective dose. For example, the patient is assumed to be standard, and as 
noted by McCollough et al [27], this standard patient is a little thin by today’s standards (nominal body 
FIGURE 4 TYPICAL ARRANGEMENT OF THE PHANTOM AND PENCIL 
BEAM IONISATION CHAMBER USED TO COLLECT CTDI 
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mass of 70 kg). Variation in the way CT scanners report CTDIvol for paediatric patients can make 
comparison difficult. Some use the 16cm phantom while others use the 32cm phantom. For example 
Siemens, Philips dose reports are based on a 32cm phantom, Toshiba reports are based on 16 cm 
phantom and GE reports use the 16cm or 32 cm depending on the scan field of view. CTDIvol can differ 
by a factor of approximately 2.5 between the two diameter phantoms [27]. 
True measurement of dose using digital or analogue dosimeters such as metal oxide semi-conductor 
field effect transistor (MOSFET) or thermoluminescent dosimeters (TLDs) (described later) can be 
done in a number of ways. In the experimental setting it is possible to measure organ dose by placing 
dosimeters in a specially designed anthropomorphic phantom. These phantoms are available in a 
range of patient types; male and female and paediatric, adolescent and adult (Figure 8). They are made 
up of contiguous slices with different tissues represented by different densities of epoxy resin. The 
resin has attenuation properties that are equivalent to real tissue. Within the slices are locations for 
placing dosimeters that will provide data of organ dose (Figure 9). Using these phantoms allows the 
researcher to carry out experimentation on different techniques, exposure factors or positioning to 
optimise dose without the involvement of real patients. 
  
FIGURE 8 THE CIRS ATOM DOSIMETRY PHANTOM FAMILY MODELS 701-706 (CIRS, NORFOLK, VIRGINIA) [29]   
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FIGURE 9 LOWER THORACIC SLICES OF A PAEDIATRIC PHANTOM SHOWING DIFFERENT DENSITY RESIN FOR THE LUNG, 
SOFT TISSUE AND BONE WITH LOCATIONS FOR DOSIMETERS. THESE DOSIMETERS CAN BE ELECTRONIC (SHOWN HERE 
BY THE TWO WIRES INSERTED INTO THE PHANTOM) OR ANALOGUE SUCH AS THERMOLUMINESCENT DOSIMETERS 
[29]. 
 
 
It is obviously impossible to directly measure organ dose in the clinical setting, so the entrance surface 
dose (ESD) can be used. ESD is defined as the absorbed dose in the skin at a given location on the 
patient and also includes backscattered radiation from the patient. As a measurement it can be 
combined with DAP to allow calculations of patient dose to be made.  
Dosimeters 
ESD and organ dose in the anthropomorphic phantom can be measured using a digital dosimeter or 
using thermoluminescent dosimeters (TLD). Most medical imaging personnel will be familiar with TLDs 
in the context of radiation protection as they are frequently used in personal dosimeter badges. TLDs 
are available in a variety of forms, from powder to square or circular chips, rods, cubes and in a range 
of materials.  
Thermoluminescence (illustrated in Figure 11) uses the atomic model of two energy bands; the 
valence band and conduction band. Within the valance band electrons are bound to individual atoms 
as opposed to the conduction band where electrons can move freely within the atomic lattice. 
Separating these two bands is an area that is referred to as the forbidden gap in which no electron 
state can exist. The impurities mentioned above create electron traps within this gap. Exposure to 
ionising radiation excites electrons allowing them to move up to the conduction band leaving holes 
within the valence band. Electrons can travel amongst the crystal lattice until either the electron can 
cross back towards the valence band and recombine with a hole or, if near a defect, it can fall into the 
energy trap. The electron is now prevented from filling a hole within the valance band until it can gain 
enough energy to once again reach the conduction band before moving back to the valance band. This 
stimulation is in this context accomplished by introducing heat [30]. The movement of the electron 
back to the valance band requires the electron to lose energy. This energy is released in the form of 
visible light and this light is detected by a photomultiplier tube. The charge (measured in Coulombs 
[C]) generated from this component is measured.   
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The choice of material depends on the nature of radiation; in diagnostic and therapeutic energies 
the chemical composition of the dosimeters is either lithium fluoride with magnesium and titanium 
impurities added or lithium fluoride with magnesium, copper and phosphorus impurities added [31].  
The difference in the materials affects their sensitivity and the measurement range the TLD is 
capable of. For example TLDs made from Calcium Fluoride Dypromsium are suitable for 
environmental monitoring and as capable of detecting doses of between 0.1 pGy to 1 Gy [32]. 
Lithium Fluoride with magnesium and titanium are suitable for medical physics dosimetry 
applications and operate at doses between 10 pGy to 10 Gy [33]. 
Conversion from charge to dose involves a calibration process. The TLD or batches of TLDs plus 
scattering material and a digital dosimeter are exposed to a range of exposures at energy (kV) 
consistent with the experiment that will be performed. The charge generated from the reading 
process and the doses recorded by digital dosimeter are used to establish the calibration factor 
through linear regression.  An example of calibration data using is shown Figure 11. 
Conduction 
Band 
Valance Band 
 
 
TLD 
TLD readout 
Thermal stimulation 
Conduction 
Band 
Valance Band 
 
TLD 
Exposure to radiation 
Conduction 
Band 
Valance Band 
TLD 
Storage 
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FIGURE 5 ILLUSTRATION OF THE PROCESS INVOLVED IN TLD DOSIMETRY 
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General radiographic equipment can be used in this process although some TLD readers will perform 
calibration using sealed sources of gamma emitting isotopes such as Strontium-90 or Yttrium-90. Such 
systems will calibrate each TLD individually rather than in batches increasing the accuracy of the final 
readings. The response of the TLDs is energy dependent therefore calibration should be performed at 
the energy that will be used in the research or measurements. If this cannot be done then energy 
conversion factors can be used but this can introduce error [34].    
Figure 11 Example of calibration data for TLDs at 80kV. Plotting data from table (a) results in graph (b) and 
shows the linear relationship between the charge generated from reading the TLD to dose. The gradient of 
this line is the calibration factor. 
 (a) 
 
 
 
 
 
 
 
 
 
(b) 
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kV mAs Digital Dose 
reading 
(mGy) 
Background 
corrected 
charge (nC)  
80 10 0.338 9.7 
80 20 0.685 18.6 
80 40 1.382 37.1 
80 80 2.749 73.2 
80 160 5.542 158.9 
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One of the disadvantages of the TLD is the time needed to prepare and setup and process them. A 
typical whole body adult phantom measurement for calculation of effective dose involves the use of 
268 individual TLDs. Reading this number using a manual TLD reader equates to approximately 6 
hours of work [35]. Research has been undertaken to follow the dental radiography dosimetry 
process to reduce the number of TLD required for effective dose measurement however, if 
comparison of organ dose and risk is to be carried out it has been shown that a measurement organ 
dose is required for all critical organs [35].  
An alternative to TLDs is the digital dosimeter. An example of this is the metal oxide semi-conductor 
field effect transistor (MOSFET) (Best Medical Canada, Ontario, Canada) (Figure 12).  
FIGURE 12 A MOSFET DOSIMETER WITH AN ARRAY OF FIVE DOSIMETERS CONNECTED TO THE MODULE [36] 
 
Exposure of the digital dosimeter results in a voltage shift between the components of the dosimeter.  
This difference is measured and is proportional to the dose absorbed by the detector. However, it is 
unlikely that the total number of digital dosimeters would be available to allow measurement of all 
critical organs in one exposure due to expense of the dosimeters. Therefore a number of repeated 
measurements with the dosimeter relocated between each would be required. As with TLDs, MOSFET 
dosimeters require calibration and their response is energy dependent meaning separate calibrations 
are required if a significant difference in beam energies is to be used in any research [37]  
Measurements using TLD or digital dosimeters have their advantages and disadvantages relating to 
preparation time, acquisition time processing following exposure, and cost. These have to be 
considered when planning research that involves the direct measurement of dose form exposure to 
ionising radiation [21, 35, 38].  
 
Summary 
This article has given insight into terms and concepts associated with dose measurement and 
modelling, as well as risk estimation. Some limitations and values of dose estimation and 
measurement methods have been considered. As support for this special issue the reader should have 
gained enough background and insight into Monte Carlo mathematical dose modelling to be able to 
appreciate some of the empirical articles. Beyond the special issue we anticipate that the article could 
serve as a teaching or CPD aid for personnel working in medical imaging.  
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PAPER 3 
OPTIMISING THE NUMBER OF THERMOLUMINESCENT DOSIMETERS REQUIRED FOR THE 
MEASUREMENT OF EFFECTIVE DOSE FOR COMPUTED TOMOGRAPHY ATTENUATION CORRECTION 
DATA IN SPECT/CT MYOCARDIAL PERFUSION IMAGING. 
Tootell, A., Szczepura, K., & Hogg, P. (2013).Radiography, 19(1), 42-47. doi: 
http://dx.doi.org/10.1016/j.radi.2012.11.001 
Abstract: 
The use of thermoluminescent dosimeters (TLDs) is regarded as time consuming and laborious. As 
part of our dosimetry research it was necessary to optimise the use of our resources, both physical 
and time. Experimental work was carried out to develop a method that allowed for a reduction in 
the number of TLDs needed for accurate effective dose measurement. For this work specific 
reference to computed tomography attenuation correction (CTAC) for myocardial perfusion imaging 
(MPI) acquisitions is made although it is proposed that the developed method could be applied to 
dose assessments using TLDs.   
Research to measure and compare the effective dose from CTAC for MPI was to be carried out using 
an ATOM 701 dosimetry phantom, Harshaw 3500 manual TLD reader and TLD-100s.  
Method: To establish the areas of the phantom where dose measurements should be carried out, a 
batch calibrated TLD-100 dosimeters were placed along the centre of the phantom. A simulated 
CTAC for MPI was performed. After reading the distribution of the dose was recorded and areas 
where dose levels were below the sensitivity threshold dose of 50μGy were noted. To test the effect 
of excluding dose measurement for some areas on the final calculation of effective dose and the 
time taken to acquire the data a repeat acquisition was performed with the full complement of TLDs 
placed in the phantom in organ locations recommended by the manufacturer. The time taken for 
loading, unloading and reading was recorded. Effective dose and organ doses were calculated. The 
calculation was repeated with TLDs outside the established range excluded and the potential time 
saved calculated.  
Results: Excluding TLDs from areas where doses were below the 50μGy threshold resulted in 82 
fewer TLDs being used (268 to 186) leading to a time saving of around 2 hours per batch. The results 
of the experiment showed that effective dose measurements were 1.75% lower with the reduced 
chipset and organ dose measurements were not significantly different (p>0.10).  
Conclusion: It is proposed that this methodology could be applied to TLD dosimetry work to establish 
the areas that should be included in the measurements. In some cases significant savings in time 
could be made.  
 
Keywords:  
Thermoluminescent Dosimetry; SPECT/CT; Nuclear Medicine; Myocardial Perfusion Imaging 
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Introduction: 
The addition of computed tomography (CT) to single photon emission computed tomography (SPECT) 
has been shown not only to provide additional information to correct the emission data for 
attenuation and scatter artefact but also to more accurately localise pathology and aid 
characterisation of lesions [1]. Since the introduction of the first commercial SPECT/CT system in 1999 
the modality’s availability and its use has grown rapidly. Early SPECT/CT systems consisted of low dose 
fixed output CT components, with newer CT systems offering capabilities similar to stand-alone 
diagnostic systems [2]. When used for attenuation correction (AC), CT tube output, and dose, is kept 
comparatively low. However a comparison between three manufacturer’s exposure parameters 
suggests dose differences could exist (See table 1).  To determine whether dose differences do exist 
and to establish their magnitude two approaches can be adopted – dose modelling and dose 
measuring. 
 
Table 1: Comparison of imaging parameters for the four systems involved in the study. (GE 
Healthcare, Buc, Paris,), (Siemens Healthcare, Erlangen, Germany), (Philips Healthcare, Veenpluis, 
The Netherlands) 
Scanner Scout 
view 
Axial/Helical kV mA Rotation Slice 
thickness 
Pitch Automatic 
exposure/dose 
modulation 
GE Infinia 
Hawkeye 
(1) 
No Axial 140 2.5 30second per 
rotation 
(214o exposure) 
10mm NA NA 
GE Infinia 
Hawkeye 4 
No Helical 140 2.5 30second per 
rotation  
(214o exposure) 
5mm 1.9 NA 
Siemens 
Symbia T6 
Yes Helical 130 20 0.6s 3mm 0.938 AEC and DOM 
Philips 
Presedence 
16 
Yes Helical 120 30 1.5s 5mm 0.938 No 
 
 
This paper focuses on the preparatory research into dose measurement using thermoluminescent 
dosimeters (TLDs) and the development of a methodology which would allow the efficient collection 
of data for the calculation of effective dose from four SPECT/CT systems in common use. It is 
proposed that the methodology this paper describes could be applied to any dose measurements 
using TLDs. 
 
Measuring and modelling dose in CT AC for SPECT/CT 
Effective dose (E) is a reflection on the risk of a non-uniform dose distribution in terms of a uniform, 
or whole-body, exposure [3]. The aim of E is to provide a dose quantity that is related to the probability 
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of health detriment due to stochastic effects [4]. Calculation of E involves the weighted sum of doses 
to tissues/organs that are known to be sensitive to radiation [3, 5, 6]. The use of E is not without its 
critics and, as noted by Martin [4] and Brenner [7], over reliance is often placed on effective dose 
values and the associated risk estimates based upon it. However as Dietze et al [8] note, E applies to 
a reference person and is not intended to provide a measure of risk to individuals. Therefore the use 
of E was deemed appropriate to allow comparison of dose from the different manufacturer’s and 
different systems’ approaches to CTAC for MPI acquisitions. 
 
Dose analysis for diagnostic CT can be carried out using mathematical simulations (e.g. Monte Carlo 
modelling) by commercially available software such as that developed by ImPactscan [9-11] or by 
using direct measurements [5, 12]. The latter would involve using dosimeters, such as 
thermoluminescent detectors (TLDs) or digital Mosfet dosimeters, placed within a suitable phantom 
[13, 14]. 
 
Software simulation allows for quick and easy calculation of effective dose [9, 13], however accurate 
results are dependent on selecting the correct CT unit within the software as calculations take into 
account specific features of each CT unit (e.g. radiation quality and field geometry). Selection of the 
correct scanner and parameters for some SPECT/CT systems is possible as some manufacturers have 
combined CT systems into their hybrid gamma cameras that are identical to their standalone systems. 
However, some manufacturers have developed new technology (often termed low-dose CT) 
specifically for attenuation correction of SPECT image data. These systems, and some of the more 
recent multi-slice CT scanners, are currently not included in dose simulation software, this means that 
dose simulation has to rely on “best fitting” the attributes of these scanners to those of a similar design 
[5, 9, 12, 13].  As noted by Groves et al [13] this introduces the potential for significant error in the 
estimated doses. 
 
Underestimation using computer simulation is frequently reported with magnitudes between 18 and 
40% [5, 12, 13]. Reasons for these underestimations have been explained by the differences in the 
physical dosimetry phantom characteristics and the Medical Internal Radiation Dose (MIRD) 
mathematical phantom that is utilised in the ImPact software [5, 9, 12, 13, 15-17]. Close examination 
of this highlights the simplified geometric shapes of the organs. Subsequently, as can be seen in fig 1, 
in CT examinations of the mid-thorax, the MIRD phantom suggests that the liver is not exposed in the 
primary X-ray beam and thus the calculated liver dose would be low. In reality a significant volume of 
this organ is included in the scan and so will contribute to the E calculations [6]. Consequently, for 
(SPECT/CT) CT dose analyses, when accurate estimations of E are required, simulations cannot be used 
and a direct measurement approach has to be adopted. 
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Despite the reported advantages of direct measurement the process of using TLDs to measure organ 
dose is regarded as laborious and time consuming [5]. For our research this is particularly true because 
we use a manual TLD reader (Harshaw 3500). Timings carried out by the research team showed that 
it took around 90 seconds to read one TLD-100 - meaning a full set of TLDs (n=268 [16, 18]) would 
require around 6 hours to complete. Any reduction in the number of TLDs would obviously lead to a 
reduction in the time needed to read the data. Resources available dictated that there was a need to 
reduce the chipset from the recommended 268 [15] to a number that would allow data collection to 
be carried out in a timely manner yet would not adversely affect data quality. 
 
A number of papers describe the process of dose measurement from a range of CT examinations and 
each utilise a different number of TLDs (ranging from 66-268) [16, 18] yet little explanation of how 
these figures were arrived it is available. Tailoring the number of TLDs to the examination type is 
common place in dose measurements in dental radiography with many papers crediting Ludlow and 
Ivanovic [19] with devising the number and locations of TLDs for measurement of effective dose 
from cone beam CT examinations. Within this paper the authors argue that it is not necessary to 
Figure 1  
(a) Image from the Impact SR250 software            (b) CT scout view of the ATOM 701  
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measure all the organs cited as critical in ICRP publication 103 [6] as some are not directly exposed 
as part of their protocol. Although some will be exposed to scattered radiation, more distal organs 
would receive less exposure due to their distance from the source and attenuation by tissues in the 
path of the scatter [19]. Excluding dose measurement of these organs, that is to say assuming a dose 
of zero, is likely to lead to an underestimation the final value of effective dose. However, organs at 
the extremes of the phantom (i.e. the brain and the male gonads), have very small tissue weighting 
factors (brain 0.01 and gonads 0.08 [6]). Application of these factors to any measured equivalent 
dose suggests that their contribution to effective dose calculations for this examination type would 
be very small and their exclusion would have negligible effect on the final calculation. 
 
The aim of our work was to take determine if it was possible to take a similar approach to Ludlow and 
Ivanovich [19] and produce a reduced yet reliable TLD chipset for the ATOM 701-D dosimetry 
phantom. For the purpose of this work specific emphasis was placed CT attenuation correction (CTAC) 
for myocardial perfusion imaging however the developed method could be applied to other dose 
measurements using TLDs.  
Method:  
To reduce the number of TLDs required to produce a measurement of effective dose from CTAC for 
MPI the characteristics of TLD performance and the anatomical region of interest was considered. 
According to published literature and manufacturer’s documentation the lower limit of dose 
measurement of TLD-100 is 50μGy [20-22]. Any area that had an absorbed dose less than this figure 
could be excluded from any measurement.  As discussed by Ludlow and Ivanovich [19] TLDs in the z-
axis receive decreasing levels of radiation with increasing distance from the exposed area and at 
some point this level would fall below 50μGy.  
To compare the results of excluding these areas an anthropomorphic dosimetry phantom was 
loaded with the recommended 268 TLDs in the critical locations identified by the phantom 
manufacturer [15] and a CT acquisition using the CTAC for MPI parameters performed. To establish 
the amount of time saved by any reduction in the TLDs, the time taken to load, unload and read 268 
chips was recorded and compared to the reduced chipset. A statistical comparison of the organ dose 
and the effective whole body dose was carried out between the full and reduced datasets. The main 
purpose of this exercise was to optimise the time taken to collect data while maintaining valid and 
reliable results.  
Equipment 
Dosimetry measurements were to be carried out using TLD-100 (Thermo-fisher) and a CIRS ATOM 
dosimetry adult male phantom model 701-B [15, 16]. This version of the phantom consists of 39 
contiguous sections of differing density epoxy resin (representing bone, lung and soft tissue) that 
when put together make up the head and torso. The 701-B is supplied with 5mm pre-drilled holes 
spaced in a 30x30mm matrix that are filled with tissue equivalent plugs. 
Preparation of the TLDs 
Prior to use, the TLDs underwent a process of cleaning and annealing to improve batch consistency 
[23] and this preparation adhered to manufacturer’s instructions by annealing at 400oC for 1 hour 
followed by 2 hours at 100oC. Quality control checks on the consistency of TLD performance was 
carried out by irradiating all the TLDs to a uniform X-ray field using a Wolverson general X-ray unit at 
130kV and 20mAs. The TLDs were treated to a post irradiation, pre-read heating cycle of 10minutes 
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at 100oC as per manufacturer’s recommendations; they were read using a Harshaw 3500 manual 
TLD reader and WinRems software [20]. The TLDs were again exposed to 130kV 20mAs and read. 
The TLDs were then grouped into batches of 20 with similar responses. 
Calibration was performed on each batch using the same general X-ray unit described above and 
100mm of Perspex scattering material and a calibrated Unfors 401 QC meter. Although individual 
calibration is possible the process is very time consuming and only small improvements to accuracy 
are noted [24]. The calibration process involved exposure of batches of 5 TLDs using exposure 
factors of 4, 8, 16, 32 and 64mAs at 130kV. Calibration factors were derived by performing linear 
regression forced through zero. 
Preparation of the Phantom 
On comparison to the organ map that is available and supplied with the “-D” configuration of the 
ATOM 701 phantom, it was found that the 30x30mm grid did not align with the detector locations 
that are optimised for precise dosimetry of specific internal organs [15]. To ensure accurate TLD 
placement for organ dose measurement the phantom was corrected by drilling additional 5mm 
holes in the appropriate locations (Fig 2). Whole body effective dose measurement using the ATOM 
701-D configuration utilises a total of 268 TLDs over 22 organs.  
Fig 2 ATOM 701-B with additional detector locations as recommended in 701-D organ map [13] 
 
The focus of the dosimetry work that was being carried out was concerning attenuation correction 
using CT for myocardial perfusion imaging. This process involves imaging a region of the thorax that 
includes the left ventricle. To allow for accurate positioning of the phantom and to ensure the same 
region of the thorax was scanned for each repeat the midline of the anterior and lateral aspects of 
the phantom were marked using permanent marker. A CT chest examination was carried out on the 
phantom and using the scout view and axial images the region of the left ventricle was established. 
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This region was marked on the phantom using permanent marker. Using the laser positioning lights 
it was possible to ensure that the same region of the phantom would be scanned each time (Fig 3). 
 
Fig 3 Marking the phantom to ensure accurate and reproducible positioning of the phantom. 
 
 
Data collection 
The research team had unlimited access to a non-clinically based CT unit and this was used to collect 
data due to limited access to hybrid SPECT/CT equipment based in clinical practice. It is recognised 
that this may affect the external validity of the results.   
To determine the dose distribution along the z-axis of the phantom TLDs where placed in each slice 
along the central column of the ATOM dosimetry phantom. A review of the manufacturer’s 
parameters for CTAC for MPI acquisitions suggests that those used by the Philips Presedence system 
would give the highest dose and would represent “the worst case scenario” in terms of patient dose. 
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A 16-slice Toshiba CT scanner (Aquillion 16) (Toshiba Medical Systems, Zoetermeer, Netherlands) set 
up to emulate these acquisition parameters and the phantom was exposed. Following exposure the 
TLDs were removed from the phantom and treated to a post-irradiation, pre-read heat cycle. Five 
TLDs remained with the phantom at all times except during acquisition, these were read for 
background correction and the mean of their readings subtracted from the exposed TLDs. 
The process was repeated three times in total to allow for a mean dose to be calculated. The 
relevant calibration factors established earlier were applied to the TLD readings and the mean dose 
for the slice number obtained.  
Results 
Data was tabulated and a dose profile curve was plotted. The slice numbers were dose fell below the 
manufacturer’s stated threshold were noted. Fig 4 illustrates the distribution of the dose from head 
to toe within the phantom. Slices 17-21 were exposed to primary beam radiation with scattered 
radiation being detected above and below this range. As expected, the dose detected decreased as 
the distance between the region exposed and the TLD increased. Table 2 details the dose for the 
TLDs in each slice of the phantom (slice one has no location for TLD placement). It can be seen that 
from slices two to ten and twenty-nine to thirty-nine dose readings are below the 50μGy threshold 
for TLD-100.  
 
Fig 4 Distribution of dose through the phantom. 
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Table 2 recoreded dose of each slice showing where levels were below the 50μGy 
threshold. 
Slice number 
Mean Dose 
(mGy) 
2 0.00 
3 0.00 
4 0.00 
5 0.02 
6 0.00 
7 0.01 
8 0.00 
9 0.02 
10 0.03 
11 0.07 
12 0.20 
13 0.32 
14 0.67 
15 1.34 
16 1.88 
17 2.57 
18 8.66 
19 9.83 
20 10.01 
21 8.11 
22 3.68 
23 2.10 
24 1.44 
25 0.68 
26 0.51 
27 0.37 
28 0.10 
29 0.02 
30 0.00 
31 0.00 
32 0.07 
33 0.05 
34 0.00 
35 0.01 
36 0.01 
37 0.02 
38 0.02 
39 0.01 
 
Comparison of organ and effective dose calculations using the full and reduced data set produced 
results shown in Table 3. The “weighted organ dose” is the figure produced when the measured 
organ dose is multiplied by the weighting factor set out in ICRP publication 103 [6]. The data is set 
out so that an easy comparison can be made between the full and reduced chipsets.
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Table 3 
 
  Full Chipset Reduced Chipset 
Organ Weighting 
Mean Organ dose 
(mSv) 
Mean Weighted dose 
(mSV) Organ dose (mSv) Weighted dose (mSV) 
Brain 0.01 0.016 0.000 0.000 0.000 
Active bone marrow 0.12 0.868 0.104 0.833 0.100 
Adrenals* (Remainder) 0.12* 1.950 0.023 1.950 0.023 
Bladder 0.04 0.088 0.004 0.000 0.000 
Breast 0.12 3.987 0.478 3.987 0.478 
Colon 0.12 0.135 0.016 0.051 0.006 
Gall Bladder* (Remainder) 0.12* 0.520 0.006 0.520 0.006 
Heart*(Remainder) 0.12* 3.699 0.044 3.699 0.044 
Kidneys* (Remainder) 0.12* 0.802 0.009 0.802 0.009 
Liver 0.04 2.318 0.093 2.318 0.093 
Lungs 0.12 2.652 0.318 2.652 0.318 
Oesophagus 0.04 2.175 0.087 2.175 0.087 
Pancreas* (Remainder) 0.12* 0.808 0.010 0.808 0.010 
Prostate* (Remainder) 0.12* 0.045 0.001 0.000 0.000 
Small Intestine* (Remainder) 0. 12* 0.144 0.002 0.000 0.000 
Spleen* (Remainder) 0.12* 2.163 0.026 2.163 0.026 
Stomach 0.12 1.415 0.170 1.415 0.170 
Testes 0.08 0.045 0.004 0.000 0.000 
Thymus* (Remainder) 0.12* 0.835 0.010 0.835 0.010 
Thyroid 0.04 0.255 0.010 0.232 0.009 
TOTAL EFFECTIVE DOSE (mSv)  1.413   1.389 
 % difference  1.75 
Excluded remaining organs: extrathoracic (ET) region, 
lymphatic nodes, muscle, and oral mucosa. 
*Weighting to “remainder organs” averaged 
across those measured.    
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Comparison of the percentage difference in effective dose using a full and reduced chipset indicates 
a reduction of 1.75% using the reduced dataset. Excluding the organs that would have a dose 
recorded of 0mSv (Brain, Bladder, Prostate, Small intestine and Testes) a related two way student T-
test indicates that there is no statistical difference between the full and reduced data sets (p>0.10).  
Discussion 
From the results it is suggested that this optimisation process and the arguments behind it could be 
applied to other areas of radiography. Exclusion of organs where dose is small will lead to 
underestimation of E but this under estimation is considered to be negligible [19] and in the case of 
our work it resulted in a reduction of E of 1.75%, which demonstrated no  statistical difference.  
In our research a number of organs demonstrated a 100% reduction in dose (brain, prostate and 
testes) yet the impact on the final calculation of E is small due to the small weighting factor that is 
applied to the organ dose. A 62% reduction is noted in the organ dose for the colon due to the 
exclusion of TLDs located in the caecum, distal ascending and descending colon and the sigmoid 
colon. If comparison of organ dose is to be made then it is advisable that the whole of the organs 
with the highest weighting factors (i.e. breast, colon, lungs and stomach) should be included in any 
measurement. However, as stated in the context of our research the exclusion of the low dose 
regions and organs had an insignificant effect on effective dose calculations.  
Our empirical work was carried out on a standalone CT system however the parameters used 
simulated those that would be used by a similar system that is part of the Philips Presedence hybrid 
system. These exposure factors would suggest that this system and these factors would result in the 
highest patient dose. However to ensure external validity the process will be carried out on the 
range of systems that form part of the main study.   
It is recognised that the dose profile could be unique to each acquisition protocol, i.e. it will be 
affected by kV, mA, slice thickness/pitch, and in some cases it may be necessary to use the full 
complement of TLDs to measure E if larger regions are to be imaged (such as CT examination of the 
abdomen and pelvis). Similarly the type of TLD used will affect the shape of the profile curve with 
the more sensitive TLD-100H likely to produce a wider dose profile.  
Our experiment to establish the dose distribution has led to a reduced number of TLDs required and 
to give an accurate measure of effective dose for CTAC for MPI. This method has made the process 
of dose measurement more efficient and a less laborious task. In the case of this experiment there 
was a 30.6% reduction in the required number of TLDs (268 to 186 per scan). This equates to 
approximately 6 ½ hours less reading time per measurement (three repeats per scan) using the 
manual TLD reader.  
 
Conclusion 
The use of TLDs for effective dose measurement is a time consuming process. By producing a dose 
profile of the ATOM 701-D we have established that it is possible to reduce the total number of TLDs 
needed by excluding the regions where the detected dose is below a recordable level.  Further work 
is planned using the more sensitive TLD-100H and repeated exposure of the same TLD to establish if 
the profile differs and more TLDs are required to give an accurate measurement of effective dose. 
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PAPER 4 
COMPARISON OF EFFECTIVE DOSE AND LIFETIME RISK OF CANCER INCIDENCE OF CT ATTENUATION 
CORRECTION ACQUISITIONS AND RADIOPHARMACEUTICAL ADMINISTRATION FOR MYOCARDIAL 
PERFUSION IMAGING 
Tootell, A., Szczepura, K., & Hogg, P. (2014). The British journal of radiology, 87(1041), 20140110. 
doi: http://dx.doi.org/10.1259/bjr.20140110 
Abstract 
Objectives:  To measure the organ dose and calculate effective dose from CTAC acquisitions from 
four commonly used gamma camera SPECT/CT systems.  
 
Method: CTAC dosimetery data was collected using thermoluminescent dosimeters on GE’s Infinia 
Hawkeye four and single slice systems, Siemen’s Symbia T6 and the Philips Precedence. Organ and 
effective dose from the administration of 99mTc-tetrofosmin and 99mTc-sestamibi were calculated 
using ICRP reports 80 and 106. Using this data the lifetime biological risk was calculated.  
 
Results: The Siemens Symbia gave the lowest CTAC dose (1.8 mSv) followed by the GE Infinia 
Hawkeye single-slice (1.9 mSv), GE Infinia Hawkeye four-slice (2.5 mSv) and Philips Precedence (3.0). 
Doses were significantly lower than the calculated doses from radiopharmaceutical administration 
(11 mSv and 14 mSv for 99m-Tetrofosmin and 99m Tc-Sestamibi respectively). Overall lifetime 
biological risks were lower suggesting that using CTAC data posed minimal to the risk to the patient. 
Comparison of data for breast tissue demonstrated a higher risk than that from the 
radiopharmaceutical.  
 
Conclusions: CTAC doses were confirmed to be much lower than from radiopharmaceutical 
administration. The localised nature of the CTAC exposure compared to the radiopharmaceutical 
biological distribution indicated dose and risk to the breast to be higher. 
 
Advances in knowledge: This research proved that CTAC is a comparatively low dose acquisition. 
However, it has been shown that there is increased risk to breast tissue especially in the younger 
patient. As per legislation justification is required and CTAC should only be used in situations that 
demonstrate sufficient net benefit. 
 
Introduction 
SPECT/CT has become common place in clinical imaging and a major role for CT is for the attenuation 
correction (AC) of SPECT data in myocardial perfusion imaging (MPI) [1, 2]. The benefits of CTAC in 
MPI are well known and many national and international professional organisations recommend its 
use to improve SPECT MPI diagnostic accuracy [3, 4]. Associated with the CT acquisition is an additional 
radiation dose which is often considered to be low yet very few papers quantify the dose and the 
associated risk.  
Effective dose is a useful figure that allows for a comparison between different techniques and 
protocols to be made. However it is widely recognised that the tissue weighting factors are averaged 
over both genders and all ages and so assessment and comparison of risk for an individual patient or 
patient group is not advised [5-8].Lifetime risk of cancer incidence, sometimes referred to as lifetime 
biological risk is a concept that has been suggested by a number of authors as an alternative to 
effective dose (E) to allow a comparison of risk from non-uniform dose distributions [5-7, 9]. Brenner 
[5-7] is arguably the strongest advocate for a move to what he terms “effective risk” as it is argued 
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that E is based on “questionable science” as the tissue-specific weighting factors used, although 
based on research, are established by committee decisions and do not take into account differing 
age and gender dependencies. Wall et al [10] similarly states that E can and should play a role in 
radiation protection of radiation workers and members of the public and for the optimisation of 
techniques involving changes in radiation quality. 
The quality of the images generated by CTAC and the clinical evaluation of these to identify 
incidental extracardiac findings has been discussed in literature [11-13]. Using phantom and human 
studies it has been shown that CTAC data has the potential to allow a reporter to identify 
extracardiac pathology. The accuracy and confidence has been shown to vary with the protocols 
used. This paper measured the organ dose and calculated the E from CTAC acquisitions from four 
different protocols. The protocols selected were those pre-set by manufacturers in four commonly 
used SPECT-CT scanners and were considered to be suitable to produce data of adequate quality to 
allow attenuation and scatter correction. The aim was to establish what differences in dose exist 
from the different protocols when the data produced is used for the same purpose.  Using this data 
the lifetime biological risk was calculated with a specific emphasis on the female breast. To 
contextualise these figures organ, E and lifetime biological risks from the administration of 
radiopharmaceuticals (99mTc Tetrofosmin and 99mTc Sestamibi) were calculated from data contained 
in ICRP reports 80 and 106 [14, 15]. Comparisons were also made to estimated doses using the dose 
length product (DLP) and published normalised values of effective dose per DLP [16]. 
Materials and Methods 
Organ dose (HT) was measured using thermoluminescent dosimeters (TLD-100 [LiF], Thermofisher 
Scientific Massachusetts), and E was calculated from these values using the ICRP 103 waiting factors 
[17]. TLDs were placed within critical organs in an adult CIRS ATOM dosimetry phantom (model no 
701B, CIRS, Virginia, USA). Four SPECT/CT systems were selected due to the variations in the CTAC 
protocols. The systems included: GE Infinia Hawkeye (single slice), GE Infinia Hawkeye (4 slice) (GE 
Healthcare, Buckinghamshire UK), Siemens Symbia T6 (Siemens Healthcare Erlangen, Germany) and 
Philips Precedence (Philips Healthcare, Amsterdam, Netherlands).  
The CIRS ATOM dosimetry verification phantom is made up of the head and torso of an adult male. 
There are thirty-nine contiguous slices containing differing density epoxy resin (representing bone, 
lung and soft tissue). The 701B is supplied with 5mm pre-drilled holes spaced in a 30 x 30 mm matrix 
that are filled with tissue equivalent plugs. Hole configuration had to be modified so that they aligned 
to specific internal organs. The modification was carried out by drilling additional holes as indicated in 
the phantom manufacturer’s documentation for organ dosimetry [18].  
The location and range to be scanned was established by performing CT scan of the phantom thorax 
and the upper and lower limit of the left ventricle identified. The scan range was measured and found 
to be 12 cm. The upper and lower borders of the scan range were marked on the phantom using 
permanent ink. Radiopaque markers were attached to the phantom to allow localisation on the scan 
projection radiograph (SPR) on the Siemens and Philips systems. The GE systems do not acquire an 
SPR as the operator uses the emission data to plan the CTAC range. Using a zero refresh rate on these 
scanners’ positioning monitors a cobalt-57 source was placed on the marks for no more than five 
seconds to allow the scan range to be established. Using the reference activity of 3.7 MBq for the 
Cobalt source, the dose from this in 5 seconds at a distance of 1 cm in air would be 6.53 x 10-4 mGy. 
This value was considered to be negligible when calculating the dose from the TLDs in the phantom 
from the CTAC acquisitions.  
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Thermo-luminescent dosimeters (TLD-100) (Thermo Scientific, Erlangen, Germany) were cleaned and 
prepared in accordance with Tootell et al [19]. TLDs were organised into batches that ensured that 
the percentage variation of each batch was between 1.8 and 2.2 %. This was done by annealing and 
exposing all the TLDs to a uniform exposure of 120kV and 20mAs using a standard X-ray unit 
(Wolverson Arcoma, Willenhall, UK). The TLDs were ranked in order of response and organised into 
five batches. Each batch was calibrated using the same general X-ray unit at beam energies equivalent 
to the CTAC protocols using a calibrated Unfors Mult-O-Meter (Unfors RaySafe, Billdal, Sweden). 
The TLDs were placed in a bespoke shielded case for transportation to the nuclear medicine 
departments involved in the study to prevent exposure to background radiation and any sources of 
radiation in the nuclear medicine departments. These TLDs were placed in the phantom in critical 
organs identified in ICRP 103 and the manufacturer user guide of the phantom to allow organ dose 
to be measured [17, 18, 20] (Table 1)  
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TABLE 1 NUMBER OF TLDS USED IN CRITICAL ORGANS 
Organ Number of TLD 
Adrenals 2 
Bladder 16 
Brain 11 
Breast 2 
Active bone Marrow  85 
Clavicle 20,  
Cranium 4 
Cervical Spine 2 
Femora 4 
Mandible 6 
Pelvis 18,  
Ribs 18 
Sternum 4 
Thoraco-lumbar Spine 9 
Eyes* 2 
Gall Bladder 5 
Heart 2 
Intestine (Small and large) 16 
Colon 11 
Small intestine 5 
Kidneys 16 
Liver 30 
Lungs 36 
Oesophagus 3 
Pancreas 5 
Prostate 3 
Spleen 14 
Stomach 11 
Testes 2 
Thyroid 10 
* Not included in effective dose calculations 
 TLDs located in the anterior of C2 and upper oesophagus were 
used to calculate extra thoracic organ dose 
 TLDs located in the left and right lingula of the mandible and to 
the left and right of the sublingual fossa were used to calculate 
salivary gland organ dose 
× TLDs located in the left and right lingula of the mandible were 
used to calculate oral mucosa organ dose 
 
A total of five TLDs remained with the phantom except during imaging for background radiation 
correction. CTAC imaging was performed using the standard manufacturer protocols for MPI 
attenuation correction (Table 2).  
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TABLE 2 PROTOCOLS USED FOR ATTENUATION CORRECTION FOR MYOCARDIAL PERFUSION IMAGING. 
Scanner Scout 
view 
Axial/
Helical 
kV mA Rotation Slice 
thickness 
Pitch 
 
Automatic 
exposure/ 
dose 
modulation 
GE Infinia 
Hawkeye (1 
slice) 
No Axial 140 2.5 30 second per 
rotation 
(214o 
exposure) 
10mm N/A N/A 
GE Infinia 
Hawkeye (4 
slice) 
No Helical 140 2.5 30 second per 
rotation  
(214o 
exposure) 
5mm 1.9mm 
per 
rotation 
N/A 
Siemens 
Symbia T6 
Yes Helical 130 20 0.6s 3mm 0.938 AEC and 
DOM 
Philips 
Precedence 16 
Yes Helical 120 30 1.5s 5mm 0.938 N/A 
 
Three CTAC exposures were performed on each SPECT-CT system to allow a cumulative dose on the 
TLDs to be acquired. CTDIvol and dose length product data was recorded to be used for dose calculation 
and comparison to measured doses. Reading of the TLDs was carried out using a Harshaw 3500 manual 
TLD reader (Thermo Electron Corporation, Reading, UK) and WinRems software (Saint-Gobain Crystals 
& Detectors, Wermelskirchen, Germany). TLD readings were corrected for background and an average 
value for each TLD calculated. Organ doses were calculated and then used to calculate E and lifetime 
biological risk using the equations shown in Figure 1. The conversion coefficient for CT chest imaging 
was applied to the DLP readings and the resulting dosimetry compared to the measured readings [16].  
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FIGURE 1 EQUATIONS FOR (A) ORGAN DOSE, (B) ACTIVE BONE MARROW DOSE, (C) EFFECTIVE DOSE AND 
(D) LIFETIME BIOLOGICAL RISK [18]. 
 
 
 
Active bone marrow dose was calculated using data on bone marrow distribution from Christy [21]. 
According to statistics, ischaemic heart disease affects a larger proportion of the population of men 
over 55 and women over 65 [22]. The maximum age considered by Christy is 40 therefore this data 
a) 
𝐻𝑇 =
1
𝑛
∑ 𝐷𝑖,𝑗
𝑛
𝑗
 
Where    
HT  = equivalent organ dose 
 j = 1,…n, the number of TLDs in organ i. 
 
b) 
𝐷𝑎𝑏𝑚 = ∑ 𝐴𝑘 ∙ 𝐷𝑘
𝑘
 
Where    
Dabm  = Dose to active bone marrow 
Ak  = proportion of active bone marrow described by Cristy [21] (∑ 𝐴𝑘 = 1) 
 
c)  
𝐸 = ∑ 𝑊𝑇 ∙ 𝐻𝑇
𝑇
 
Where    
E = effective dose to the entire body 
   WT = tissue weighting factor of tissue (T) defined by ICRP 103 [20] 
   HT = equivalent dose absorbed by tissue (T) 
 
 
d) 
𝑅 = ∑ 𝑟𝑇 ∙ 𝐻𝑇
𝑇
 
Where    
R = lifetime biological risk (defined as the generic lifetime radiation-attributable  
cancer risk) 
   rT = lifetime radiation-attributable organ-specific cancer risk estimates (per unit  
equivalent dose to tissue T) 
   HT = equivalent dose absorbed by tissue (T)  
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was used in the equation for calculating the equivalent dose to active bone marrow.  
Values for rT used in this study are tabulated in the Health Protection Agency report HPA-CRCE-028 
for 11 cancers of high risk organs over age ranges 0-9, 10-19, 20-29 etc. up to 90-99 [10]. Cancers of 
other radiosensitive organs share a collective risk estimate. This study followed the method 
described by Li et al [9] by applying this value to a weighted average dose of other radiosensitive 
organs (Figure 2). 
 
FIGURE 2 EQUIVALENT DOSE TO OTHER ORGANS DEFINED IN ICRP 103[17] 
 
 
 
 
 
Other organs included the salivary glands, brain, heart, kidney, gallbladder, spleen, pancreas, 
adrenal glands, thymus, small intestine, extrathoracic region and oral mucosa. Data collection using 
TLDs for lymph nodes, muscle, bone surface and skin was not performed as they are large 
organs/systems and it was deemed these would contribute very little to the overall E and lifetime 
biological risk calculations as only a small proportion of the tissue would be exposed during the 
imaging process and their exclusion would have negligible effect. The weighting for the remaining 
organs was averaged over those organs where dose was measured [23].   
Organ and E for the radiopharmaceutical administration were calculated using data provided in ICRP 
report 80, report 106, diagnostic reference levels (DRL) indicated in the Administration of 
Radioactive Substances Advisory Committee’s publication and guidance published by the British 
Nuclear Medicine Society and adopted by the British Cardiac Society and the British Nuclear 
Cardiology Society [15, 24-26]. The total dose and risks for a stress and rest procedure using a total 
1600MBq of 99mTc-tetrofosmin and 99mTc-sestamibi were compared to the additional dose and risk 
from the CTAC acquisitions performed using parameters described in Table 2. Data for lifetime 
biological risk incidence was obtained from Wall et al [10]. 
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Results 
Table 3 shows the dose effective dose for a single CTAC acquisition of the four protocols used in the 
study. 
 
 
TABLE 3 ORGAN AND EFFECTIVE DOSES FOR A SINGLE CTAC ACQUISITION MEASURED USING TLDS. 
Organ 
Dose (mSv) 
GE Infinia 
Hawkeye 1 
GE Infinia 
Hawkeye 4 
Siemens 
Symbia T6 
Philips 
Precedence  
Brain 0.0 0.0 0.1 0.1 
Salivary glands 0.0 0.0 0.1 0.2 
Thyroid 0.1 0.3 0.8 0.4 
Oesophagus 1.3 1.9 1.2 2.3 
Lungs 1.8 2.7 1.5 2.8 
Breast 3.5 3.3 2.0 4.1 
Liver 1.3 2.4 1.3 2.4 
Stomach 0.5 1.2 0.9 1.5 
Colon 0.0 0.1 0.2 0.2 
Bladder 0.0 0.0 0.2 0.2 
Testes 0.0 0.0 0.1 0.2 
Active (red) bone marrow 0.6 0.6 0.9 0.9 
Remainder 0.1 0.1 0.1 0.1 
Effective Dose 1.0 1.2 0.9 1.5 
 
Table 4 shows the comparison in E measured using TLD and E calculated using the DLP.  
TABLE 4 EFFECTIVE DOSE USING DLP*K (CONVERSION COEFFICIENT (MSV/MGY*CM) WHERE K=0.017 [16] 
System 
protocol 
CTDIvol 
(mGy) 
DLP       
(mGy*cm) 
Calculated 
Effective 
Dose (EDLP) 
(mSv)  
Measured 
Effective 
Dose (ETLD) 
(mSv) 
Percentage 
difference 
(%) 
GE single 
slice 
4.11 49 0.83 1.0 13.5 
GE four slice 3.9 46 0.78 1.2 46.3 
Siemens 
Symbia T6 
1.75 21 0.36 0.9 85.7 
Philips 
Precedence 
3.5 42 0.71 1.5 71.5 
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E and organ dose for the lung, oesophagus, colon, liver and stomach from the administration of 99mTc 
Tetrofosmin and 99mTc Sestamibi are shown in Table 4 and two CTAC acquisitions (performed for 
both rest and stress protocol) are shown in Table 5. 
 
 
TABLE 5 EQUIVALENT AND EFFECTIVE DOSES FOLLOWING ADMINISTRATION OF RADIOPHARMACEUTICALS 
FOR A REST/STRESS PROCEDURE AND TWO CTAC ACQUISITIONS. 
 
 
 
Organ  
Dose (mSv) 
99mTc 
Tetrofosmin  
99mTc 
Sestamibi 
 
GE 
single 
slice 
GE four 
slice 
Siemens 
Symbia 
T6 
Philips 
Precedence 
Lung 5.1 7.1 3.6 5.4 3.1 5.5 
Oesophagus 5.3 6.5 2.5 3.8 2.4 5.6 
Colon 28.8 34 0.2 0.2 0.6 0.5 
Liver 5.3 16 2.6 4.7 2.7 4.9 
Stomach 7.4 10 1.1 2.4 1.7 3.1 
Breast 3.7 5.7 7.1 6.6 4.1 8.2 
E (mSv) 11 13.3 1.9 2.5 1.8 3.0 
 
Following the method described by Wall et al [10] conversion to lifetime cancer risk per million (106) 
was performed and are shown in Table 6. 
TABLE 6 TOTAL RISK (PER MILLION) FROM RADIOPHARMACEUTICAL AND CTAC ACQUISITIONS USING 
DIAGNOSTIC REFERENCE LEVELS AND MANUFACTURER PROTOCOLS 
Examination  
Risk (per 106) 
Age at exposure 
40-49 50-59 60-69 70-79 
99mTc Tetrofosmin 525 386 244 130 
99mTc Sestamibi 608 447 284 152 
CTAC GE single slice 63 52 39 24 
CTAC GE four slice 101 83 61 37 
CTAC Siemens Sybmia T6 80 63 45 27 
CTAC Philips Precedence 103 86 64 40 
 
Consideration was given to the risk to the breast from radiopharmaceutical administration and CTAC 
acquisition. The phantom used in the study was male and no additional breast tissue was added 
however, the acquired data allowed for a comparison of the risks within the context of this study. 
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TABLE 7 RISK TO BREAST (PER MILLION) FROM RADIOPHARMACEUTICAL AND CTAC ACQUISITIONS USING 
DIAGNOSTIC REFERENCE LEVELS AND MANUFACTURER PROTOCOLS 
Examination  
Risk (per 106) 
Age at exposure 
40-49 50-59 60-69 70-79 
99mTc Tetrofosmin 31 31 8 3 
99mTc Sestamibi 48 48 12 5 
CTAC GE single slice 60 60 15 6 
CTAC GE four slice 55 55 14 5 
CTAC Siemens Sybmia T6 34 34 9 3 
CTAC Philips Precedence 69 69 17 6 
 
Discussion 
Comparison of EDLP and ETLD showed significant differences in the two values with EDLP being 
consistently lower. This agrees with published literature [27-29]. However, the average percentage 
difference between the two is 54.2% which far exceeds figures quoted by Groves et al [27] of 18% 
and Hurwitz et al [29] of 25%. Criticisms of k state that the factors are based on old technology and 
old data; they are based on several scanners that were in use circa 1990 and the tissue weighting 
factors used in their calculation are from ICRP 60 [16, 30, 31]. There are also a number of 
assumptions made that would increase the error in the calculated effective dose. For example, the 
patient is assumed to be standard and, as noted by McCollough et al [32], this standard patient is a 
little thin by today’s standards (nominal body mass of 70 kg). Possible sources of error were 
considered and additional quality checks performed on the TLDs. The batches were checked for 
uniformity and were found to be within the 2% level established before the experiment commenced 
at higher and lower doses of X-radiation. The images acquired as part of the CTAC exposure were 
also compared and it was clear that the same region of the phantom was exposed each time. 
Whether the cited criticisms of k are the main contribution to these differences is unclear from this 
research. 
Comparing E of the CTAC acquisitions to those from the administration of the radiopharmaceuticals it 
can be seen that these figures are smaller but acquisition of AC data using CT does contribute 
additional dose to the patient. From this research this is in the magnitude of 7.3% to 27.3%. 
Comparison of CTAC to the “typical effective dose” for a CT chest of 6.6 mSv supports the popular 
opinion that CTAC is a low-dose CT procedure [10].   
Consideration of risk again highlights large differences between the radiopharmaceutical and CTAC 
acquisition. When considered with the reported benefits of CTAC in improving the sensitivity and 
specificity it can be said that the reported benefits of attenuation and scatter correction using CT 
benefits do outweigh the risks [33-35].  
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A comparison of doses from the CTAC acquisitions showed some interesting findings. The protocol 
from the Siemens Symbia T6 gave the lowest E, this was significantly different to the protocols from 
the Philips Precedence and GE Hawkeye 4 slice systems (paired T Test, p<0.05). However statistical 
comparison of the protocols from the Symbia T6 to the GE Infinia Hawkeye single slice showed no 
statistical difference (paired T Test p=0.37). The Siemens Symbia T6 CT component is a higher 
specification system that has been shown to produce diagnostic quality CT images so it would be 
expected that E would be higher [12]. Close examination of the imaging parameters in Table 2 does 
highlight two interesting features, including the use of automatic exposure control (AEC) and dose 
modulation (DOM) during the acquisition. This technology (referred to as CARE Dose4D) manipulates 
the tube current in two ways. Firstly the tube current is varied based on the attenuation data 
acquired as part of the SPR. Secondly, attenuation in the patient is measured in real-time during the 
helical acquisition, where the mA is modulated to equalise the photon flux reaching the detectors 
during the scan. The aim of both these techniques is to keep noise levels consistent throughout the 
scan to allow for anatomical variations in attenuation, hence optimising image quality and patient 
dose.  
The GE systems have a low specification CT component with many of the exposure parameters being 
fixed. On first glance it could be assumed that with a tube current of 2.5 mA, the dose from CTAC 
acquisitions would be significantly lower than the Siemens which has a mA of 20. However, taking the 
rotation time into account the effective mAs of each slice is much higher. Calculations using the mA 
and rotation time and angle of rotation illustrate that an effective mAs of 44.6 is used for each slice in 
these acquisitions. Performing a T-test between the two GE systems together illustrates a statistically 
significant difference in dose (p=0.0002), with the four slice system giving the higher dose. Reasons 
for this could be due to the method of acquisition as the four-slice system acquires data helically rather 
than axially. 
The protocol used by the Phillips Precedence gave the highest E of the four systems. The Phillips 
Precedence is a 16 slice “full diagnostic” system but as can be seen in Table 2, parameters used are 
significantly lower than those that would be used in diagnostic CT imaging. The opportunity for further 
dose reduction should be recognised by the Operator and options for dose optimisation on an 
individual patient basis utilised. The authors recognise that the imaging parameters used are set by 
the manufacturer and a departmental process of optimisation may have the potential to further 
reduce E. Manipulation of parameters such as mA, rotation time, pitch and/or acquisition method 
(helical or axial) have the potential to reduce dose while ensuring adequate data quality. 
The phantom used in this study is representative of an adult male phantom and so risk and 
calculations of E are specific to this gender. Dose to breast and risk calculations were carried out and 
are shown in Table 7 however It is recognised that the risk to the female breast is likely to be 
different to the quoted figures due to the absence of additional breast tissue that would be present 
in the female phantom but as a comparison within the context of this study, some interesting results 
were found. This comparison highlights that although the overall lifetime biological risks associated 
with the CTAC exposure are much lower, organ specific risks may be comparable or higher. For 
example the addition of a CTAC using the Philips Precedence protocol to a 99mTc Tetrofosmin stress 
and rest study in a 40-49 year old increases the risk to the breast from 31 per million to 100 per 
million.  
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Conclusion 
The authors recognise that local optimisation of administered radioactivity and CT imaging 
parameters should be performed and actual values for E and risk will vary accordingly. However, as a 
comparison exercise this paper provides the information on the associated risks of performing CTAC. 
On comparison to doses and risks from the administration of radiopharmaceutical, the CTAC poses a 
small increase to risk especially to the older population. However, it has been shown that 
consideration should be given to risks to individual organs and in this case Practitioners should be 
aware of the increased risk to breast tissue especially in the younger patient. As per legislation 
justification is required and CTAC should only be used in situations that demonstrate sufficient net 
benefit to the patient. 
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PAPER 5  
EFFECT OF RECONSTRUCTION METHODS AND X-RAY TUBE CURRENT–TIME PRODUCT ON NODULE 
DETECTION IN AN ANTHROPOMORPHIC THORAX PHANTOM: A CROSSED-MODALITY JAFROC 
OBSERVER STUDY 
Thompson, J. D., Chakraborty, D. P., Szczepura, K., Tootell, A. K., Vamvakas, I., Manning, D. J., & 
Hogg, P. (2016). Medical Physics, 43(3), 1265-1274. doi: http://dx.doi.org/10.1118/1.4941017  
 
Introduction 
Radiation dose in computed tomography (CT) is a highly topical concern in medical imaging and 
there is a recognition of increased dose with the use of multi-detector CT (MDCT).[1-5] However, 
radiation dose risk needs to be balanced with benefits, and MDCT has been a significant 
development in acute medicine[6-9] where a quick and accurate diagnosis is important for patient 
outcome. 
Low noise and high spatial resolution are important considerations for accurate radiological CT 
reports. Until recently, filtered back projection (FBP) had been the image reconstruction method of 
choice. Unfortunately, data non-linearity and image reconstruction artefacts are prevalent with FBP 
and a loss of spatial resolution is an unwanted trade-off when attempting to reduce image noise. 
[10-12]10–12 Improved computer processing capability currently allows the use of iterative 
reconstruction (IR) in CT as an alternative to FBP. Incorporating physical models into the algorithm 
allows image quality to be maintained at lower dose and lower noise levels [13] and dose reductions 
~ 23-79% have been reported when using IR in place of FBP [14-17].  
Adaptive iterative dose reduction 3D (AIDR3D, Toshiba Medical Systems, Minato-ku, Japan) is a 
recently developed iterative reconstruction (IR) algorithm for CT data, where it has been suggested 
that using AIDR3D in place of FBP could allow dose saving ~ 75% [18]. A detailed explanation of how 
AIDR3D works in the projection and reconstruction domains has been published [19].19 
Several studies [19-21] have assessed this new algorithm using objective and subjective measures. 
Common to all is an objective evaluation of image noise, evaluating either the standard deviation of 
pixels values in regions of interest in various quasi-uniform anatomical regions [19-20]or the noise 
power spectrum (NPS) in a phantom model [21]. All studies report reductions in image noise. Spatial 
resolution was assessed objectively using the modulation transfer function21 and subjectively using a 
5-point scale to assess the pulmonary vessels [20];both of these methods suggested that spatial 
resolution (or sharpness) was reduced with AIDR3D in comparison to FBP [20-21]. Subjective 
evaluations of images, using 5-point visual scoring systems, were used to assess diagnostic 
acceptability [19-21], artefacts [20-21], and pathology [19]. With one exception subjective image 
quality was stated as being better with AIDR3D [20]. Despite the inconsistencies listed above, all 
studies suggested that AIDR3D could offer a large dose reduction in the thorax: by a factor of 6 from 
150 mAs down to 25 mAs, [19] when using a low dose acquisition in place of a standard dose 
acquisition, [20] or as an average of 36% over a range of tube current-time product settings 
(comparing FBP and AIDR3D directly) [21].Ohno et al [19] and Yamada et al [20] both used the 
computed tomography dose index (CTDI) to assess radiation dose, when in fact it is only a measure 
of absorbed dose to a standardized phantom and does not account for patient size and potential 
cancer risk [22]. The above studies are further limited by a the lack of an ROC type analysis and low 
case numbers: e.g., 37,and 50 patients respectively [19-20]. 
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We are aware of only one paper that assesses the value of IR in the thorax with observer 
performance methods. A study by Katsura et al [23] assessed the value of using a model-based IR 
algorithm (MBIR) against adaptive statistical IR (ASIR; GE Healthcare, Waukesha, WI). An ultralow-
dose MBIR acquisition with a fixed tube current was compared to a low-dose acquisitions using ASIR 
and automatic tube current modulation. The study used 59 patients and 2 observers, with 84 
nodules present in 41 patients, with the remaining 18 patients having no lung nodules. Nodule 
detection rates were similar between the two acquisitions (p=0.57), and the authors reported dose 
saving of more than a factor of 4, from a DLP of 66mGy-cm to 14.5mGycm. However, it is not 
possible to claim that nodule detection rates were equivalent without performing an equivalence 
study [24,25]. Stated simply, not being able to reject the null hypothesis of equal performance does 
not imply the two modalities have equal performances. The work of Katsura et al differs from 
previous work and this study in that they compared two IR algorithms and not FBP. In this work we 
make methodological improvements on previous studies to evaluate the performance of AIDR3D and 
FBP for nodule detection over a range of tube current-time product. Initial results questioning the 
advantages of IR over FBP in an anthropomorphic chest phantom were presented as a conference 
paper in early 2015 [26]. 
 
Method 
A free-response study was conducted using an anthropomorphic chest phantom to determine 
nodule detection performance for images constructed using FBP and IR over a range of mAs values. 
This was combined with an accurate assessment of radiation dose using a separate phantom.  
Phantoms 
An anthropomorphic chest phantom (Lungman N1 Multipurpose Chest Phantom, Kyoto Kagaku 
Company, Japan) representing a 70Kg male was loaded with simulated nodules measuring 5, 8, 10 
and 12mm in spherical diameter and +100, -630 and -800 Hounsfield Units (HU) densities. The higher 
electron density (+100HU) nodules are composed of polyurethane, hydroxyapatite and a urethane 
resin; the lower electron density (-630 and -800HU) nodules are composed of urethane. 
An ATOM 701D (ATOM 701; CIRS, Norfolk, VA) whole-body dosimetry verification phantom was used 
to measure organ doses. Prior to data collection the median-sagittal and mid-coronal planes, and the 
scan range that covered the lung apices and costo-diaphragmatic recesses, were marked on the 
dosimetry phantom using an indelible marker. This allowed accurate and reproducible positioning 
and scanning of the dosimetry phantom. 
Image Acquisitions 
All image acquisitions were completed on a Toshiba Aquilion One 320-slice MDCT scanner (Toshiba 
Medical Systems, Minato-ku, Japan) in volume mode. Each volume covered 160mm in the transaxial 
(z-axis) plane, where the volume is also the collimation size in this instance, and three volumes were 
required to provide complete coverage of the anthropomorphic chest phantom. A tube current-time 
product range (10, 20, 30 and 40 mAs) was investigated for both reconstruction algorithms (FBP and 
IR) while all other CT acquisition parameters remained constant (120kVp, 0.5 second rotation time, 
pitch 1, 64x0.5 mm detector configuration, 1mm slice reconstruction, 512x512 matrix size, 320 mm 
scan and reconstruction field of view, 0.625mm pixel size, a medium bowtie filter, appropriate for 
the 320mm field of view). The images were reconstructed with FBP and AIDR3D, Figure 1. 
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Figure 1: Sample images to demonstrate the effect of tube current-time product (horizontally) and 
reconstruction method (vertically). A simulated nodule measuring 10mm and -630HU is visualised 
in the antero-medial aspect of the simulated lung. 
 
The anthropomorphic chest phantom was loaded with three different nodule configurations. 
Nodules were distributed as described in Table 1, with nodules considered peripheral if they were in 
close proximity to the chest wall. For each tube current-time product and image reconstruction, 34 
abnormal transaxial image slices (containing 1-3 nodules, mean 1.35±0.54) and 34 normal transaxial 
image slices corresponding to the same anatomical position for each modality were chosen for the 
observer study. Nodule positions were recorded at the time of insertion, and confirmed on the 
lowest noise images (40 mAs, reconstructed with AIDR3D) to act as the truth (gold standard) for the 
observer study. 
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 Anterior Posterior Central Peripheral 
Zone Right Left Right Left Right Left Right Left 
Upper - 3 3 1 - 1 - 2 
Mid 2 1 9 7 3 4 2 5 
Lower 2 - 3 2 3 2 4 5 
 
Dosimetry 
TLDs (TLD100H LiF:Mg,Cu,P, Thermo Scientific, Waltham, MA) (n=271 plus n=5 for background 
correction) were grouped into batches of similar response (intra batch variation ≤2%). Processing of 
the TLDs was carried out using Harshaw 3500 manual TLD reader (Thermo Scientific, Waltham, MA). 
Each batch of TLDs was calibrated. Annealed TLDs were positioned within the dosimetry phantom at 
locations corresponding to 23 of the critical organs identified in ICRP report 10327 for each of the 
four imaging conditions. Effective dose was calculated from the organ doses by applying radiation 
and tissue-weighting factors specified in the same publication [27]. 
Effective risk was calculated using PCXMC software (STUK, Helsinki, Finland), a Monte Carlo program 
for estimating patient doses. The software estimates the patient risk of death due to radiation-
induced cancer, according to the risk model of the BEIR VII committee [28,29]. 
This CT system acquires data in volume mode. The volume of 160mm is not fully contained within 
the dimensions of a typical CT dose phantom and standard pencil CT ionization chamber [30]. This CT 
scanner reports CTDIvol values that are adjusted for wide beam CT when acquiring data in volume 
mode.  
Observer Study 
Six radiologists (12.2±9.1 years reporting experience) and five radiographers trained to perform CT 
examination (18±5.3 years CT imaging experience) completed the observer study. For each 
combination of tube current-time product and reconstruction method, each observer interpreted 68 
cases (i.e., single transaxial CT images) using the FROC paradigm. The interpretations were 
performed in two sessions, each lasting approximately 1 hour. Each observer viewed the cases in a 
different randomised order. They were unaware of the tube current-time product and 
reconstruction methods used to generate each image, but were informed that half of the images 
contained 1-3 simulated nodules of varying size and contrasts and the remaining contained none. All 
observers completed a training exercise prior to the main study. Ten non-identifiable images 
containing nodules and ten not containing any nodules, which were cases not used in the main 
study, were used to demonstrate the appearance of the anthropomorphic chest phantom and 
simulated nodules, while also giving the opportunity to learn how to localise nodules and use the 
rating scale and familiarize themselves with the user interface. The same monitor (PG21HQX, Wide, 
20”, LCD, Wide Corporation, Korea) (1536x2080 pixels, 3.2 megapixel resolution) was used for all 
observers and evaluations under the same controlled viewing conditions. 
The free-response receiver operating characteristic (FROC) method was used to acquire the observer 
data. Observers were instructed to mark the centre of each simulated nodule using a single mouse 
click; this would cause a "pop-up" a slider bar rating scale to appear by which they could rate 
confidence on a 1-10 integer scale. Using a 20-pixel acceptance radius, marks were classified as 
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nodule localisation (LL) if they were within the acceptance radius of the nearest nodule, or non-
nodule localisation (NL). Image display and FROC study functionality was managed by ROCView  
display and data acquisition software [31]. Images were viewed on a fixed lung window (1500, -500) 
to maximise nodule visibility and reduce observer variability. 
Statistical Analysis 
In this study the equally weighted JAFROC figure of merit was used, denoted by 𝜃 [32]. The JAFROC 
figure of merit is the weighted empirical probability that a nodule rating is higher than any rating on 
a normal case [32]. In this study all nodules on a case were assigned the same weight. The weighting 
gives equal importance to each case, independent of the number of true nodules in it. To check for 
consistency, inferred-ROC analysis was also performed. To do this we used the highest rating on a 
case to define the inferred-ROC rating for that case. 
In this study there were two factors (in the statistical sense) that would ultimately influence the 
performance of the observer – tube current-time product and image reconstruction method. In a 
typical analysis of multi-modality multiple reader multiple case, typically termed an MRMC 
ROC/FROC study, modality is considered as a single factor with 𝐼 levels, where 𝐼 is usually small, but 
greater than 2. For example, if comparing two image reconstruction methods, 𝐼 = 2. The measure of 
performance or figure of merit for modality 𝑖(𝑖 = 1, 2, … , 𝐼) and reader 𝑗(𝑗 = 1, 2, … , 𝐽), where 𝐽 is 
the number of readers, is denoted 𝜃𝑖𝑗. Current MRMC ROC/FROC analysis compares the observed 
difference in reader-averaged figures of merit between modalities 𝑖 and 𝑖′ (𝑖 ≠ 𝑖′) to the estimated 
variability of the difference. For example, the reader-averaged difference in figures of merit is 𝜃𝑖• −
𝜃𝑖′• , where the dot symbol represents and average of the corresponding index, specifically, the 
reader index. The variability of the difference is estimated using the Hillis-modified Obuchowski-
Rockette (ORH) method [33], with resampling (i.e., jackknifing) used to determine the two 
covariances needed for the ORH method. With 𝐼 levels, the number of possible 𝑖 versus 𝑖′ 
comparisons is 𝐼(𝐼 − 1)/2. If the current study were analysed in this manner, where 𝐼 = 8 (4 levels 
of tube current-time product and two image reconstruction methods) then this would imply 28 
comparisons. The large number of comparisons is sub-optimal in terms of statistical power and does 
not inform us of the main points of interest: whether performance depends on (i) tube current-time 
product and/or (ii) reconstruction method. 
Unlike conventional ROC type studies, the images in this study are defined by two factors. The first 
factor, tube current-time product, had four levels: 10, 20, 30 and 40 mAs. The second factor, 
reconstruction method, had two levels: FBP and AIDR3D. Each factor is combined with the other, so 
they are fully-crossed factors (in the statistical sense). The figure of merit is represented by 𝜃𝑖1𝑖2𝑗  
where represents the levels of the first factor (mAs), and 
represents the levels of the second factor (reconstruction method), . This called for two 
sequential analyses to be performed: the first was mAs analysis, where the figure of merit was 
averaged over the 𝑖2 or the reconstruction index; the second was reconstruction analysis, where the 
figure of merit was averaged over the 𝑖1 or the mAs index. For example, the mAs analysis figure of 
merit difference is 𝜃𝑖1•• − 𝜃𝑖′•• , where the first dot represents the average over the reconstruction 
index and the second dot represents an average over readers. In either analysis the figure of merit is 
dependent on only a single factor, and therefore the standard ORH method applies. 
The mAs analysis determines whether there is a tube current-time product effect and in this analysis 
the number of possible comparisons is six. The reconstruction analysis determines whether AIDR3D 
offers any advantage over FBP and in this analysis the number of possible comparisons is one. 
i1 i1 =1,2,..., I1( ) I1 = 4 i2 i2 =1,2,..., I2( )
I2 = 2
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Multiple testing on the same dataset increases the probability of Type I error, therefore a Bonferroni 
correction (Appendix A) was applied by setting the threshold for declaring significance at 0.025; this 
is expected to conservatively maintain the overall probability of a Type I error at α = 0.05. We use 
the term crossed-modality analysis to describe this type of analysis of ROC/FROC data. 
Since the phantom is unique, and conclusions are only possible that are specific to this one 
phantom, the case (or image) factor was regarded as fixed. For this reason only results of random-
reader fixed-case analyses are reported. Software for crossed-modality modified JAFROC analysis 
was implemented in the R programming language [34], and is downloadable from the https://cran.r-
project.org/web/packages/RJafroc/index.html. 
A Welch’s independent sample t-test was performed to assess any difference in performance 
between radiologists (n=6) and radiographers (n=5); the null hypothesis of no difference was tested 
at an alpha of 0.05.  
Contrast-to-Noise Ratio of Nodules 
The contrast-to-noise ratio (CNR) of all nodules was measured using ImageJ [35] software. The CNR 
is a measure of image quality based on contrast (in this instance between nodule and background), 
rather than the raw signal [36]. Nodule measurements were made on images viewed by the 
observer. A region of interest (ROI) was placed just within the outer edge of each nodule and the 
mean pixel value was recorded. A background ROI was placed within a portion of the lung field 
containing no nodule or vascular markings, and the mean pixel value and standard deviation were 
recorded. A linear least squares analysis was performed to determine the impact of tube current-
time product and image reconstruction method on the CNR of all nodules. Test alpha was set at 0.05 
for detecting significant differences in CNR between images reconstructed with FBP and AIDR3D. 
Results 
A Welch’s unpaired t-test of observer averaged figures of merit revealed no significant difference in 
nodule detection performance between radiologists and CT trained radiographers (p = 0.1124, mean 
difference 0.051 (95% CI -0.015, 0.117). Based on this all observers were included in the subsequent 
analysis. 
Averaged 
over 
index 
Reconstruction Method 
& Tube Current-Time 
Product 
Crossed-Modality JAFROC 
FOM (95% CI) 
Inferred ROC FOM (95% CI) 
i1 
FBP 0.867 (0.832,0.903)  0.918 (0.894,0.941)  
AIDR3D 0.869 (0.833,0.904)  0.915 (0.891,0.938)  
i2 
10mAs 0.835 (0.769,0.875) 0.892 (0.865,0.919) 
20mAs 0.867 (0.827,0.908) 0.910 (0.884,0.937) 
30mAs 0.878 (0.864,0.910) 0.925 (0.904,0.945) 
40mAs 0.891 (0.858,0.925) 0.938 (0.916,0.960) 
Table 2: Figures of merit and 95% confidence intervals (CI) for crossed-modality JAFROC analysis 
and highest-rating inferred ROC analysis. Analysis i1 is averaged over tube current-time product 
(mAs) and analysis i2 is averaged over reconstruction method (FBP or AIDR3D). 
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For a statistically significant difference to be declared the p-value of the treatment pair t-test and 
that of the overall F-test must both be significant (Appendix B). For the first of the sequential 
crossed-modality JAFROC analyses, the mAs analysis, where the figure of merit is averaged over the 
𝑖2 or the reconstruction index, significant differences were revealed between multiple pairs of tube 
current-time product settings (F(3,30) = 15.96, p<0.001). For the second of the sequential analyses, 
the reconstruction analysis, where the figure of merit was averaged over the 𝑖1 or the mAs index, 
there was no statistically significant difference in nodule detection performance between FBP and 
AIDR3D (F(1,10) = 0.08, p = 0.789). Individual figures-of-merit are displayed in Table 2 and Figure 2; 
inter-treatment differences are presented in Figure 3. The Inter-treatment differences for inferred 
ROC analysis are presented in Figure 4. These yielded similar results; mAs analysis (F(3,30) = 15.18, 
p<0.001) and reconstruction analysis (F(1,10) = 0.27, p = 0.615), i.e., consistent with crossed-
modality JAFROC analysis. The important outcome is that no statistical difference was demonstrated 
between images reconstructed with FBP and AIDR3D. A statistically strong effect (p < 0.001) was seen 
with tube current-time product. Figure 3 shows weighted JAFROC FOM differences and 95% 
confidence intervals for all 6 pairings of tube current-time product. A difference is significantly 
different from zero if the corresponding confidence interval does not include zero. Figure 3 shows 
that except for the 20-30 mAs and 30-40 mAs comparisons, the rest were all statistically significant. 
Figure 4 shows corresponding results using the inferred ROC FOM: the results are consistent with 
those shown in Figure 3. As expected, the inferred ROC differences are smaller in magnitude than 
the corresponding JAFROC FOM differences (the ROC FOM ranges from 0.5 to 1, while the JAFROC 
FOM ranges from 0 to 1). 
 
Figure 2: Figures of merit and 95% CI for crossed-modality JAFROC analysis (top) and highest-rating 
inferred ROC analysis (bottom).1 
                                                          
1 The error bars indicate the 95% confidence level.  
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Figure 3: Inter-treatment differences for crossed-modality modified JAFROC analysis. A difference 
is considered significant if the 95% confidence interval does not include zero and the p-value of 
the overall F test is less than 0.025. Statistical differences are seen between 10-20, 10-30, 10-40 
and 20-40 mAs2. 
 
 
Figure 4: Inter-treatment differences for the inferred ROC analysis. Statistical differences are 
observed for the same treatment pairs, as with JAFROC FOM in Figure 3, with slight variation in 
the magnitudes of the differences (as expected the inferred ROC differences are smaller in 
magnitude than the corresponding JAFROC FOM differences).2 
                                                          
2 The error bars indicate the 95% confidence level. 
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Statistically significant differences in nodule detection performance were observed between 
multiple pairs of tube current-time product settings when the p-value of the overall F-test was 
p<0.001; significant pairs were 10 mAs and 20 mAs (p<0.001), 10 mAs and 30 mAs (p<0.001), 10 mAs 
and 40 mAs (p<0.001), and 10 mAs and 20 mAs (p=0.008); no difference was found between 20 mAs 
and 30 mAs or between 30 mAs and 40 mAs (p > 0.025). 
The results of effective dose and effective risk are summarized in Table 3. The observations are 
consistent with the expected strict linear dependence of dose on tube current-time product. The 
CTDIvol values for each tube current-time product setting are also reported. 
 
Tube current-time product 
(mAs) 
10 20 30 40 
CTDIvol (mGycm2) 0.7 1.4 2.1 2.6 
Effective Dose (mSv) 0.49 0.97 1.64 2.11 
Effective Risk (%) 1 in 714 
(0.0014) 
1 in 345 
(0.0029) 
1 in 208 
(0.0048) 
1 in 167 
(0.0060) 
 
Table 3: Effective dose and effective risk for the tube current-time product range investigated in 
this study. An approximately linear increase in dose and risk is observed. 
 
Results for CNR are summarised in Table 4. Analysis by least squares revealed that measures of CNR 
were statistically higher for the simulated nodules on images reconstructed with AIDR3D (p<0.001). 
The reconstruction method did not impact on the contrast between nodule and background 
(p=0.223), but the image noise was statistically higher on images reconstructed with FBP (p<0.001). 
This is to be expected as the HU of the nodules and background should not change when using 
different reconstruction method, and therefore the only variable element within the CNR is the 
image noise. The relationship between image noise and tube current-time product for each image 
reconstruction method is demonstrated in Figure 5. Mean noise is lower at all tube current-time 
product settings for images reconstructed with AIDR3D in place of FBP. At 40 mAs, the noise level is 
very consistent when images are reconstructed with AIDR3D, demonstrated by the small standard 
deviation. 
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 Mean values and standard deviation 
Tube Current-Time 
Product (mAs) 
10 20 30 40 
Nodule 
CNR 
FBP 2.58±2.42 3.36±3.43 4.13±4.46 4.90±4.65 
AIDR3
D 
4.52±4.30 6.85±7.15 9.17±9.27 11.5±9.16 
Contrast 
FBP 423±316 412±324 443±337 419±407 
AIDR3
D 
410±315 471±318 441±336 417±311 
Noise 
FBP 190±63.6 137.53±71.1 110±51.41 104±58.5 
AIDR3
D 
117±70.0 74.7±57.4 67.6±63.4 40.9±19.7 
Table 4: A summary of the mean contrast-to-noise ratio of all simulated nodules, mean contrast 
between nodule and background and the mean noise levels on all images containing nodules for 
both reconstruction methods and over the range of tube current-time product investigated in this 
study. 
 
Figure 5: The mean noise and standard deviation as calculated from all images containing nodules 
for AIDR3D (top) and FBP (bottom) respectively over the tube current-time product range 
investigated in this study. The difference in image noise between reconstruction methods was 
significant (p<0.001) according to a least squares analysis. 
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Discussion 
This study has evaluated nodule detection in CT images reconstructed with AIDR3D and FBP over a 
range of tube current-time product. We found no statistically significant difference in nodule 
detection when images were reconstructed with either FBP or AIDR3D. However, we did find that the 
level of image noise was statistically higher in images reconstructed with FBP. This disparity, 
consistent with earlier studies, between image noise, a physical measure, and nodule detection, an 
observer performance measure, is an important finding given the steps taken to improve statistical 
power in this study. We removed case variability through the use of a phantom and the large 
number of readers (n=11) used minimized reader variability, the crossed-modality methodology 
averaged the data over all tube current-time product settings for a more stable measure, and taking 
location into account, i.e., FROC study, increases statistical power compared to the ROC method. The 
other important finding of this work, evident in Fig. 2, is that tube current-time product was found to 
have a significant effect on nodule detection, with detection compromised below 20 mAs as 
compared to 40 mAs. However, the fact that the 95% CI for the 20-30 comparison, includes zero, 
does not imply that the two are equivalent. A different type of statistical procedure is needed to 
infer equivalence between the two tube current-time product settings [24]. Software for this type of 
testing is not readily available. 
Many previous studies [19-21, 37,38] have found a similar result to the present study when 
assessing image noise, be in by measuring CNR, NPS or signal-to-noise ratio (SNR): they all find that 
the physical metrics improve as a result of reduced image noise with the IR algorithm. Our study is 
consistent with previous results: significant effect on physical measures between processing 
algorithms but insignificant effect in objective observer performance. We believe the difference is 
due to the fact that an objective FROC observer performance measure, such as used in this study, 
takes the combined effect of all factors affecting nodule detectability into account, including visual 
search, while physical measure focus on a few individual measures in isolation and do not account 
for visual search. Moreover, the physical measures considered in this manuscript do not represent 
state-of-the-art because they do not account for spatial corrections in the images. Newer model 
observer methods account for some of these correlations [39-41], and they are just beginning to 
account for visual search [42]. However, observer performance studies suffer from much larger 
sources of variability than physical measures, so more careful statistical analysis is needed. As noted 
by the late Dr. Robert F. Wagner, finding physical measures, or combinations of physical measures, 
that correlate with the more time-consuming observer measures is one of the "holy-grails" of 
medical imaging [43]. 
Diagnostic acceptability must be maintained when looking to optimise the dose delivered to the 
patient. Many studies have suggested that IR algorithms can be used to optimise dose with a range 
of percentage reductions previously quoted (36-75 %) [18-20]. This requires the pre-optimisation 
start point to be reasonable and it is the post-optimisation dose that should be given the greatest 
consideration. 
For true optimisation, the risk to the patient must also be understood. Patient dose is frequently 
reported using sub-optimal estimation methods (CTDI, DLP, body part specific conversion factors) 
and the lifetime risk associated with X-ray exposures is rarely reported. The method used in the 
current work is considered a reliable method to accurately represent dose and risk and we would 
encourage future studies of IR algorithms to adopt this technique. 
Lee et al [44] quote a mean effective dose of 1.84±1.05 mSv in a study of paediatrics, where the 
purpose of the examination was to evaluate lung metastases. The mean weight of the patients was 
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41.4 kg, somewhat lighter than the estimated 70Kg patient size in our study. When using ASIR-FBP 
blending and FBP alone, Qi et al [45] showed that radiation dose to the patient could be optimised at 
an average effective dose of 4.25 mSv (range 2.6-6.3 mSv) with ASIR-FBP blending compared to an 
average of 8.65mSv (range 7.9-9.5 mSv) with FBP alone. This finding is supported by Chen et al [46], 
but their post-optimisation dose was much lower at 0.74 mSv. Both studies investigated ASIR in a 
patient population, and both proposed ASIR blending at 50% as being optimal. The large difference 
in estimated effective dose in these studies is likely due to the amount of noise permitted in the 
images by the automatic exposure control (AEC) and image quality paradigm. The noise index, in the 
GE systems of the above papers, is referenced to the standard deviation of pixel values in a water 
phantom, compared to patient attenuation measured in the CT planning image, in order to maintain 
a constant level of image noise [47]. Qi et al chose a noise index of 15, while Chen et al chose a noise 
index of 30, where a higher noise index provides a greater reduction in tube current. Neither 
observer performance evaluation nor equivalency study was performed in either of these works, and 
further assessment is required before dose optimisation can be claimed with IR algorithms. 
Previous optimistic claims of dose reduction with IR algorithms are mainly based on physical 
measures. While our methods were sensitive enough to find statistical differences in nodule 
detection performance attributed to tube current-time product, we were unable to detect any 
statistical difference in nodule detection on the basis of image reconstruction algorithm. It is not 
surprising that pixel-variance is a poor predictor of lesion detectability; for example it can be 
reduced almost arbitrary, by smoothing the image. The inadequacy of pixel variance as a predictor of 
lesion detectability was noted in 1999 by Burgess, but this work is not well appreciated [48]. IR 
algorithms require further investigation, with observer performance and equivalency testing playing 
a more prominent role. 
Conclusion 
We have successfully demonstrated the use of a crossed-modality JAFROC analysis that allows us to 
take co-existing factors into account in order to determine the dependence of nodule detection on 
each factor. We believe this is a useful methodological improvement, since system performance is 
usually dependent on more than just a single factor. No significant difference in nodule detection 
performance was demonstrated between images reconstructed with FBP and AIDR3D. Tube current-
time product was found to influence nodule detection, but further work is required for dose 
optimization. 
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Appendix A: Bonferroni Correction 
Under null hypothesis (NH) true conditions, a valid significance testing procedure maintains the 
probability of a Type I error (incorrect rejection of the NH) at the chosen value of alpha, i.e., 5% in 
our study. The Bonferroni correction falls under the subject of multiple significance tests. To quote 
Bland and Altman [49]: "Many published paper include large numbers of significance tests. These 
may be difficult to interpret because if we go on testing long enough we will inevitably find 
something that is significant. We must beware of attaching too much importance to a lone 
significant result among a mass of non-significant ones". 
In the current context there are two significance tests, the first for the mAs effect (with 6-levels) and 
the second for the reconstruction effect (with 2-levels). For the mAs-effect the DBMH procedure 
accounts for the 6 pairings and maintains the NH rejection rate at 5%. In other words, if the study 
were repeated 2000 times independently under NH true conditions (obviously this is only possible 
using a data simulator) there would be about 100 incorrect rejections of the NH for the mAs-effect. 
However, one is also attempting to draw conclusions about the effect of the two reconstruction 
algorithms, i.e., applying a second significance testing procedure. Again, the DBMH procedure 
maintains the Type I error rate at 5% for this comparison, so for 2000 simulations one expects about 
100 incorrect NH rejections for the reconstruction effect. The question arises: to what extent the set 
of specific simulations where the NH was rejected for the mAs comparison (e.g., the 23rd, 30th, …, 
1940th, etc. simulations, for a total of about 100) are common or distinct from the set of specific 
simulations that incorrectly rejected the algorithm effect. If the two sets are identical, then one still 
has a total of 100 NH rejections and the overall NH rejection rate is 5% and no correction is needed, 
which is the best-case scenario. The worst-case scenario is that the two sets are completely 
different, in which case the total number of NH rejections is 200. The only way to control for this is 
to set a more stringent criterion for rejecting the NH. For example, if the criterion were set to reject 
2.5% of the time for each type of comparison, there would be 50 NH rejections for the mAs 
comparison study, and 50 different rejections for the algorithm comparison study, for a total of 100 
NH rejections. To summarize, the Bonferroni correction involves using a smaller value of alpha, equal 
to the desired value divided by the number of significance tests. It is a conservative correction that, 
depending on the correlations between the two significance test results, tends to yield an effective 
alpha of less than 5%. A conservative correction is not always desirable because it leads to loss of 
statistical power and more sophisticated procedures are available [50]. 
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Appendix B: JAFROC Statistics and Degrees of Freedom 
JAFROC software reports the results of an overall F-test of the NH that all modalities being tested 
have identical FOMs. The analysis obtains two estimates of variance, the first due to the differences 
between modalities and the second due to other causes. If the observed ratio of the first variance to 
the second variance is large enough, the FOMs are expected to be significantly different. The ratio 
follows the F-distribution, which is characterized by two quantities called the numerator and 
denominator degrees of freedom, ndf and ddf respectively. In general, if the ratio of the two 
variances is large and the degrees of freedom are large, the study tends to be more significant 
(smaller p-value) [51]. 
 
 
120 
 
PAPER 6 
A PHANTOM-BASED JAFROC OBSERVER STUDY OF TWO CT RECONSTRUCTION METHODS: THE 
SEARCH FOR OPTIMISATION OF LESION DETECTION AND EFFECTIVE DOSE   
Thompson, J. D., Chakraborty, D. P., Szczepura, K., Vamvakas, I., Tootell, A., Manning, D. J., & Hogg, 
P. (2015). Paper presented at the Proc. SPIE 9416, Medical Imaging 2015: Image Perception, 
Observer Performance, and Technology Assessment, Orlando, Florida. 
 
ABSTRACT 
Purpose: To investigate the dose saving potential of iterative reconstruction (IR) in a computed 
tomography (CT) examination of the thorax. 
Materials and Methods: An anthropomorphic chest phantom containing various configurations of 
simulated lesions (5, 8, 10 and 12mm; +100, -630 and -800 Hounsfield Units, HU) was imaged on a 
modern CT system over a tube current range (20, 40, 60 and 80mA). Images were reconstructed with 
(IR) and filtered back projection (FBP). An ATOM 701D (CIRS, Norfolk, VA) dosimetry phantom was 
used to measure organ dose. Effective dose was calculated. Eleven observers (15.11±8.75 years of 
experience) completed a free response study, localizing lesions in 544 single CT image slices. A 
modified jackknife alternative free-response receiver operating characteristic (JAFROC) analysis was 
completed to look for a significant effect of two factors: reconstruction method and tube current. 
Alpha was set at 0.05 to control the Type I error in this study. 
Results: For modified JAFROC analysis of reconstruction method there was no statistically significant 
difference in lesion detection performance between FBP and IR when figures-of-merit were 
averaged over tube current (F(1,10)=0.08, p = 0.789). For tube current analysis, significant 
differences were revealed between multiple pairs of tube current settings (F(3,10) = 16.96, p<0.001) 
when averaged over image reconstruction method. 
Conclusion: The free-response study suggests that lesion detection can be optimized at 40mA in this 
phantom model, a measured effective dose of 0.97mSv. In high-contrast regions the diagnostic value 
of IR, compared to FBP, is less clear. 
 
Keywords: Free-response, modified JAFROC, iterative reconstruction, CT, effective dose, dose 
optimization, lesion detection 
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Introduction 
Background 
The increasing popularity of computed tomography (CT) as a diagnostic imaging modality 
raises concerns in regard of radiation dose.1 In the UK the use of CT is increasing at a higher 
rate annually than any other modality.2 Since the inception of CT in the 1970’s, filtered back 
projection (FBP) has been the mainstay of image reconstruction methods. Image production 
with FBP does not tolerate a large reduction in tube current (mA), while all other acquisition 
parameters remain constant, due to the associated increase in image noise.3 This can make 
dose optimization problematic, where it is preferable to have low noise and high spatial 
resolution images for interpretation. Iterative reconstruction (IR) has recently gained 
acceptance in the clinical setting due to improvements in computation power; previously this 
had not been practicable due to the length of time it had taken to reconstruct a series of 
images. The impact of this development may have a welcome impact in dose and image 
optimization; specifically because there is less dependence of spatial resolution on image 
noise with IR.3 The innovation associated with IR has allowed improved image quality for 
the same radiation dose, with recent studies comparing FBP and IR suggesting dose saving 
over the range of 23-76%.4 In this study we seek to assess the diagnostic value of a relatively 
new IR image reconstruction algorithm for lesion detection in an anthropomorphic chest 
phantom. 
 
Methodology 
Image Acquisition 
CT images were acquired on the Toshiba Aquilion ONE 320-slice multi-detector CT (MDCT) scanner 
(Toshiba Medical Systems, Minato-Ku, Japan). A range of tube current (20, 40, 60 and 80mA) was 
used while all other acquisition parameters remained constant: 120 kilovolt potential (kVp), 0.5-
second rotation time, pitch 1, 64x0.5mm detector configuration and a 320mm scan field of view 
(FOV). Images were reconstructed at 1mm thickness using a 320mm reconstructed FOV on a matrix 
size of 512x512 for a pixel size of 0.625mm. 
An anthropomorphic chest phantom (Lungman N1 Multipurpose Chest Phantom, Kyoto Kagaku 
Company, Japan) representing a 70Kg male was loaded with several different configurations of 
spherical simulated lesions from a pool of fifteen different sizes and density (5, 8, 10, 12mm; +100, -
630 and -800 Hounsfield Units, HU). The higher density (+100HU) lesions are composted of 
polyurethane, hydroxyapatite and a urethane resin; the lower density (-630 and -800HU) lesions are 
composed of urethane. The phantom was scanned on each tube current setting, and reconstructed 
with FBP and IR for all lesion configurations. Lesion positions were recorded at the time of 
placement and acquisition, to provide a ‘truth’ reference map. 
From the acquired data, the same 34 normal and 34 abnormal transaxial image slices were selected 
from each acquisition-reconstruction combination were chosen for the observer study. Table 
position and image slice number were used to ensure the same transaxial slice was selected on each 
occasion. No physical movement of the phantom occurred between acquisitions; this ensured 
continuity and precise replication of lesion positions for all CT acquisitions. The result was eight sets 
of precisely matched image data for four variations of tube current and the two image 
reconstruction methods, Figure 1. 
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Dose Measurement 
An ATOM 701D (CIRS, Norfolk, VA) whole-body dosimetry verification phantom was used to measure 
organ dose. Annealed thermoluminescent dosimeters (TLD100H LiF:Mg,Cu,P, Thermo Scientific, 
Waltham, MA) were positioned in clinically relevant places for each of the four conditions and 
effective dose calculated.5 
 
Observer Study 
Eleven observers (15.11±8.75 years of experience) completed the observer study. Observers were 
introduced to the appearances of the phantom and simulated lesions, and they were instructed that 
all the lesions were spherical and that no other pathological mimics that may have been caused by 
the phantom were of interest in this study. Each observer evaluated 544 single CT images for 
simulated lesions. They were informed that half of the images being evaluated would contain 
simulated lesions and that there were 1-3 simulated lesions (mean 1.35±0.54) in each abnormal 
image, the remaining images contained no simulated lesions. A single transaxial CT image was 
treated as an individual case. Observers completed the image evaluation in two separate sessions in 
order to reduce the effects of fatigue. Images were presented in a different randomized order for 
each observer. 
ROCView6 was run on the same monitor (PG21HQX, Wide, 20”, LCD, Wide Corporation, Korea; 
1536x2080 pixels, 3.2 megapixel resolution) to collect free-response data for all evaluations.  
Observers localized lesions with mouse clicks; localizations were classified as lesion localization (LL) 
or non-lesion localization (NL) by a 20-pixel acceptance radius. Observers were instructed to mark 
the center of each suspected lesion. This prompted an unmarked (no graduations) slider-bar rating 
scale to appear; moving the slider to the right demonstrated an increasing level of confidence. The 
slider bar collected ratings over a 10-point scale. Images were viewed on a fixed lung window (1500, 
-500) to maximize lesion visibility and reduce this source of variability due to the observer. 
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Figure 1: A single transaxial slice showing a solitary simulated lesion (black arrow, top left). Images 
reconstructed with IR are shown on the top row for all tube current values and the corresponding 
images reconstructed with FBP are on the bottom row. The simulated soft tissue of the 
anthropomorphic chest phantom illustrates the difference in image noise. 
 
 
 
Statistical Analysis – Crossed-modality JAFROC analysis 
In the analysis of ROC type studies the modality is generally regarded as a single factor with I levels, 
where I is usually small (e.g., I = 2, 3 or 4). The figure of merit, for example the area under the ROC 
curve, for modality i (i = 1, 2, ..., I) and reader j (j = 1, 2, ..., J, where J is the number of readers), is 
denoted . The analysis compares the observed difference in reader-averaged figures of merit 
between modalities i and i' (i ≠ i') to the estimated variability of the difference. The reader-averaged 
difference in figures of merit is , where the dot symbol represents an average over the 
corresponding index. The variability of the difference is estimated using the modified Obuchowski-
Rockette (OR) method,7,8 with resampling (e.g., jackknifing) used to determine the two covariances 
needed for the OR method. In the study the equally weighted JAFROC figure of merit was used for 
. The JAFROC figure of merit is the weighted empirical probability that a lesion rating is higher than 
any rating on a normal case. In this study all lesions on a case were assigned the same weight. The 
weighting gives equal importance to each case, independent of the number of true lesions in it. For 
consistency checking, inferred-ROC analysis was also performed using the highest rating on a case to 
define the inferred-ROC rating of the case. 
With I levels, the number of possible i vs. i' comparisons is I(I-1)/2. For example, if I = 2, the number 
of comparisons is 1 and if I = 3, the number of comparisons is 3. If this study were analyzed in this 
manner, then the number of modalities I = 8 (4 levels of mA for each of two reconstruction methods) 
would imply 28 comparisons. Besides decreasing statistical power, the results of such comparisons 
would not be particularly informative regarding the two questions of main interest: (i) whether 
performance depends on mA and (ii) whether performance depends on the reconstruction method. 
q ij
qi· -qi '·
q
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In this study each image is actually defined by two factors. The first factor is tube current, which had 
4 levels: 20, 40, 60 and 80 mA. The second factor is reconstruction method which had two levels: 
FBP and IR. Since each level of the first factor occurs in combination with each level of the second 
factor, the factors are crossed. The figure of merit is represented by  where  ( ) 
represents the levels of the first factor and  ( ) represents the levels of the second 
factor. In this study , corresponding to the four levels of the mA factor, and , 
corresponding to the two levels of the reconstruction method factor. The approach followed was to 
conduct two sequential analyses: (i) in the first, termed mA analysis, the figure of merit was 
averaged over the , or reconstruction index, and (ii) in the second, termed reconstruction analysis, 
the figure of merit was averaged over the , or mA index. For example, in mA-analysis the 
difference figure of merit was , where the first dot on the figure of merit represents an 
average over the  index and the second dot represents an average over readers. In either analyses 
the resulting figure of merit depends on a single modality factor and reader, to which the standard 
OR method was applied. The mA analysis addresses the question of whether there is a mA effect and 
in this analysis the number of possible comparisons is six. The reconstruction analysis addressed the 
question of whether there is a reconstruction method effect and in this analysis the number of 
possible comparisons is one. To control for the increased probability of a Type I error due to multiple 
testing on the same dataset, the Bonferroni correction was applied by setting the threshold for 
declaring significance at 0.025; this is expected to conservatively maintain the overall probability of a 
Type I error at  = 0.05. We use the term crossed-modality analysis to describe this type of 
modified analysis of ROC-type data.  
Since the phantom is unique, and conclusions are only possible that are specific to this one 
phantom, the case (or image) factor was regarded as fixed. For this reason only results of random-
reader fixed-case analyses are reported. Software for crossed-modality JAFROC analysis was 
implemented in the R programming language, and is freely available on request from DPC. 
 
Results 
Crossed-modality JAFROC analysis 
For the crossed-modality modified JAFROC analysis of reconstruction method where the data was 
averaged over tube current, , there was no statistically significant different in lesion detection 
performance between FBP and IR (F(1,10)= 0.08, p=0.789). For the crossed-modality modified 
JAFROC analysis of tube current (mA) where data was averaged over reconstruction method, , 
significant differences were revealed between several pairs of tube current settings (F(3,10)=16.96, 
p<0.001). The figures of merit for all modalities can be found in Table 1. The corresponding highest-
rating inferred ROC figures of merit can be found in Table 2. Statistical differences were observed 
between 20mA and 40mA, 20mA and 60mA and 20mA and 80mA. Additionally, a statistical 
difference was also observed between 40mA and 80mA, but 40mA and 60mA were statistically 
similar, as was the final pair of 60mA and 80mA; these differences are summarized in Figure 2.  
 
Effective dose 
The effective dose (mSv) was 0.49mSv, 0.97mSv, 1.64mSv and 2.11mSv for CT acquisitions at 20mA, 
40mA, 60mA and 80mA respectively, while all other acquisition parameters were kept constant.  
qi1i2 j i1 i1 =1,2,..., I1
i2 i2 =1,2,..., I2
I1 = 4 I2 = 2
i2
i1
qi1·· -qi '1··
i2
a
i1

i2
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Table 1. : Modified JAFROC analysis results showing figures-of-merit and 95% confidence intervals 
(CI) for modalities averaged over the i1 (mA) and i2 (reconstruction method) indexes. 
Crossed 
Modality 
Analysis 
Reconstruction Method & 
Tube Current setting 
Modified JAFROC FOM (95% CI) 
Averaged over i1 
FBP 0.867 (0.832,0.903) 
IR 0.869 (0.833,0.904) 
Averaged over i2 
20mA 0.835 (0.769,0.875) 
40mA 0.867 (0.827,0.908) 
60mA 0.878 (0.864,0.910) 
80mA 0.891 (0.858,0.925) 
 
 
Table 2. : Highest-rating inferred ROC analysis results showing figures-of-merit and 95% confidence 
intervals (CI) for modalities averaged over the i1 (mA) and i2 (reconstruction method) indexes. 
Crossed 
Modality 
Analysis 
Reconstruction Method & 
Tube Current setting 
Highest-rating inferred ROC FOM (95% CI) 
Averaged over i1 
FBP 0.918 (0.894,0.941) 
IR 0.915 (0.891,0.938) 
Averaged over i2 
20mA 0.892 (0.865,0.919) 
40mA 0.910 (0.884,0.937) 
60mA 0.925 (0.904,0.945) 
80mA 0.938 (0.916,0.960) 
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Figure 2: The treatment pairs for analyses averaged over i1 and i2, displaying the magnitude of 
difference and 95% confidence intervals for the crossed-modality JAFROC analysis. For a difference 
in performance to be declared significant the 95% confidence interval must not include zero. 
Therefore, statistical differences are observed between 20mA and 40mA, 20mA and 60mA, 20mA 
and 80mA and also between 40mA and 80mA. 
 
Conclusions 
For this phantom simulation there was no significant difference in lesion detection performance 
when IR was used in place of FBP. This is in great contrast to previous claims of large percentage 
dose saving with iterative reconstruction techniques. In this phantom, tube current was optimized at 
40mA, an effective dose of 0.97mSv, with clear evidence that lesion detection performance was not 
maintained at 20mA. This suggests dose saving potential of 50%, on the basis of the tube current 
range investigated in this work. The quoted figure of dose saving must always be evaluated in 
consideration of the starting point. 
Future work would seek to assess the value of iterative reconstruction in low-contrast body areas, 
such as the abdomen. 
The crossed-modality JAFROC analysis method described in this paper has relevance for situations 
where co-existing factors exist and contribute to observer performance. In the current work, the 
individual comparisons of all tube current and reconstruction method options would have been 
inconclusive. 
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PAPER 7 
EFFECTIVE DOSE AND EFFECTIVE RISK FROM POST–SINGLE PHOTON EMISSION COMPUTED 
TOMOGRAPHY IMAGING OF THE LUMBAR SPINE  
Tootell, A., McEntee, M., Szczepura, K., & Hogg, P. (2016). Journal of Medical Imaging and Radiation 
Sciences, 47(3), 267-275. doi: http://dx.doi.org/10.1016/j.jmir.2016.04.012 
 
Abstract 
Purpose 
Planar bone scans play an important role in the staging and monitoring of malignancy and 
metastases. Metastases in the lumbar spine are associated with significant morbidity, therefore 
accurate diagnosis is essential. Supplementary imaging after planar bone scans is often, required to 
characterise lesions, however, this is associated with additional radiation dose. This paper provides 
information on the comparative effective dose and effective risk from supplementary lumbar spine 
radiographs, low-dose CT (LDCT) and diagnostic CT (DCT). 
Method 
Organ dose was measured in a phantom using thermo-luminescent dosimeters. Effective dose and 
effective risk were calculated for radiographs, LDCT, and DCT imaging of the lumbar spine.  
Results 
Radiation dose was 0.56mSv for the antero-posterior and lateral lumbar spine radiographs, 0.80mSv 
for LDCT, and 3.78mSv for DCT. Additional imaging resulted in an increase in effective dose of 
12.28%, 17.54% and 82.89%for radiographs, LDCT and DCT respectively. Risk of cancer induction 
decreased as age increased. The difference in risk between the modalities also decreased. Males had 
a statistically significant higher risk than female patients (p=0.023) attributed to the sensitive organs 
being closer to the exposed area. 
Conclusion 
Effective Dose for LDCT is comparable to radiographs of the lumbar spine. Due to the known benefits 
image fusion brings it is recommended that LDCT replace radiographs imaging for characterisation of 
lumbar spine lesions identified on planar bone scan. DCT is associated with significantly higher 
effective dose than LDCT. Effective risk is also higher and the difference is more marked in younger 
female patients.  
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Introduction 
Planar whole-body bone scintigraphy (BS) using Technetium 99m phosphates or phosphonates [1] 
and a gamma camera continues to play an important role in the staging and monitoring of malignant 
disease due to its ability to demonstrate lesions earlier than conventional radiographic methods [1, 
2]. The lumbar spine is a common site for bony metastases arising from primary tumour sites in the 
prostate and breast due to venous drainage into the vertebral plexus [3]. Metastases in the spine are 
associated with significant morbidity, therefore accurate and early diagnosis is important for 
effective patient management [3-5]. Multiple lesions in the spine detected using BS does not provide 
a definitive diagnosis but are suggestive of metastatic disease [6]. When solitary spinal lesions are 
discovered a definitive diagnosis is challenging due to the spectrum of potential pathological 
processes. These cases are often referred for additional imaging to localise and/or characterise 
them.  
Over a decade ago research lead to a significant change in scanning technique [1]. BS evolved to 
include single photon emission computed tomography (SPECT) and later computed tomography (CT), 
with SPECT-CT now regarded as an essential tool in diagnosing and assessing metastatic bone 
disease [7].  Prior to tomographic imaging, patients were referred for supplementary imaging to help 
localise or characterise a lesion: typically using conventional plain radiography, CT or MRI. Hybrid 
imaging systems now allow fusion of CT and SPECT images, providing the clinician with physiological 
data overlaid on anatomical information. This removes the necessity for side-by-side comparison.  
The benefits of image fusion in nuclear medicine imaging are covered extensively in literature, which 
reports an increase in the accuracy, sensitivity, specificity and diagnostic confidence [8-11].  These 
benefits are associated with additional risk, since supplementary imaging requires additional 
radiation dose to the patient. Research has shown that the additional dose from CT acquisitions 
acquired as part of a SPECT-CT study are not insignificant and on occasions can exceed the dose from 
the administration of the radiopharmaceutical. Increases in effective dose of between 2% and 600% 
are reported [12].  
The early use of CT in combination with SPECT was aimed at attenuation correction (AC) and 
consisted of a CT component with fixed acquisition parameters. These scanner types are frequently 
referred to as low-dose with an effective dose 80-85% lower than diagnostic quality CT scans [12-
15]. Diagnostic CT (DCT) can be used to aid diagnosis rather than correcting the emission data alone 
[16] and also provide localisation data [17]. Regardless of the modality the additional dose has to be 
taken into account in the justification of the exposure [18, 19]. Justification should ensure that the 
benefit of the exposure outweighs the potential risk from the additional exposure.  
The additional dose from the CT component of SPECT-CT has been investigated [12-15]. Larkin et al 
[14], Sharma et al [12] and Montes et al [15] use the dose length product and conversion (k) factors 
to calculate effective dose. Hara et al [13] measured organ dose with thermoluminescent dosimeters 
(TLD) however only organs within the primary beam were measured. The paper does not recreate 
the clinical situation where organs outside the primary beam would be subject to scatter radiation.  
The aims of our research are to calculate effective dose and effective risk from imaging of the 
lumbar spine using radiographs, LDCT and DCT. From this data the additional dose over BS alone are 
calculated. Male and female effective risk will be compared to figures from SPECT alone and SPECT 
plus supplementary imaging.  
Method 
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Using an adult dosimetry phantom (ATOM 701D (CIRS Inc, Virginia USA)), organ dose was measured 
using thermo-luminescent dosimeters (TLD100H (Thermo Fisher Scientific Massachusetts, USA)) . 
Effective dose and effective risk were calculated as described below. Three imaging systems were 
used in this study. The first was radiographs using a Wolverson Acroma General X-ray system 
(Willenhall, UK) with an Agfa computed radiography system (Agfa Health Care, Mortsel, Belgium). 
The second was multi-detector diagnostic CT (DCT) (Toshiba Aquillion 16, Toshiba Medical Systems 
Corporation, Tochigi-ken, Japan). The third was a low-specification CT component from a hybrid 
SPECT-CT system (low-dose CT (LDCT)) (GE Infinia Hawkeye 4, GE Healthcare, Little Chalfont, UK). 
Imaging equipment quality control for tube output and automatic exposure devices met the 
required standards and manufacturer guidelines [20-22]. Air-calibrations for the two CT systems 
were performed as part of the warm-up procedures. The imaging parameters were based on those 
used in the clinical environment and had undergone an optimisation process through audits of 
image quality and diagnostic reference levels. The automatic exposure control for radiographs and 
the mA modulation function for the DCT were used. For LDCT exposure factors for an average sized 
patient were used (Table 2). 
The Phantom 
The anthropomorphic dosimetry phantom consists of 39 contiguous sections of differing density 
epoxy resin (representing bone, lung and soft tissue) that when put together make up the head and 
torso of an adult male. TLD locations were positioned for precise dosimetry of specific internal 
organs. Whole body effective dose calculation was completed using the ATOM 701-D configuration 
that utilises a total of 271 TLDs over 22 organs [23, 24].  
For AP and lateral lumbar spine, the area of interest adhered to criteria set out in a standard 
radiography technique book [25]. The medial-sagittal and medial-coronal planes, the field of view 
and the centre for antero-posterior and left lateral projections of the lumbar spine were marked 
onto the phantom’s surface with permanent marker pen and radiolucent markers were used to aid 
positioning of the CT acquisitions (Figure 1). 
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FIGURE 1 MARKING THE PHANTOM FOR AP AND LEFT LATERAL LUMBAR SPINE PROJECTIONS AND CT 
LUMBAR SPINE. 
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Positioning the phantom for the LDCT acquisition on the SPECT-CT hybrid system involved the use of 
external positioning aids. Commercially available laser spirit levels allowed the phantom to be 
centrally positioned on the table and parallel to its long axis. A scout view is not routinely acquired 
as planning of the CT range is performed on patients using the emission data. To ensure close 
replication of clinical practice the scan range was determined by setting a zero refresh rate on the 
positioning monitor and placing a 57Co source on the markings on the phantom until it was visible on 
the scanner’s positioning monitor. These two points corresponded to the upper and lower limit of 
the CT acquisition. To ensure the use of the unsealed source in this manner did not contribute to the 
dose recorded by the TLDs, the dose recorded in 5 seconds at a distance of 1 cm in air was 
calculated. Using the reference activity of 3.7 MBq for the Cobalt source resulted in 6.53 x 10-4 mGy. 
This value is below the sensitivity of the TLDs and so was considered negligible when calculating the 
dose from the TLDs in the phantom.  
 
Thermoluminescent dosimeters 
The TLDs were read using a Harshaw 3500 manual TLD reader one day after their exposure. To 
ensure accuracy and reproducibility the TLDs were subjected to quality control checks. The TLDs 
were annealed by heating to 240oC for 10 minutes. They were then exposed to a uniform field of X-
radiation using a general x-ray unit, processed and grouped together into batches of similar 
response. To ensure repeatability the batches were annealed and exposed to the same uniform field 
and their responses compared. A paired student t-test was performed and there was no significant 
difference in the responses of the two exposures (p>0.1). The inter batch coefficient of variance was 
calculated and was less than 2.0%. Calibration was performed on each batch using a general x-ray 
unit at energies of 120kV and 80kV to correspond with settings used in the imaging protocols [26]   
The TLDs were positioned in the phantom at locations of the organs identified in ICRP 103 (Table 1) 
at the organ positions specified by the manufacturer [23, 24, 27]. Five TLDs remained with the 
phantom at all times apart from during image acquisition for background correction. 
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TABLE 1 NUMBER OF TLDS USED IN CRITICAL ORGANS 
Organ Number of TLD Organ Number of TLD 
Adrenals 2 Liver 30 
Bladder 16 Lungs 36 
Brain 11 Oesophagus 3 
Breast 2 Pancreas 5 
Active bone 
Marrow  
85 
Clavicle 20,  
Cranium 4 
Cervical Spine 2 
Femora 4 
Mandible 6 
Pelvis 18 
Ribs 18 
Sternum 4 
Thoraco-lumbar Spine 9 
Prostate 3 
Eyes* 2 Spleen 14 
Gall Bladder 5 Stomach 11 
Heart 2 Testes 2 
Intestine (Small 
and large) 
16 
Colon 11 
Small intestine 5 
Thyroid 10 
Kidneys 16 Thymus 4 
* Not included in effective dose calculations 
 TLDs located in the anterior of C2 and upper oesophagus were used to calculate extra thoracic 
organ dose 
 TLDs located in the left and right lingula of the mandible and to the left and right of the sublingual 
fossa were used to calculate salivary gland organ dose 
× TLDs located in the left and right lingula of the mandible were used to calculate oral mucosa organ 
dose 
 
To increase the signal to noise ratio of the TLD readings three complete exposures were performed 
using the acquisition parameters shown in Table 2. This resulted in a cumulative dose being recorded 
on the TLDs which was divided by three to give a dose per exposure. Effective dose for the three 
modalities was calculated using tissue weighting factors listed in ICRP report 103 [27] (see Table 3). 
Statistical analysis was performed using two-way ANOVA with post hoc testing with Bonferroni 
correction.  
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TABLE 2 PARAMETERS USED FOR IMAGING THE LUMBAR SPINE IN CR, DIAGNOSTIC CT AND LOW DOSE CT 
Radiographs 
 kV AED chamber Post mAs 
AP 75 Central Mean 60 (SD=0) 
Left lateral 80 Central Mean 72 (SD=0) 
 
Diagnostic CT 
Scan Projection Radiograph 
 kV mAs Scan range 
AP 120 150 250 mm 
Left Lateral 120 45 250 mm 
 
Axial scan 
Mode kV mA Rotation (s) Pitch 
Detector 
range 
Scan range 
Helical 120 Auto 
Lower: 100 
 
Upper: 450 
 
SD:        7.5 
0.75 0.938 16 mm  
16x1 mm 
245 mm 
Upper- Mid T12 
Lower- 
 Upper S3 
 
Low Dose CT 
Mode kV mA 
Rotation 
(rotations 
per 
minute) 
Pitch (distance 
per rotation) 
(mm) 
Detector 
range 
Scan range 
 
Helical 
 
120 
 
2.5 
 
2 
 
1.9 
 
20 mm 
4 x 5 mm 
 
245 mm 
Upper- Mid T12 
Lower- Upper S3 
 
 
 
TABLE 3 TISSUE WEIGHTING FACTORS FROM ICRP REPORT 103 [18] 
Tissue WT ∑wT 
Bone Marrow, Colon, Lung, Stomach, Breast, Remainder tissues* 0.12 0.72 
Gonads 0.08 0.08 
Bladder, Oesophagus, Liver, Thyroid 0.04 0.16 
Bone Surface×, Brain, Salivary glands, Skin× 0.01 0.04 
*adrenals, extrathoracic region, gallbladder, heart, kidneys, lymphatic nodes× ,oral mucosa, pancreas, 
prostate, small intestine, spleen, thymus 
×excluded in this study. 
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Risk calculations were carried out following a method described by Brenner [28, 29]. Lifetime risk of 
cancer incidence figures were obtained from Wall et al [30]. The sum of the product of the measured 
organ dose (mGy) and the life time risk of cancer incidence for that organ (percentage per mGy) 
gave the effective risk. Resources dictated that the phantom used within this study was male, 
however by using TLD readings from locations that correspond with the gonads and uterus and 
excluding the male testes and prostate it was possible to calculate an effective risk for females.  
Organ and effective dose from the administration of 800 MBq 99mTc labelled phosphate or 
phosphonates was calculated using dose per unit activity (mSv/MBq) from Bombardieri et al [1]. 
Comparisons were made between the dose from additional imaging and the initial bone scan 
acquisition. 
 
Results 
A comparison of dose data as displayed by the modalities is shown in Table 4. DLP and CTDi are 
significantly higher for DCT compared to LDCT. This supports the findings of the dosimetry data that 
DCT will result in a higher dose. Comparison of the effective dose from the three supplementary 
imaging techniques is shown in Figure 2. Imaging using DCT results in a higher effective dose 
compared to radiographs and LDCT. The error bar for DCT is larger due to the 2% error in the TLDs 
being applied to a larger dose reading.    
TABLE 4 COMPARISON OF DAP/DLP AND CTDI 
 Radiographs LDCT DCT 
DAP (mGy.cm2) 2873 -- -- 
DLP (mGy.cm) -- 96.0 349.6 
CTDi (mGy) -- 3.97 20.0 
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FIGURE 2 EFFECTIVE DOSE FROM THE SUPPLEMENTARY IMAGING MODALITIES3 
 
Effective dose is calculated from the sum of the weighted organ doses and does not indicate the 
difference to individual organs. Table 5 and Table 6 illustrate the organ dose from and increase due 
to the supplementary imaging modality compared to the calculated organ dose from the 
administration of the radiopharmaceutical. Certain organs, for example the colon, liver and stomach, 
exhibit a large increase due to the low uptake of radiopharmaceutical but are situated within the 
scan range. There is a consistent difference in organ dose between DCT and LDCT and DCT and 
radiographs showing the distribution of the organ dose is consistent for the supplementary imaging 
modality.  
  
                                                          
3 The error bars displayed in this figure were calculated through the propagation of the 2% error of the TLDs. 
The error of each TLD was applied to the recorded dose and the potential upper (+2%) and lower (-2%) values 
of the TLDs were calculated. These values (upper, measured and lower) were used in effective dose 
calculations and displayed in Figure 2.  
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TABLE 5 COMPARISON OF ORGAN DOSE FROM THE THREE SUPPLEMENTARY MODALITIES COMPARED TO THE 
BONE SCAN (800MBQ PHOSPHATE OR PHOSPHONATE). 
  Absorbed dose (mGy) 
Organ BS Radiographs LDCT DCT 
Active bone marrow 7.36 0.15 0.33 1.75 
Bladder 38.40 0.55 0.59 3.83 
Brain 1.36 0.00 0.00 0.01 
Breast 0.57 0.04 0.07 0.44 
Colon 2.16 1.58 2.12 9.00 
Liver 0.96 1.42 1.42 7.23 
Lungs 1.04 0.11 0.15 1.16 
Oesophagus 0.80 0.06 0.11 0.72 
Stomach 0.96 1.29 2.14 9.86 
Thyroid 1.04 0.01 0.02 0.09 
Remainder organ 1.52 0.79 1.10 5.21 
 
 
TABLE 6 INCREASE IN ORGAN DOSE FOR THE ORGANS 
 Absorbed dose (mGy) 
Organ BS only 
BS & Radiographs  BS & LDCT  BS & DCT  
mGy % increase mGy % increase mGy % increase 
Active bone 
marrow 7.36 7.51 2.09 7.69 4.49 9.11 23.76 
Bladder 38.40 38.95 1.43 38.99 1.55 42.23 9.97 
Brain 1.36 1.36 0.04 1.36 0.02 1.37 0.73 
Breast 0.57 0.61 7.72 0.64 12.39 1.01 77.86 
Colon 2.16 3.74 73.26 4.28 98.2 11.16 16.54 
Liver 0.96 2.38 147.58 2.38 147.73 8.19 753.27 
Lungs 1.04 1.15 10.14 1.19 14.83 2.20 111.76 
Oesophagus 0.80 0.86 7.87 0.91 13.93 1.52 89.4 
Stomach 0.96 2.25 134.74 3.10 222.95 10.82 1027.35 
Thyroid 1.04 1.05 0.83 1.06 2.23 1.13 8.81 
Remainder 1.52 2.31 52.04 2.62 72.41 6.73 342.47 
 
Using data published by Wall et al[30], life time cancer risk for all cancers and cancers of the organs 
identified in Table 6 were calculated. Comparison of risk between bone scan (BS) only, BS with 
conventional radiography, BS with low dose CT, and BS with diagnostic CT from 40 to 89 years are 
shown in Figure 3, Figure 4 and Figure 5. 
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FIGURE 3 EFFECTIVE RISK FROM EXPOSURE FOR ALL CANCERS FOR A EURO-AMERICAN POPULATION 
 
 
FIGURE 4 EFFECTIVE RISK FROM EXPOSURE FOR ALL CANCERS FOR A FEMALE EURO-AMERICAN POPULATION 
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FIGURE 5 EFFECTIVE RISK FROM EXPOSURE FOR ALL CANCERS FOR A MALE EURO-AMERICAN POPULATION 
 
 
Discussion 
Image fusion has been shown to increase accuracy and reporter confidence [8-11]. It has been 
suggested that DCT that can further aid diagnostic decisions due to its ability to acquire and display 
submillimetre structures thus showing the accurate location and internal architecture of a lesion [31-
35]. To date little data directly comparing the additional organ and effective dose and effective risk 
for all available supplementary imaging options has been published. Results show that the effective 
dose from lumbar spine imaging using radiographs was 0.56 mSv (±0.09), LDCT 0.80 mSv (±0.12) and 
DCT was 3.78 mSv (±0.56), The calculated effective dose from the administration of 800 MBq of 
99mTc labelled phosphate or phosphonate is 4.56 mSv. Thus the additional effective dose from 
supplementary imaging is 12.3% for radiographs, 17.5% for LDCT and 82.9% for DCT. 
This increase in effective dose was hypothesised and this result is in agreement with other research 
[12-14, 36]. However consideration of effective dose does not provide the narrative as it is not 
apparent which organs contribute to this increase. Table 6 shows there are increases in organ dose 
from the supplementary imaging techniques. Comparison of organ doses using two way ANOVA 
showed that there was a statistically significant difference between the three options (p=0.001). 
Post hoc testing with Bonferroni correction showed that there was a statistically significant 
difference between BS & DCT and BS & LDCT (p=0.001) and BS & DCT and BS & radiographs 
(p=0.001).  There was no statistical difference between BS & LDCT and BS & radiographs (p=0.810). 
On this basis there is a strong rationale for the use of LDCT over radiographs for imaging the lumbar 
spine. There is no statistically significant increase in organ dose and literature suggests that accuracy 
and clinician confidence is increased when using LDCT compared with radiographs.  
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There is no change to the urinary bladder dose and there is a relatively small increase in dose (from 
38.4 mGy to 42.23 mGy (9.91%) for BS & DCT, 38.99 (1.55%) for LDCT and 38.95 mGy (1.43%) for BS 
& radiographs). The stomach receives one of the lowest doses from the radiopharmaceutical (0.96 
mGy). Following supplementary imaging this figure increases to 10.82 mGy (+1027.35%) for BS+DCT, 
3.10 mGy (+222.95%) for BS & LDCT and 2.25 mGy (+134.74%) for BS & radiographs. These results 
are due to the organ being directly in the field of view when imaging the lumbar spine. While these 
results are specific to lumbar spine imaging they have shown that the supplementary imaging can 
significantly increase organ dose.  
Effective dose is commonly used in medical imaging to compare the risks from different modalities 
or techniques.  Effective dose should not be used to calculate risk to an individual patient or patient 
types as it does not consider the age of the patient. Effective risk is a method described by Brenner  
[28, 29, 37] and Wall [30] in which tissue weighting factors are replaced with organ-specific 
radiation-induced cancer risk , such as those published by The Nuclear and Radiation Studies board 
[38], and Wall [30]. Discussion about the use of effective dose and effective risk are beyond the 
remit of this article but are reported widely in literature [28-30, 37, 39-42].  
Figure 4 and Figure 5 illustrate the difference in the lifetime risk of radiation induced cancer 
between the supplementary modalities with increasing age. The difference between these values 
does decrease with age and when comparison is made between the effective risk for patients over 
70 the difference is very small. The higher organ doses for BS & DCT is reflected in the higher risks 
for these ages with an incidence of 217 per million exposures for females and 154 per million 
examinations for males.  
A limitation of this study is that the whole of the lumbar spine was imaged by the three modalities. 
In clinical practice a localised CT scan based on the planar and SPECT bone scan could be performed 
as opposed to the whole lumbar spine. This would limit the exposure to the area of interest meaning 
that organ doses would be less.  This is likely not to be the case for radiographs where the full 
lumbar spine would be imaged. In other words, LDCT would likely be lower than radiographs. 
This study uses the standard adult male phantom for dosimetry measurements. External validity of 
the research could be improved with the use of a female anthropomorphic phantom. However initial 
comparison of risk between male and female shows that the figures for male patients are higher. 
The reason for the difference is due differences in the sensitivities of the tissues. Sensitive organs in 
the female patient such as the breast tissue receive very little additional dose in imaging the lumbar 
spine as these are outside the field of view. Also, the specific focus of this work is the lumbar spine; a 
lesion requiring further clarification in the thoracic spine would result in breast tissue receiving a 
higher dose and would affect effect risk. Further research into supplementary imaging of other 
common sites of bony pathology is therefore warranted.  
In older patients there is little additional risk however, in younger patients, risk is greater. In patients 
over 70 the difference in risk from the additional imaging decreases to the point where performing a 
DCT instead of LDCT could be justified. DCT can provide diagnostic image quality and afford good 
diagnostic value in the characterisation of a lesion.   
Even-Sapir et al [31] suggest that referral for and justification of DCT over LDCT should be taken on a 
case-by-case basis and the benefits of the higher image quality and therefore high dose balanced 
against the risks [31]. There are likely to be instances when higher resolution images are required 
and in these cases the higher dose and associated risk from DCT is justified. The diagnostic value of 
the supplementary imaging options is beyond this work but research has shown the benefit of 
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supplementing SPECT with CT [8, 31, 43, 44]. Further research in the usefulness of higher 
dose/higher quality CT acquisitions compared to low dose would facilitate the risk/benefit 
discussion. 
Accepted practice is to use CT as a supplementary imaging modality over radiographs due to the 
benefits image fusion brings [45-47]. Recent papers consider the use of 16 slice or higher CT 
scanners and they note that the improved image quality allows reporters to comment upon the 
internal structure of a lesion as well as identifying its location [8, 9, 31, 43, 44, 48]. The current work 
has shown acquisitions using DCT result in a statistically significant higher dose. 
Conclusion 
Our work demonstrates that a DCT acquisition result in an effective dose and effective risk that is 
significantly higher than a LDCT acquisition.  The LDCT system used in our work has demonstrated a 
small increase in dose and risk compared with radiographs. However LDCT brings the benefits of 
improved diagnostic confidence and thus are recommended as the preferred choice of bone scan 
supplemental imaging for bony metastases.  
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PAPER 8 
ANALYSIS OF EFFECTIVE AND ORGAN DOSE ESTIMATION IN CT WHEN USING MA MODULATION: A 
SINGLE SCANNER PILOT STUDY 
Tootell, A., Szczepura, K., & Hogg, P. (2017). Radiography, 37(0), 842–847. doi: 
https://doi.org/10.1016/j.radi.2017.02.006 
Abstract 
Effective dose (ED) estimation in CT examinations can be obtained by combining dose length product 
(DLP) with published ED per DLP coefficients or performed using software. These methods do not 
account for tube current (mA) modulation which is influenced by patient size.  
Aim 
To compare different methods of organ and ED estimation to measured values when using mA 
modulation in CT chest, abdomen and pelvis examinations.  
Method 
Organ doses from CT of the chest, abdomen and pelvis were measured using digital dosimeters and 
a dosimetry phantom. ED was calculated. Six methods of estimating ED accounting for mA 
modulation were performed using ImPACT CTDosimetry and Dose Length Product to ED coefficients. 
Corrections for the phantom mass were applied resulting in 12 estimation methods. Estimated organ 
doses from ImPACT CTDosimtery were compared to measured values. 
Results 
Calculated EDs were; chest 12.35 mSv (±1.48 mSv); abdomen 8.74 mSv (±1.36 mSv) and pelvis 4.68 
mSv (±0.75 mSv). There was over estimation in all three anatomical regions. Correcting for phantom 
mass improved agreement between measured and estimated ED. Organ doses showed 
overestimation of dose inside the scan range and underestimation outside the scan range. 
Conclusion 
Reasonable estimation of effective dose for CT of the chest and abdomen can be obtained using 
ImPACT CTDosimetry software or k-coefficients. Further work is required to improve the accuracy of 
ED estimation from CT of the pelvis. Accuracy of organ dose estimation has been shown to depend 
on the inclusion or exclusion of the organ from the scan range.  
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Introduction 
Advances in technology have facilitated Computed Tomography’s (CT) expansion in providing rapid 
complex submillimetre imaging allowing more accurate diagnoses to be made [1-3]. In many 
instances CT is the first line investigation, however this has resulted in it becoming the dominant 
source of radiation risk/dose in medical imaging [3]. As with any medical imaging procedure 
involving radiation, there is a need for all involved to be aware of and monitor dose to patients; this 
is achieved by dose estimation as direct measurement of organ dose is not possible in the clinical 
environment. 
Effective dose is often calculated by combining dose length product [DLP], (the product of the CT 
dose index volume (CTDivol) and scan length) with published coefficients (k-coefficient) [4-7]. This 
approach uses data published by the American Association of Physicists in Medicine (AAPM) [4]. 
Critics of this method state that the use of tissue weighting factors from ICRP 60 and scanner data 
from as early as 1990 means that the coefficients lack relevance to modern multidetector scanners 
in use today [7]. Updated figures have been published and used by Elbakri and Kirkpatrick [5] and 
Huda et al [6].  Both these articles argued that due to the updated tissue weighting factors published 
by the ICRP the conversion factors require updating too. Huda et al [6] provide figures that are 
independent of the make and model of scanner whilst Elbakri and Kirkpatrick [5] argued that 
accuracy can be improved further by taking into account scanner-specific results. In Elbakri and 
Kirkpatrick’s paper figures for a range of scanner types are provided [5]. 
An alternative method of effective dose estimation can be performed by  combining CTDivol with 
data produced using Monte Carlo mathematical simulation. Data provided by the UK’s National 
Radiological Protection Board (NRPB) can be used to calculate effective dose by utilising ImPACT’s CT 
dosimetry tool (CTDosimetry V1.0.4) [8]. Although convenient, the data used in the Monte Carlo 
simulation was generated from early CT systems (not multidetector) therefore effective dose 
estimation has to be performed by fitting the characteristics of newer scanners to older designs [9]. 
This has the potential to introduce error [10].  
Tube current modulation (mA modulation) is not taken into account when dose estimations are 
performed using the software or k-coefficients. mA modulation is standard on modern CT imaging 
equipment and it has the ability to manipulate the exposure and therefore dose as the patient is 
imaged. The ability to accurately estimate dose using fixed tube current has been shown but organ 
dose generally decreases with the use of tube current–modulated acquisition and this should be 
taken into account in any estimation method, but patient size can directly affect the dose reduction 
achieved [11].  
The Medical Internal Radiation Dose (MIRD) mathematical phantom used in the development of the 
k-coefficients by the AAPM, Elbakri and Kirkpatrick and Huda et al and the stylised/mathematical 
phantom used in ImPACT’s dosimetry tool  represents a patient mass of 70 kg which is regarded as a 
low in comparison to modern demographics [4-6, 8, 12]. Research by Castellano stated that there is 
a change in effective dose for a change in mass with effective dose lower in larger patients for the 
same imaging parameters [13]. Castellano provides ratios for scaling effective dose using 70 kg as 
the reference value. The scaling factors indicate a 13% decrease in effective dose per 20 kg increase 
in mass for chest and abdomen CT acquisitions and a 9% decrease in effective dose per 20 kg 
increase in mass for pelvis acquisitions. For fixed exposure parameters, effective dose decreases as 
patient mass increases suggesting that dose is likely to be overestimated [13]. 
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This initial work utilised a single scanner type and phantom size and with a focuses on organ and 
effective dose calculation accuracy using mA modulation in CT of the chest, abdomen and pelvis. 
This paper examines different methods of dose estimation and compares these to direct 
measurements of organ doses made using an anthropomorphic phantom and MOSFET dosimeters. 
Effective dose calculations were compared against values generated using k-coefficients and ImPACT 
software. To account for mA modulation mass weighted corrections were applied in an attempt to 
improve accuracy for effective dose calculations. 
 
Method 
For CT of the chest, abdomen and pelvis twelve methods of estimating effective dose were used 
(Table 1). CT dosimetry software published by the ImPACT CT scanner evaluation group (ImPACT 
CTDosimetry spreadsheet v 1.0.4, ImPACT, London, UK) was used to estimate organ and effective 
dose. For each anatomical region, the DLP was recorded. Dose per DLP figures published by the 
American Association of Physicists in Medicine (AAPM) [4], Huda et al [6] and Elbakri and Kirkpatrick 
[5] were used to calculate effective dose (Table 2). One method of calculating effective dose from 
directly measured organ doses using MOSFETs was undertaken for CT of the chest, abdomen and 
pelvis using  MOSFET dosimeters (Best Medical Canada, Kanata, Canada) and a male ATOM 
dosimetry phantom model 701-D (CIRS Inc. Virginia, USA). In all cases a Toshiba Aquillion 16 
Multidetector CT scanner was used (Toshiba medical systems, Otawara-Shi, Japan). This system 
utilises filtered back projection reconstruction and for the purpose of the data collection 
manufacturer recommended reconstruction algorithms and a mA standard deviation of 5. The CT 
system uses Toshiba’s SUREExposure3D method of tube current modulation during exposure. This 
uses the anterior-posterior and lateral scan plan radiograph to ascertain the optimum exposure. The 
system modulates the tube current  in the z-axis and during rotation [14]. 
Direct dose measurements (MOSFET) were taken as the gold standard against which estimation 
methods were compared [15, 16].  
 
 
TABLE 1 METHODS OF DOSE ESTIMATION 
1. ImPACT effective mA 
2. ImPACT average mA 
3. ImPACT mA modulation 
4. AAPM k-coefficient 
5. Huda et al k-coefficient 
6. Elbakri and Kirkpatrick k-coefficient 
7. Mass corrected ImPACT effective mA 
8. Mass corrected ImPACT average mA 
9. Mass corrected ImPACT mA modulation 
10. Mass corrected AAPM k-coefficient 
11. Mass corrected Huda et al k-coefficient 
12. Mass corrected Elbakri and Kirkpatrick k-coefficient 
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TABLE 2 COEFFICIENTS FOR CALCULATION OF EFFECTIVE DOSE FROM DLP 
 k-coefficient mSv/mGy.cm 
 AAPM [4] Huda et al [6] Elbakri and Kirkpatrick [5] 
Chest 0.014 0.017 0.020 
Abdomen 0.015 0.016 0.017 
Pelvis 0.015 0.018 0.017 
 
Dose measurement 
MOSFET dosimeters provide an accurate and reproducible method of collecting organ dosimetry 
data [17]. In this work four banks of five dosimeters were used (n=20).  Calibration was performed as 
per manufacturer instructions at a tube voltage of 120 kV using the supplied calibration jig and a 
calibrated RaySafe X2 with R/F sensor (Unfors RaySafe AB, Bildal, Sweden). The error of these was 
2.01%.  
Indelible ink and radiopaque markers were used on an adult ATOM dosimetry phantom to ensure 
reproducible and accurate positioning and scanning of the phantom. MOSFET detectors were 
located within the phantom in the positions corresponding to the critical organs required for 
effective dose calculations [18-20] (see Table 3). Dose measurement was performed in 20 locations 
at a time as we had total of 20 MOSFET sensors (Figure 1). In total 269 locations were used to 
measure organ dose and compute effective dose. For each MOSFET position, three exposures were 
made and a mean and standard deviation calculated to minimise random error.  
FIGURE 1 FLOW DIAGRAM ILLUSTRATING THE DATA COLLECTION PROCESS FOR DOSE MEASUREMENT  
 
 
Scan plan radiograph 
performed 
Phantom positioned 
for CT abdomen
MOSFETS readied
MOSFETs read
Scan repeated
(3 in total)CT performed. 
Phantom positioned 
for CT pelvis
Phantom positioned 
for CT chest
Dosimeters located into phantom
(locations 1-20, 21-40… 269)
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TABLE 3 TABLE STATING THE NUMBER OF MOSFET LOCATIONS USED FOR ORGAN DOSE MEASUREMENT 
Organ Number of dosimeter locations  
Adrenals 2 
Bladder 16 
Brain 11 
Breast 2 
Active bone Marrow  85 
Clavicle 20,  
Cranium 4 
Cervical Spine 2 
Femora 4 
Mandible 6 
Pelvis 18 
Ribs 18 
Scapulao 9 
Sternum 4 
Thoraco-lumbar Spine 9 
Gall Bladder 5 
Heart 2 
Intestine (Small and large) 16 
Colon 11 
Small intestine 5 
Kidneys 16 
Liver 30 
Lungs 36 
Oesophagus 3 
Pancreas 5 
Prostate 3 
Spleen 14 
Stomach 11 
Testes 2 
Thyroid 10 
Thymus 4 
 locations in the anterior of C2 and upper oesophagus were used to calculate extra thoracic 
organ dose 
 locations in the left and right lingula of the mandible and to the left and right of the sublingual 
fossa were used to calculate salivary gland organ dose 
× locations in the left and right lingula of the mandible were used to calculate oral mucosa organ 
dose 
o locations in close proximity to the left and right glenoid fossa were used for dose to the upper 
humeri 
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For each scan, the dose length product (DLP) and the recorded effective mAs were noted. The mean 
DLP was calculated. Axial images were reconstructed at 1 mm slices to match the acquisition’s 
collimation. The mAs values for each axial image were recorded and an average mAs was calculated 
(Table 4).  
TABLE 4 IMAGING PARAMETERS 
 Chest Abdomen Pelvis 
kV 120 120 120 
Auto mA standard deviation 5 5 5 
Rotation time (s) 0.5 0.5 0.5 
𝑚𝐴𝑠𝑒𝑓𝑓 235 235 235 
𝑚𝐴𝑠?̅? 203.21 201.41 211.34 
Acquired slice thickness 
(detector length in z-axis) 
16 x 1 mm 16 x 1 mm 16 x 1 mm 
Pitch 0.938 0.938 0.938 
𝐷𝐿𝑃?̅? 904.49 792.72 791.76 
𝐶𝑇𝐷𝐼?̅? 33.2 33.2 33.2 
 
Comparison of ATOM and ImPACT standard phantoms 
The ATOM phantom and the standard phantom within the ImPACT CT dosimetry software are of 
different dimensions. To compensate, scaling of the ImPACT phantom was performed. The ATOM 
phantom from the apex of the skull to the upper border of the symphysis pubis was measured at 830 
mm. The length of the ImPACT standard phantom between the same reference points was 890 mm. 
Therefore a 1 mm slice in the ATOM phantom equated to a 1.07 mm slice in the standard phantom 
ImPACT CT dosimetry software. The proportions of the chest, abdomen and pelvis were compared to 
ensure that accurate comparisons were being made; Figure 2 illustrates good agreement between 
the two phantoms’ proportions for these. 
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FIGURE 2 COMPARISON OF THE PROPORTIONS OF THE CHEST, ABDOMEN AND PELVIS OF THE TWO 
PHANTOMS. THE DOSIMETRY PHANTOM (LEFT) HAS BEEN SCALED BY A FACTOR OF 1.07 RELATIVE TO THE 
SOFTWARE PHANTOM 
 
The phantom used in ImPACT’s CT dosimetry software that was used in the development of the DLP 
for effective dose calculations is based on a whole body mass of 70 kg [5, 6, 8, 21]. The ATOM 
phantom has a mass of 73 kg and consists of the head and torso only. According to Tozeren this 
accounts for only 55.4 % of total body mass [22] (Table 5).  
TABLE 5 RELATIVE WEIGHT OF BODY SEGMENTS FOR AN ADULT MALE [22] 
Region/limb Percentage contribution to total body mass (%) 
Torso 48.3 
Head and Neck 7.1 
Upper legs 21.0 
Lower legs 9.0 
Feet 3.0 
Upper arms 6.6 
Lower arms 3.8 
Hands 1.2 
TOTAL 100 
 
Using the data, a total body mass of the ATOM phantom was calculated. The resulting mass was 
much greater at 131.8 kg; an increase in mass of 88.29%. Using the work of Castellano [13] Figure 3 
was created to calculate the correction factor for mass. An assumption was made that this 
relationship remained constant (R2=1).  
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FIGURE 13 GRAPHS SHOWING EFFECTIVE DOSE SCALING COEFFICIENT CALCULATIONS FOR THE 
CHEST/ABDOMEN AND PELVIS. 
 
Dose calculations using ImPACT CT Dosimetry software was performed in three ways;   
(i) Using the effective mAs quoted by the scanner for the full range of the acquisition,  
(ii) Using the average mAs for the full range of the acquisition,  
(iii) Using the mAs for each axial slice and summing the organ and effective doses to give 
final figures.  
For method 3 in Table 1 a macro was created to be used within the ImPACT Excel spreadsheet that 
calculated the start and finish position for each slice and the corresponding mAs to calculate the 
effective dose per slice, which was then summated for the whole scan. The Toshiba Aquillion 16 has 
an overbeaming requirement of 2 rotations (1 at each end of the scan) [23]. With a collimation of 
16x1 mm and a pitch of 0.938 an additional 15.0 mm at each end of the scan is required. When 
scaled, this is equivalent to 16.05 mm at the start and end of the acquisition in the simulation. The 
mA for the first and last slices was used as the mA for the respective upper and lower overbeamed 
sections of the scan for the mA modulation calculation. Comparisons between mass corrected and 
non-corrected figures using data from Table 5 were made.  
 
Comparison of Organ doses 
Effective dose is calculated by summing the weighted equivalent organ doses. Any difference in 
measured and estimated organ doses would be carried through into the final effective dose 
estimations. Comparison of estimated and measured organ doses was carried out to establish any 
sources of error. Unlike methods using DLP and conversion factors, dose estimation using ImPACT CT 
Dosimetry software allows figures for organ dose to be collated so this comparison could only 
analyse dose estimations using ImPACT CT Dosimetry software. It was also not feasible to correct for 
mass as accurate estimation of the distribution of intrathoracic and visceral fat was not possible. The 
difference between simulated and measured organ doses was calculated for each method (i. ImPACT 
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effective mA. ii. ImPACT average mA. iii. ImPACT mA modulation). These values were compared 
statistically using a single factor ANOVA.  
 
Results 
Effective doses calculated from the MOSFET organ dose measurements (Figure 4) were 12.35 mSv 
(±1.48 mSv) for CT of the chest; 8.74 mSv (±1.36 mSv) for CT of the abdomen and 4.68 mSv (±0.75 
mSv) for CT of the pelvis.  
FIGURE 4 CALCULATED EFFECTIVE DOSE4 
 
 
 
                                                          
4 The error bars displayed in Figure 4 are a combined standard deviation of the MOSFET readings. The mean 
and standard deviation of the three repeated measures was calculated for each dosimeter location. To 
calculate organ dose, the mean of the organs dosimeter data was calculated and the organ’s standard 
deviation calculated by combining the individual standard deviations using the equation 
 𝑆𝐷𝑒𝑣𝑜𝑟𝑔 = √(𝑆𝐷1)2 + ⋯ + (𝑆𝐷𝑛)2. Tissue weighting factors were applied to the organ dose and standard 
deviation. The sum of the weighted organ provided the effective dose and the square root of the summed 
squared standard deviations provided the error in the effective dose.  
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Table 6 and Figure 5 illustrate the comparison of effective dose between measured and calculated 
values, with and without correction of phantom mass. Figure 5 demonstrates that using mass 
corrected values leads to greater accuracy for the calculated effective dose in comparison to the 
measured values.  
TABLE 6 EFFECTIVE DOSE MEASUREMENT AND CALCULATION METHODS. 
 Effective Dose (mSv) 
Method Chest Abdomen Pelvis 
Calculated (MOSFET) 
12.35  
(±1.48) 
8.74 
(±1.36) 
4.68 
(±0.75) 
Estimated (Uncorrected for mass) 
ImPACT effective mA 19.00 15.00 10.00 
ImPACT average mA 17.00 14.00 9.90 
ImPACT mA modulation 17.08 13.86 9.93 
AAPM conversion factors [4] 12.66 11.89 11.88 
Huda et al  conversion factors [6] 15.38 12.68 14.25 
Elbakri and Kirkpatrick conversion factors [5]  17.91 13.24 13.22 
Estimated (Corrected for mass) 
Mass corrected ImPACT effective mA 12.30 9.71 7.20 
Mass corrected ImPACT average mA 11.00 9.06 7.13 
Mass corrected ImPACT mA modulation 11.05 8.97 7.15 
Mass corrected AAPM conversion factors [4] 8.19 7.69 8.55 
Mass corrected Huda et al conversion factor [6] 9.95 8.21 10.26 
Mass corrected Elbakri and Kirkpatrick conversion factors [5] 11.59 8.57 9.51 
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FIGURE 5 COMPARISON OF CORRECTED AND UNCORRECTED EFFECTIVE DOSE ESTIMATIONS OF THE (A) CHEST 
(B) ABDOMEN AND (C) PELVIS TO CALCULATED EFFECTIVE DOSE 
FIGURE 5A  
  
FIGURE 5B 
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FIGURE 5C 
 
 
Comparison of estimated organ for CT of the chest, abdomen and pelvis is shown in Table 7. A very 
strong positive correlation between the three estimation methods (r>0.99) and no significantly 
statistical difference is shown (Single Factor ANOVA, p>0.9).  
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TABLE 7 COMPARISON OF ESTIMATED ORGAN DOSES USING MEAN, EFFECTIVE AND MODULATED MAS FOR CT OF THE CHEST, ABDOMEN AND PELVIS. 
  
 
Organ dose (mGy) 
Chest Abdomen Pelvis 
 
Measured 
ImPACT CTDosimetry 
Measured 
ImPACT CTDosimetry 
Measured 
ImPACT CTDosimetry 
Organ  𝑚𝐴𝑠?̅?  𝑚𝐴𝑠𝑒𝑓𝑓  𝑚𝐴𝑠𝑚𝑜𝑑  𝑚𝐴𝑠?̅?  𝑚𝐴𝑠𝑒𝑓𝑓  𝑚𝐴𝑠𝑚𝑜𝑑  𝑚𝐴𝑠?̅?  𝑚𝐴𝑠𝑒𝑓𝑓  𝑚𝐴𝑠𝑚𝑜𝑑 
Gonads 0.04 0.00 0.00 0.00 0.16 0.07 0.07 0.07 5.58 37.00 39.00 36.00 
Bone Marrow 8.10 12.00 14.00 12.22 4.55 8.50 9.30 8.59 5.45 10.00 10.00 10.01 
Colon 0.51 0.35 0.40 0.32 14.3 19.00 20.00 18.76 16.6 23.00 24.00 22.81 
Lung 24.7 45.00 52.00 45.27 5.48 9.50 10.00 9.44 0.16 0.04 0.05 0.04 
Stomach 11.3 8.80 10.00 7.87 26.0 41.00 45.00 40.78 2.02 1.00 1.10 1.04 
Bladder 0.09 0.02 0.02 0.02 1.93 1.10 1.20 1.16 19.8 47.00 49.00 47.93 
Breast 27.7 35.00 40.00 36.79 1.47 1.80 2.00 1.79 0.08 0.04 0.04 0.04 
Liver 18.9 14.00 17.00 12.71 22.4 38.00 41.00 37.70 0.71 0.62 0.65 0.62 
Oesophagus 22.7 53.00 61.00 53.35 3.02 1.40 1.60 1.43 0.07 0.01 0.01 0.01 
Thyroid 16.3 8.00 9.30 8.39 0.37 0.14 0.16 0.14 0.05 0.01 0.01 0.01 
Brain 0.32 0.30 0.35 0.31 0.01 0.01 0.01 0.01 0.03 0.00 0.00 0.00 
Salivary Glands 2.41 0.30 0.35 0.31 0.39 0.01 0.01 0.01 0.07 0.00 0.00 0.00 
Remainder 11.0 13.00 15.00 12.84 11.7 19.00 21.00 19.27 4.09 6.90 7.20 7.00 
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Discussion  
The options of mA value that are used within the ImPACT CTDosimetry software values (effective, 
average or modulated) has an insignificant effect on the estimated effective dose with the 
coefficient of variation of 6.4%, 4.4% and 0.5% for the chest, abdomen and pelvis respectively. 
Establishing the mAs per slice is a time consuming process and for convenience, the effective mAs 
can be used when estimating effective dose using ImPACT CTDosimetry software. This value is easily 
obtained from CT imaging equipment. 
With the exception of the AAPM k-coefficient, uncorrected effective dose was over estimated 
(Figure 5). There was closer agreement for the CT of the chest (Figure 5a) with over estimation 
ranging from 2.48% to 42.4% (0.31 mSv to 6.65 mSv). There was poorer agreement in the abdomen 
(Figure 5b) and pelvis (Figure 5c) with over estimation of 30.54% to 52.74% (3.15 mSv to 6.26 mSv) 
and 72.48% to 101% (6.26 mSv to 9.57 mSv) respectively.   
Tube current modulation takes into account patient size within set parameters. The phantom used in 
this study is larger than the phantom used within ImPACT’s software and in the development of the 
k-coefficients therefore effective dose should be lower [4-6, 13]. Correcting for mass improved 
agreement between the effective dose estimations and calculations. Differences were -40.51% to -
0.41% (-4.16 mSv to 0.05 mSv) in the chest, -12.78% to 3.60% (-1.05 mSv to 0.32 mSv) in the 
abdomen. It can be seen from Figure 5a,b and c that the majority of the mass corrected values fall 
within the error of the MOSFET dosimeters indicating no significant differences between the 
calculated and estimated values. Effective dose for the pelvis (figure 5c) showed the greatest 
disagreement after correcting for mass with differences to MOSFET ranging from 41.76% to 74.70% 
(2.47 mSv to 5.58 mSv). The disagreement between effective dose of the pelvis suggests that the 
correction factor used requires further research utilising phantoms of different sizes.  
ANOVA showed no statistical difference in the estimation of organ dose using the average, effective 
or modulated mA (p=0.9). Using the mean of these three methods a comparison of estimated and 
measured organ doses shown in Table 7 highlights a pattern. It is apparent that organs within the 
scan range have an average estimate that is higher than measured values and those organs outside 
the scan range i.e. those organs whose dose comes from scattered radiation, have estimates that are 
lower than the measured values. To explore the effect this would have on effective dose estimations 
and calculations the tissue weighting factors were applied and the percentage contribution to 
effective dose of organs within and outside the scan range was calculated (Table 8). It is recognised 
that certain organs would be part in and part out of the scan range but for the purpose of this 
analysis, organs that were mostly in the scan range were classified as ‘in’ and vice versa.   
 
 
TABLE 8 PERCENTAGE CONTRIBUTION OF ORGANS INSIDE AND OUTSIDE THE SCAN RANGE TO EFFECTIVE 
DOSE CALCULATIONS 
 Percentage contribution to calculated effective dose (%) 
 Inside outside 
Chest 71.5 28.5 
Abdomen 58.5 41.5 
Pelvis 91.4 8.6 
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The chest and abdomen show better balance between contributions of organs inside and outside 
the scan range which would explain why these estimations are in closer agreement when compared 
to the chest and pelvis. The pelvis, however, has an imbalance with the greatest contribution to the 
effective dose calculation coming from organs inside the scan range- specifically the bladder, gonads 
and colon. With the suggested tendency of ImPACT dosimetry software to over-estimate organ dose 
inside the primary beam the reason for the large difference in calculated effective dose using 
measured organ dose to estimated effective dose is apparent. Reasons for these errors require 
further investigation and should focus on the suitability of the Monte Carlo data sets used in 
ImPACT’s CTDosimetry software, the “best-fitting” of newer scanners to data in the ImPACT 
CTDosimetry software. 
It is recognised that this work is not without limitations. Only one scanner type and phantom was 
used. The tube current modulation parameters remained constant through the data collection. Only 
filtered back projection reconstruction was used. To validate the mass correction of effective dose 
estimations further validation of mass correction is required using phantoms of different sizes. 
Investigation into the mass correction for CT of the pelvis is required as our work has shown that 
over estimation occurs even after correction for mass.  Should accurate organ dose estimations be 
required, clinicians should be aware of the under and over estimation of dose for organs inside and 
outside the scan range.   
Conclusion 
Our work has shown that a for this scanner type and exposure parameters a reasonable estimation 
of effective dose for CT of the chest and abdomen can be obtained using ImPACT CTDosimetry 
software or the k-coefficients referenced.  The use of the k-coefficients is the quicker method 
compared to using ImPACT software but these do not give an indication of organ doses. Our work 
has shown that there is a pattern for overestimation of organ dose inside the scan range and 
underestimation outside the scan range. Additional investigations using other scanners are required 
to establish if this is a consistent pattern. Further work is required to improve the accuracy of the 
mass correction factor for the pelvis and to test the external validity of the method varying the mass 
of the phantom and across different makes and models of CT scanner.  
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APPENDIX 
NUCLEAR MEDICINE SCANNING PROTOCOLS    
 
 
ISOTOPE  BONE  SCAN 
 
REFERRAL CRITERIA 
 
All Consultants and Junior Medical staff can refer in accordance with R.C.R. 
guidelines 
 
GPs, if known malignancy and pain or after discussion with Consultant Radiologist 
 
JUSTIFICATION CRITERIA 
 
 
Metastatic bone disease 
Arthralgia 
Paget’s disease 
Perthes disease/ irritable hip 
Osteomyelitis 
Bone pain 
Infected/loose prostheses or other 
metalwork 
Alk Phos  
PSA 
 
? Fracture e.g scaphoid, N.o.F. 
Stress fracture 
Shin splints 
Back pain 
Infection 
Primary bone tumour 
Vascularity – AVN, R.S.D 
Sacro-iliitis 
Mandibular condyle hyperplasia 
 
PROTOCOL 
 
Booking method 
 
 
On receipt of a signed request form 
request on Order Comms or if urgent, 
by phone if confirmed by fax 
 
Patient preparation None 
 
Radiopharmaceutical 500Mbq 99TcmMDP (supplied by 
RLUH) 
 
Personnel competent to administer Isotope scan dept. staff with prior 
authorisation 
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Method of administration Intravenously, following flush with 
normal saline if venflon or butterfly 
needle used 
Paediatric patients Activity scaled down in accordance 
with the ARSAC guidelines.(weight of 
child required) 
 
Advice after administration Drink plenty of fluids and empty 
bladder  
Frequently 
 
Time delay before scan 3 hours preferably, minimum 2.5hrs 
 
Equipment GE Discovery 670Pro with LEHR 
collimator  
 
Scanning procedure 
 
 
 
 
 
 
 
The bladder should be emptied 
immediately before any view of the 
pelvis 
Select patient on acquisition 
workstation , acquire study and select 
parameters for imaging 
 
Whole body imaging either with W.B 
facility or statics (patient dependant) 
Static images of  affected area 
Posterior and Anterior views may be 
obtained simultaneously 
Dynamic studies may be necessary 
for some referrals e.g ? R.S.D 
Dynamic acquisition –  flow images 15 
frames @ 8 seconds per frame (delay 
may be required, 5secs for wrists & 
knees, .   10secs for feet) then blood 
pool image 5 mins.   128x128 matrix 
 
Patient position 
 
Supine or erect 
Analysis and display No analysis required unless SI joint 
profiles are necessary 
Display all acceptable images with 
annotation 
 
Supplements When the clinical question is for 
suspected loosening or infection of a 
KNEE prosthesis, a 3-phase scan 
should be performed as routine. 
 
SPECT for mandibular condyle 
hyperplasia. 
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SPECT/CT may be required 
according to protocol (see end of 
Bone imaging protocol) 
 
Request of supplementary imaging for 
any isolated hot spots (see protocol 
and authorisation) 
 
 
 
REPORTING 
 
When the scan is complete the images are processed on Xeleris workstation and a 
screen capture of final image sent to Carestream. Consultant to select relevant 
SPECT CT images to send to PACS where indicated. 
Radiologist to report on to CRIS  and secretarial staff to type report and send out to 
appropriate Consultant or Ward 
 
 
 
SPECT/CT PROTOCOL FOLLOWING BONE SCANS 
 
The Radiographers in Nuclear Medicine are authorised to perform SPECT/CT on 
any patients that have a known malignant disease and present with a single “hot” 
spot on the Bone scan.   
This “hot” spot should be in the Thoracic or Lumbar spine or in the Pelvis (except 
degenerative disease in the hips). 
 
SPECT CT may be indicated in targeted bone scans for Orthopaedics as vetted by 
Radiologist. 
 
For initial staging of Breast / Prostate malignancy, any uptake in spine should ideally 
proceed to SPECT CT rather than plain films (if unsure ask Radiologist to review). 
 
For patient with a history of malignancy and symptoms specific to one area, SPECT 
CT if abnormal on bone scan. 
 
Pre-planned Orthopaedic SPECT CT of feet / ankles to be booked for Whiston where 
possible. 
 
Electronic vetting allows for the Radiologist to comment if SPECT CT is indicated or 
should be considered of a specific area usually described as symptomatic if it does 
not fall within any of the above criteria.  If in doubt, try to contact Dr Howes / Dr Patel 
to review the images.  
 
 
 
 
